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ABSTRACT OF THE DISSERTATION 
CONJUGATED POLYMER-BASED BIOMATERIALS THROUGH CONTROLLED SELF-
ASSEMBLY 
by 
Megan Twomey 
Florida International University, 2016 
Miami, Florida 
Professor Joong Ho Moon, Major Professor 
Synthetic polymeric materials have gained significant use as biological materials (biomaterials) in biomedical 
and pharmaceutical applications. As a result, a demand for well-defined polymers with tunable properties 
has emerged. The synthetic versatility of polymeric biomaterials allows the opportunity to understand the 
structure-property relationship of materials and their cellular interactions. A novel class of polymeric 
biomaterials are conjugated polymers (CPs), which possess desirable physicochemical and excellent 
photophysical properties, including inherent fluorescence. The synthetic versatility of CPs allows easy 
modification of the conjugated backbone to tune emission and side chain structures to adjust biocompatibility 
through increased water solubility, controlled biodegradability, and incorporation of targeting units. The aim 
of this dissertation is to better understand conjugated polymer nanoparticle (CPN) structure and self-assembly 
in an aqueous environment, and how those structural features affect cellular interactions to establish a 
structure-function relationship. 
This work presents the fabrication of several different CPNs for cancer cell targeting and labelling, and 
differentiation of biologically important molecules. Core−shell nanoparticles were prepared using a semi-
flexible cationic CPN complexed with hyaluronic acid (HA), a polyanion. The resulting CPNs exhibited high 
cancer cell specificity with low adsorption to normal cells, as a result of HA’s affinity towards overexpressed 
receptors on cancer cell surface. A systematic investigation on the aggregation properties of CPNs that vary 
by side chain and backbone structures in response to different biologically important anionic polysaccharides 
in a complex biological medium was conducted. Mitochondria-specific CPNs were fabricated from a semi-
flexible CPN modified with the mitochondrial-targeting triphenylphosphonium (TPP) group. The subcellular 
v 
localization and cellular toxicity were dependent on backbone flexibility, hydrophilicity, and molecular 
weight. Dual-targeting CPNs grafted with folic acid (FA) side chains and complexed with hyaluronic acid 
(HA) were fabricated for improved uptake and bioimaging of cancer cells. 
The work presented here shows how modifications to CPN backbone and side chain structures modulate their 
cellular interactions. The physicochemical and biophysical properties of CPNs affect biocompatibility and 
understanding those properties will lead to the development of novel CP-based biomaterials.  
vi 
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CHAPTER I 
 
Introduction  
2 
1.1  Materials chemistry 
Synthetic polymeric materials have gained significant use as biological materials (biomaterials) in biomedical 
and pharmaceutical applications. As a result, a demand for well-defined polymers with tunable properties 
has emerged. The method of system’s materials chemistry utilizes the investigation of the interactions 
between components of a system, to understand how those interactions drive the function and performance 
of the overall system.1 The development of functional materials is built on rational design, 
synthesis/fabrication, and systematic characterization of properties. In order to design a material for a desired 
application successfully, an in-depth understanding of the structure-function relationship is crucial. This 
understanding allows the development of a material that possesses the necessary and desired properties. More 
importantly, an understanding of how those properties relate to a material’s chemical and physical structures. 
The systematic approach to material design is essential as it is no longer effective to isolate only one 
component to solve complex scientific challenges. As advances in effective material development occur, it 
is increasingly evident that these advances are only achieved when an integrated approach is employed. 
1.2 Challenges for polymeric biomaterials 
Biomaterials are defined as substances other than food or drugs used for therapeutic and diagnostic 
applications that can be composed of both natural and synthetic components.2 Biomaterials are usually 
polymeric to address the biological, physical, and chemical demands of their applications. These biomaterials 
have been at the forefront of treating diseases and improving healthcare, and are most often biologically 
derived or inspired molecules. Modern biomaterials have been used as synthetic and natural replacements for 
biological tissues, materials for medical device implantation, carriers for drug delivery systems, and materials 
for array-based sensing for diagnostic applications.2 However, these materials still suffer from issues with 
biocompatibility, mechanical properties, and proper degradation. There are several specific biological 
challenges that need to be addressed to further biomaterial development (discussed in additional in section 
1.9), including targeting materials for drug delivery to specific cells and organelles, materials for sensing 
various biochemical signals, and strategies for improved biocompatibility of materials. Synthetic materials, 
such as polymers, offer a simple and effective approach to address these issues. The synthetic versatility of 
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polymeric materials allows an opportunity to understand the structure-property relationship of materials and 
their cellular interactions. 
1.3 Conjugated polymers 
A novel class of polymeric biomaterials are conjugated polymers (CPs), which are polyunsaturated and 
consist of a backbone chain of alternating single and double (or triple) bonds.10 Examples of CPs are depicted 
in Figure 1.1. The semi-conductive properties of CPs are the result of the electronic conjugation of 
delocalized pi (π) electrons (generalized example shown in Figure 1.2) along the backbone, which provides 
these compounds with desirable physiochemical and excellent photophysical properties, including inherent 
fluorescence.11 The energy band gap is defined by the highest occupied molecular orbital (HOMO) and lowest 
unoccupied molecular orbital (LUMO) formed from the sp and sp2 hybridized carbon atoms along the 
conjugated backbone and is the origin of the photophysical and semi-conductive properties.4 
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Figure 1.1. Common examples of conjugated polymers. 
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Figure 1.2. Example configuration of delocalized electrons of a π conjugated system. 
 
Recently, CPs have been applied to several electronic and sensing applications, including solar cells, light-
emitting diodes, and a variety of chemical and biological sensors.12-16 While these applications encompass a 
wide variety of CPs, the Moon research group focuses on poly(para-phenyleneethynylene) (PPE) and 
poly(para-phenylbutadiynylene) (PPB)-based polymers, because of their ease of synthesis, for biological 
applications including cellular imaging, cancer cell targeting and labelling, and sensing of biologically 
important substances. The synthetic versatility of CPs allow easy modification of the conjugated backbone 
to tune emission and side chain structures to adjust biocompatibility through increased water solubility, 
controlled biodegradability, and incorporation of targeting units.  
1.3.1 Synthesis 
The backbone and side chain structures of CPs gives rise to unique properties. The conjugated backbone 
provides a structural platform for tuning the electronic properties, and side chain structure can be used to 
modulate hydrophobicity/hydrophilicity and provide functionalization. The synthesis of PPEs and PPBs 
utilizes the cross-coupling reactions of Sonogashira and Glaser, respectively. The Sonogashira reaction uses 
a palladium catalyst, with a catalytic amount of copper and base, to couple an aryl (or vinyl) halide to a 
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terminal alkyne, and has been shown to be very versatile.10 Glaser coupling is used for homocoupling of 
terminal acetylenes in the presence of a copper catalyst under an oxygen-rich environment. Glaser coupling 
also occurs with the Sonogashira reaction and results in a homocoupled side product when nonoxidative 
conditions are not maintained. Generalized reactions for PPE and PPB synthesis using Sonogashira and 
Glaser coupling, respectively, are shown in Figure 1.3. 
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Figure 1.3. Sonogashira and Glaser coupling for PPE and PPB synthesis, respectively. 
1.3.2. Photophysics 
In an ideal environment (i.e., organic solvent, contaminant-free), CP chains are well-solvated and exhibit 
photophysical properties originating from the delocalized electrons along the conjugated backbone.2 These 
delocalized π electrons (depicted in Figure 1.2) are responsible for the characteristic absorption of light and 
subsequent relaxation from excited electronic states via fluorescence.3 The intrinsic fluorescence  makes CPs 
an advantageous choice over other macromolecules, specifically for sensing and imaging applications. The 
semi-conductive and photophysical properties of CPs are driven by the HOMO-LUMO gap, which is also 
responsible for the wavelength of absorbed and emitted light. These processes can be described by a Jablonski 
diagram (Figure 1.4), which represents the energy states of a molecule’s electrons and the transitions between 
states.5 When a molecule absorbs light, the electron in the ground singlet state (S0) is excited to a vibrational 
level in the excited singlet state (S1), in a rapid process (~10-15 s). The excess in energy can be released in 
several ways to return back to the ground state. Through internal conversion via non-radiative decay, the 
excited electron relaxes to the lowest vibration level of the excited singlet state (S1). In fluorescence, the 
excited electron returns to the ground state (S0) by emitting a photon, which is a fast (~10-9 s) and favorable 
process, and responsible for the desirable photophysical properties of CPs. An alternative pathway for an 
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excited electron to return to the ground state is via phosphorescence, where the electron undergoes 
intersystem crossing (ISC) and spin-forbidden electronic transitions in a much slower process (~10-3 s). The 
emission efficiency, or fluorescence brightness, is quantified using the quantum yield, which is the ratio of 
photons emitted to photons absorbed. The brightness of new fluorescent materials is determined relative to a 
known bright standard. 
 
Figure 1.4. Jablonski diagram showing the various processes when a molecule is irradiated by light. 
 
1.4 Conjugated polymer nanoparticles 
For biological applications, CPs must be compatible with aqueous environments. Because of the hydrophobic 
nature of the conjugated backbone, ionic and hydrophilic side chains can be incorporated to achieve the 
necessary aqueous solubility. When a CP dissolved in an organic solvent is added to an excess amount of 
aqueous solvent, the hydrophobic CP chains aggregate and form nanoparticles. These CP nanoparticles (i.e., 
CPNs) are then purified via dialysis to remove the organic solvent. This type of nanoparticle (NP) preparation 
is termed the reprecipitation method, and the resulting NPs are in the range of 5-150 nanometers (nm) in 
diameter.6 The process of how CP chains aggregate and self-assemble in an aqueous environment is driven 
by the hydrophobic backbone where both inter-chain aggregation and intra-chain collapse can occur. While 
the hydrophobic effect is the main driving force of NP formation, the nature of polymer chain self-assembly 
can be modulated by the side chain structure, where ionic groups can cause repulsion between chains and 
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increased hydrophilicity can improve solubility. Recently, Ko et al. demonstrated controlled chain-chain 
interactions of CPNs fabricated from primary amine-containing PPEs as exhibited by different aggregation 
structures and photophysical properties determined by organic acid treatment of the CPs.28 The different 
aggregation structures were the result of minimal π-π stacking in loosely aggregated CPNs treated with mild 
acetic acid (AA) and extensive π-π stacking in densely aggregated CPNs treated with dicarboxylic tartaric 
acid (TA). The resulting aggregation state of CPNs is, therefore, a cooperative assembly determined by the 
π-π stacking, hydrogen bonding, and the interplay of hydrophobic, van der Waals, and electrostatic forces.8 
In addition, NP formation can be adjusted on the basis of polymer stock concentration and molecular 
weight/distribution of the polymer.7 
1.5 Polymer characterization 
To understand the structure-function relationship for a material and its application, it is necessary to 
characterize the structure properly, which can be achieved using a variety of techniques. After synthesis and 
purification, the polymer’s molecular weight is determined by gel permeation chromatography (GPC), which 
is a type of size exclusion chromatography (SEC) and the most convenient method for use with polymers.9 
The technique of GPC is a physical chromatographic separation determined by size, where larger molecules 
pass through the porous column more rapidly than smaller molecules that elute slowly as they are retained 
within the pores of the column. The molecular weight distribution is determined relative to standards (i.e., 
polystyrene or polyethyleneglycol) and described by the weight average molecular weight (Mw), number 
average molecular weight (Mn), and polydispersity index (PDI). An example GPC chromatogram is depicted 
in Figure 1.5. 
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Figure 1.5. Example GPC chromatogram illustrating molecular weight distribution. 
The chemical structure of a polymer can be ascertained quantitatively using nuclear magnetic resonance 
(NMR) spectroscopy, which is an analytical structure determination method. The basic principles of NMR 
rely on the changes in magnetic moments of magnetically active nuclei, such as 1H, 13C, 19F, and 31P, when 
exposed to a radio frequency and a strong external magnetic field. The energy that is emitted upon relaxation 
of the excited nuclei is characteristic to the nuclei themselves and the chemical environment they are exposed 
to within the molecule. The NMR spectrum provides information about the proportion of nuclei generating 
the signal given by the integrated area under each peak, and the nature of neighboring nuclei given by the 
splitting pattern of the peak. The technique of NMR is a very powerful structural elucidation technique, 
however, it provides structural information for the average polymer rather than exact structures of individual 
polymer chains. 
The presence of certain functional groups in a polymer can be determined using Fourier Transform-Infrared 
(FT-IR) spectroscopy, which is a qualitative technique that provides structural information about the bonds 
between atoms within a molecule. When IR radiation is passed through a sample, it is absorbed and 
transmitted on the basis of frequencies of vibrations between the bonds of atoms present in the sample. The 
absorption region is characteristic of a functional group as the radiation is characteristic of that bond and can 
be used to confirm the presence or absence of certain groups in monomer and polymer samples. 
1.6 Polymer self-assembly characterization 
While chemical structure characterization is critical for developing new materials, it is crucial to understand 
how that material exists in solution and, eventually upon interaction with biological interfaces. This will 
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ultimately determine how well the material will perform its function and provide information to understand 
structure-property relationship. The absorption and emission profiles of PPE- and PPB-containg CPNs are 
characteristic of the electronic states of the polymer structure (discussed in section 1.5), which are generally 
broad compared to small molecules, and more defined compared to PPV polymers due to the rigidity of the 
conjugated backbone. The absorption and emission wavelength maxima are characteristic of the type of 
conjugated backbone and conjugation length, this is the result of the configuration of the delocalized π 
electron cloud (discussed in section 1.3). As conjugation length increases, the HOMO-LUMO gap decreases 
and results in a bathochromic shift (towards red) of the wavelength maxima.  
The effect of π-π stacking between polymer chains also drives the wavelength maxima and shape of 
absorption and emission profiles. The CP chains can be compared to that of small organic dyes that exhibit 
specific superstructures, J and H aggregates, as shown in Figure 1.6. When the delocalized π electron cloud 
of neighboring polymer chains align face-to-face, there is a hypsochromic shift (towards blue) in wavelength 
maxima due to an increase in energy between the HOMO and LUMO, this is called an H aggregate.35 In 
comparison to when neighboring polymer chains align end-to-end, there is a bathochromic shift because of 
a decrease of the HOMO-LUMO gap, this is called a J aggregate.35 Red shifting in wavelength maxima also 
occurs when there is strong π-π stacking between polymer chains, which causes an increase in effective 
conjugation length that decreases the HOMO-LUMO gap. Absorption and emission spectra are indicative of 
polymer self-assembly, and used to observe and understand the changes in polymer aggregation when 
external stimuli are applied (i.e., solvent, pH, salt concentration, or polyanions).  
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Figure 1.6. Schematic representation of the spectral shift in H and J-aggregates based on chromophore 
arrangement. 
 
Absorption of light is not only characteristic of a material’s electronic states, but also the concentration of 
absorbing molecules in solution. The absorbance (A) of a solution is defined as the logarithm ratio of incident 
light (I0) to transmitted light (I) and is described by the Beer-Lambert law: 
𝑨𝑨 = 𝒍𝒍𝒍𝒍𝒍𝒍𝟏𝟏𝟏𝟏 𝑰𝑰𝟏𝟏𝑰𝑰 = 𝜺𝜺𝒍𝒍𝜺𝜺    (Eq. 1.1) 
where ε is the molar absorptivity (i.e.; an intrinsic property of the absorbing material) in mol-1·L·cm-1, l is 
the path length of the absorbing solution in centimeters (cm), and c is the concentration of absorbing 
material in mol·L-1. 
In addition to characterizing the structural and photophysical properties of polymer self-assembly, it is 
important to characterize the physical properties of the polymer nanoparticle. These properties will also 
provide insight into understanding the material’s function and performance. Dynamic light scattering (DLS), 
also called photon correlation spectroscopy, is a technique used to determine particle size by measuring the 
intensity of light scattered by particles in suspension. Light is scattered after the interaction with the electric 
field of a particle, which causes an incident photon to induce an oscillating dipole in the electron cloud and 
radiation is dispersed in all directions as the dipole changes. The fundamental theory of DLS is built upon 
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the Brownian motion of spherical particles, which describes the random movements of particles because of 
collisions caused by the solvent that surrounds those particles. The scattered light is recorded over time and 
the correlation function is used to determine the mean size and polydispersity index, which is an estimate of 
the distribution width. DLS relates the speed of the particles in terms of the diffusion constant to the particle 
size as expressed by the Stoke-Einstein equation: 
rh = kT6πηD     (Eq. 1.2) 
where rh is the hydrodynamic radius, k is the Boltzmann constant, T is temperature in Kelvin, η is the solvent 
viscosity, and D is the diffusion coefficient. The particle size, termed the hydrodynamic radius, is defined as 
the radius of a hard sphere that diffuses at the same speed as the particle measured and is dependent on the 
size of the particle core and the surface structure of the particle, including any ions in solution. Surface 
structure is an important factor since the particle diffusion speed will be changed on the basis of the thickness 
of the electric double layer of the particle.  
The zeta potential (illustrated in Figure 1.7) is measured using electrophoresis, where the movement of a 
charged particle relative to the medium under an applied electric field is recorded. The particle moves towards 
the electrode of opposite charge and is opposed by viscous forces acting on the particle. When an equilibrium 
is reached between these two forces, the particle moves with a constant velocity that is dependent on the 
electric field strength, dielectric constant of the medium, viscosity of the medium, and zeta potential.  
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Figure 1.7. Schematic representation of zeta potential of a negatively charged particle. 
 
The velocity of the particle in an electric field is termed electrophoretic mobility and is related to the zeta 
potential using the Henry equation: 
UE = 2 ε Z f(κa)3η      (Eq. 1.3) 
where UE is the electrophoretic mobility, ε is the dielectric constant of the medium, Z is the zeta potential, η 
is the viscosity of the medium, and f(κa) is the Henry’s function. For nano-sized particles in solution, or 
colloids, the stability is dependent on the repulsive forces between the particles. Repulsion can be achieved 
via steric repulsion, where adsorbed bulky groups prevent particles from coming into contact with each other, 
and electrostatic stabilization, where particles are distributed on the basis of their like charges. In aqueous 
suspensions, most colloids carry an electric charge, which can be the result of ionized surface groups, 
differential loss of ions from the crystal lattice structure, and adsorbed charges species. The magnitude of the 
zeta potential is a direct indication of particle stability; greater than +/- 30 mV is considered stable, and 
indicative of the particle’s surface charge. The zeta potential provides important information about what is 
happening at the interface of the material’s surface and its solution. 
+
+
+
+
+++
+++
+ +
+
+
+
+ +
-
+
+
+
-
+
++-
+++
-
-
+
+
+
+
+
Negative surface charge
Stern layer
Slipping plane
0
mV
Distance from particle surface
Surface potential
Stern potential
Zeta potential
13 
While DLS is typically used to measure the bulk composition of particles in solution, it is only accurate for 
monodispersed systems. Larger particles will scatter more light than smaller ones, and therefore, contribute 
more to the overall size measurement. An emerging technique for analyzing single particles in a 
polydispersed system is nanoparticle tracking analysis (NTA). A laser beam is passed through the sample 
and the scattered light is captured by a charge-coupled device (CCD) camera mounted onto a microscope 
that records a video at 30 frames per second.17 The software determines the displacement of individual 
particles by tracking the x and y movement of each particle’s center, frame-by-frame. Once the displacement 
is calculated, the diffusion coefficient and size are determined using the Stokes-Einstein equation (Eq. 1.1). 
The technique of NTA is more favorable for polydispersed samples, like CPNs, and is capable of determining 
size at much lower concentrations than DLS. However, DLS is a user friendly technique, with a short analysis 
time, and provides reliable and consistent data since it measures the average sample. 
1.7 Biological use of nanoparticles 
Nanotechnology has made tremendous advancements for diagnostics, therapeutics, and imaging. The use of 
nanoparticles offers several advantages over traditional delivery methods (i.e., free drugs) including 
encapsulation, enhanced retention, controlled release, and reduced toxicity to off-target sites. In particular, 
typical chemotherapeutics have a narrow therapeutic because of poor solubility, limited circulation time, and 
cytotoxicity to healthy tissue. By using water-soluble polymers, nanoparticle-based drug delivery systems 
can enhance aqueous solubility of therapeutics. Nanoparticles can be used to increase half-life and address 
the pharmacokinetics issues to improve therapeutic effects. The tunability of nanoparticle structure is an 
excellent platform to improve target-ability, in both reducing off-target effects, and enhanced retention and 
accumulation in diseased tissue. Several nanocarrier therapeutics with a variety of formulations have been 
approved by the Food and Drug Administration (FDA) for clinical trials and use, including inorganic 
nanoparticles,20 liposomes, micelles,21 protein nanoparticles,22 polymeric micelles,23 polymer-drug 
conjugates,24 and polymer nanoparticles.25 Nano-sized systems have a favorable small size that leads to 
passive targeting and preferential delivery to diseased tissue because of the enhanced permeability and 
retention (EPR) effect, as illustrated in Figure 1.8. The EPR effect arises as a consequence of the nature of 
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tumor tissue, which is hypervascular, has up regulation of proangiogenic signaling, and poor lymphatic 
drainage that allows for accumulation of large molecules (≥ 40 kDa) in the microenvironment.19 Additionally, 
the small size has reduced side effects as nanoparticles escape recognition from the reticuloendothelial system 
(RES) in healthy tissue.30 
 
Figure 1.8. Schematic representation of the enhanced retention and permeability (EPR) effect that occurs in 
diseased tissue. Adapted from Stockhofe et al.36 
 
1.7.1 Cellular uptake of nanoparticles 
To develop materials for biological use, there are several barriers that must be traversed to be effective. The 
first is the physiological barrier, where nanomaterials have been shown to easily traverse as a consequence 
of their size. The second important barrier is the cellular barrier and in particular, the cell membrane. The 
cellular membrane is responsible for the selective flow of ions and molecules into and out of the cell. Most 
importantly, the cell membrane is responsible for the maintenance of separation between the cytosol and 
extracellular environment.18 Extracellular molecules are selectively transported into the cell via endocytosis 
pathways: phagocytosis (i.e., “cell-eating”), pinocytosis (i.e., “cell-drinking”), macropinocytosis (MPC), and 
receptor-mediated endocytosis, including clathrin-mediated (CME) and caveolae-mediated (CvME).26 These 
endocytosis mechanisms are based on the molecule’s size, properties, and internalization machinery. 
However for most cell types, nanoparticles are internalized via MPC, CME, and CvME. The pathway of 
MPC is a non-selective internalization of large volumes of extracellular medium where the cell membrane 
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forms a pocket and pinches off a vesicle about 0.5-5 µm in diameter.31 The pathway of CME involves clathrin-
coated pits that form a polygonal clathrin lattice that bind ligands and molecules, where the clathrin-coated 
pits pinch off clathrin-coated vesicles about 100-150 nm in size. The clathrin-coated vesicles depolymerize 
going from early endosome to lysosome because of the drop in pH.31 The pathway of CvME involves small 
hydrophobic domains with caveolin, which is a cholesterol binding protein. An approximately 50 nm 
caveolar vesicle forms a caveosome and follows a non-acidic and non-digestive intracellular route.31 
Depending on the mechanism of uptake, the cell will either recycle out or sort and traffic the nanoparticles 
to a specific organelle for further processing.27 Recently, Mendez et al. demonstrated the subcellular 
localization and toxicity of CPNs were dependent on the chemical structure of the side chains and conjugated 
backbone.29 Cellular uptake and toxicity were modulated by adjusting amine-density of the side chain, 
primary vs. tertiary, and hydrophilicity, primary amine vs. triethylene oxide. Therefore, it is important to 
understand how the physicochemical and biophysical properties of nanocarriers affect the interaction with 
the cell membrane, and subsequent uptake and trafficking. Synthetic nanoparticle systems have the unique 
properties that allow for both passive and active targeting, making an excellent platform for improving 
therapeutics. 
1.8 Characterization of cellular interactions 
The first step to characterize biophysical properties is to ensure the material is non-toxic to target cells. The 
most commonly used assays measure viable cells, rather than dead cells, as there are several widely used and 
high throughput methods established. In general, cells are treated with a compound that when metabolized 
by viable cells forms a colored product that can be measured using a microplate reader, typically using 
absorbance. 
When determining quantitative cellular uptake of nanoparticles, flow cytometry is used. Briefly, a fluid 
stream of cells is passed through a beam of light, and both fluorescence and scattered light are recorded. 
Fluorescence intensity relative to the cell gives the quantitative uptake of the nanoparticle. Scattered light is 
used to differentiate live cells from dead ones to obtain an accurate fluorescence value. Cellular uptake 
pathways can be determined by pre-treating cells with commercially available pharmacological inhibitors.32 
Clathrin-mediated endocytosis can be distinguished under a potassium depletion condition or by treating with 
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chlorpromazine, which dissociates clathrin coated pits on the cell surface and disrupts the regulation of actin 
cytoskeleton. Caveolae-mediated endocytosis can be distinguished when the presence of cholesterol is 
disrupted. Methyl-β-cyclodextrin is known to deplete cholesterol from the plasma membrane by forming 
inclusion complexes. Cholesterol is involved in both macropinocytosis and caveolae-mediated endocytosis. 
Genistein inhibits tyrosine kinases that are involved in the pinching of caveolae. LY2994 inhibits 
phosphatidylinositol 3-kinase, which recruits factors involved in macropinocytosis. Cytochalasin D inhibits 
actin polymerization, leading to actin filament disassembly, and this disassembly affects both 
macropinocytosis and caveolae-mediated endocytosis.32 
Visualization of cellular uptake of fluorescent nanoparticles is achieved using high resolution microscopic 
imaging. Trafficking and subcellular localization can be evaluated by co-staining with standard fluorescent 
dyes as there are a wide variety of commercially available dyes to stain organelles. Co-localization of the 
dyes (i.e.; green CPN and red commercial dye) is defined as the co-occurrence indicated by the spatial overlap 
of the dyes. The correlation indicated by the co-distribution of the dyes in proportion to each other within 
and between structures.33 To evaluate quantitatively co-localization, the Pearson’s Correlation Coefficient 
(PCC) method is used to determine the degree of association between the dye signals on a pixel-by-pixel 
basis. The PCC method takes into account the average intensity of each pixel and normalized so the PCC 
score is independent of dye brightness and background signal. PCC values range from +1 and -1, indicating 
perfectly linearly and inversely correlated, respectively.34 
1.9 Summary 
By exploring nanoparticles for biological use, a better understanding of the biological hurdles and ways to 
improve nanoparticle design can be achieved. Nanoparticle design and improvement stems from a thorough 
characterization of material composition, size, shape, surface modification, and flexibility, which will 
ultimately determine biocompatibility. The aim of my dissertation is to better understand CPN structure and 
aggregation, and how those structural features affect cellular interactions to establish a structure-function 
relationship. Chapter 2 details the fabrication of core−shell nanoparticles using a semi-flexible cationic CPN 
complexed with a polyanion, hyaluronic acid (HA), which has a high affinity towards receptor overexpressed 
on cancer cells. The resulting fluorescent core−shell nanoparticles exhibited high cancer cell specificity with 
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low adsorption to normal cells, compared to a rigid control CPN that formed random spherical complexes 
with HA. The dramatic difference in ionic complex formation based on the flexibility of CPN backbone led 
to the work in Chapter 3, which details a systematic investigation on the aggregation properties of CPNs that 
vary by side chain and backbone structures in response to different biologically important anionic 
polysaccharides. These differential interactions were analyzed using analytical statistical methods to 
demonstrate that structurally diverse CPNs can be used for the differentiation of biological molecules in a 
complex biological medium. Chapter 4 details the fabrication of a semi-flexible CPN modified with the 
mitochondrial-targeting triphenylphosphonium (TPP) group. The subcellular localization and cellular 
toxicity were affected by backbone flexibility and molecular weight, in a time-dependent fashion. In 
accordance with Chapter 2, the TPP-containing CPNs were treated with HA to modulate solubility and 
cellular interactions. Chapter 5 details the synthesis of dual-targeting red emissive CPNs grafted with folic 
acid (FA) side chains and complexed with hyaluronic acid (HA). Modulation of uptake kinetics and amount 
of internalized CPNs was achieved by the dual ligand-targeting CPNs designed for folate and hyaluronan 
receptors. 
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2.1 Abstract 
Core-shell conjugated polymer nanoparticles (CPNs) were fabricated by complexing a semi-flexible 
conjugated polymer (CP) with hyaluronic acid (HA). Incorporation of a small amount of flexible unit into 
the rigid rod conjugated backbone introduces conjugated backbone reorganization under ionic complexation 
to increase π-π interaction, resulting in core-shell nanoparticles with a hydrophobic core wrapped with a HA 
shell. The core-shell nanoparticles exhibited no cellular toxicity and high cancer cell specificity with minimal 
binding to normal cells. 
2.2 Introduction 
Recently, conjugated polymers (CPs) have attracted much attention for sensing,1−4 labeling,5−10 and 
delivery11−13 of biological substances owing to their excellent photophysical and biophysical properties. CPs 
are synthetic macromolecules containing fully conjugated π-electrons along the backbones, resulting in high 
luminescence brightness, high photostability, and excellent energy transfer.14,15 By incorporating hydrophilic 
polar side chains and functional entities such as sensing units or targeting ligands, various conjugated 
polyelectrolytes (CPEs) and conjugated polymer nanoparticles (CPNs) have been synthesized and used for 
biological applications in aqueous environments.16−18 
The photophysical excellence and robustness of CP-based nanomaterials are typically useful for labeling 
target cells or tissues. Biophysically, amphiphilicity of the CPEs and CPNs is important for cellular 
interaction and subsequent cellular entry because the cell surface contains both negatively charged 
proteoglycans and hydrophobic membrane lipids. Especially, particles with high surface-to-volume ratios 
exhibit size, shape, and functional group-dependent cellular interactions and entry efficiency.19,20 Therefore, 
functional modifications and structural modulations of CP-based nanomaterials are highly anticipated to 
obtain desired biophysical properties for improved cellular applications. 
Previously, we fabricated positively charged CPNs by treating a nonaqueous soluble, primary amine-
containing rigid rod CP with organic acids followed by dialysis.21,22 The aggregation structures of CPNs, 
after complete removal of organic acids, were dependent on the nature of organic acids. Acetic acid treatment 
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produced loose aggregation of rigid rod CP backbones, while increased π−π interactions among the 
backbones were observed when the same batch of polymer was treated with tartaric acid (i.e., dicarboxylic 
acid). From this observation, we hypothesized that if CPs containing flexible units along the backbones are 
treated with polymeric acids, π−π interaction among the backbones will be dramatically increased because 
the semiflexibility of the nonaqueous soluble backbones will help backbone reorganization to maximize 
hydrophobic chain interaction. If complexation between the nonaqueous soluble CP and polyanion 
contributes to increasing aqueous solubility of CPs, random complex formations is expected with no 
significant spectral changes. To test this hypothesis and functionalize the CP with cancer cell-specific ligands, 
we employed a linear polysaccharide, hyaluronic acid (HA), which contains N-acetyl-D-glucosamine and D-
glucuronic acid units. HA has specific binding with cell surface receptors such as CD44 and RHAMM, which 
are overexpressed in many cancer cells.23 Numerous cancer drugs and polymers have been modified with 
HA for targeted drug and gene delivery.24−28 
In this chapter, core-CP−shell-HA nanoparticles are obtained when semi-flexible CPs are treated with 
polyanionic HA, while nonflexible CPs produce random complexes upon HA treatment. The core−shell 
nanoparticles are nontoxic to cells and exhibit high cancer cell specificity through the specific binding of HA 
to cancer cell surface receptors. 
2.3  Results and Discussion 
A semi-flexible poly(phenylenebutadiynylene) (PPB), which contains a small fraction of flexible 
nonconjugating units along the rigid conjugated backbones, was prepared by following our published 
method21 and used for the complexation with HA (Figure 2.1). The semi-flexible PPB was treated with 
organic acids, dialyzed against water, and complexed with HA. The semi-flexible PPB exhibits characteristic 
photophysical properties of the fully conjugated PPBs because the amount of nonconjugated unit is limited 
(∼5−10%) not to perturb the π- electron conjugation along the backbone.  
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Figure 2.1. (a) Chemical structure of the semi-flexible PPB. (b) A schematic presentation of structural 
reorganization of the semi-flexible PPB upon HA complexation. The semi-flexible PPB in water was 
prepared by deprotection of Boc group using organic acid treatments followed by dialysis. 
 
The photophysical and physical properties of the semi-flexible PPB in water were similar to the 
characteristics of loosely aggregated CPs with fully conjugated backbones. When the semi-flexible PPB was 
mixed with HA, the resulting complex exhibited dramatic changes in both absorption and emission spectra. 
As shown in Figure 2.2, a new strong absorption peak appeared at ∼474 nm (30 nm red-shifted upon 
complexation) (Figure 2.2a), and the emission intensity of the complex decreased significantly (Figure 2.2b). 
We believe that unlike complexes formed between conjugated rigid oligomers and polysaccharides, which 
exhibit both red-shift and fluorescent increase through chain end-to-end alignment induced by linear 
polysaccharides,29,30 the loosely aggregated, nonaqueous soluble PPBs connected with flexible linkers were 
able to reorganize to increase interpolymer π−π interactions, similarly to the high molecular weight, fully 
conjugated poly(phenyleneethynylene) (PPEs) at the air−water interface under mechanical forces.31 As a 
control, a fully conjugated PPE containing the same amine side chains was treated with HA, and the 
spectroscopic behaviors were monitored. We employed the structurally similar PPE as a control due to poor 
solubility of PPB without flexible linkers. Upon complexation with HA, the control PPE exhibited only a 
small increase in the absorption maximum (<5 nm) without a spectral shape change (Figure 2.2c), and the 
fluorescent intensity decreased slightly (Figure 2.2d). This implies that no significant structural 
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reorganization of PPE occurred upon HA complexation, supporting that the semiflexibility of PPB is 
responsible for the significant spectral changes upon ionic complexation. 
 
Figure 2.2 Absorbance and emission spectra of semi-flexible PPB (a, b) and rigid PPE (c, d) before and after 
HA complexation. A sharp absorption peak at 474 nm (a) and decreased emission intensity of the semi-
flexible PPB after HA complexation supports the formation of ordered aggregation among the semi-flexible 
conjugated backbones. No significant changes were observed upon HA complexation of the control PPE (c, 
d). 
While the hydrodynamic radius of the semi-flexible PPB at the low concentration (10 μM) could not be 
determined due to insufficient scattering intensity from the loose aggregations, the ionic complexes produced 
strong light scattering, implying the formation of dense particles. The hydrodynamic radius of the semi-
flexible PPB/HA complex was successfully determined to be 51.35 ± 0.77 nm. Zeta potential value of the 
semi-flexible PPB/HA nanoparticles in water at neutral pH was −25.5 ± 11.7 mV (Supporting Information 
Figure S2.1). The hydrodynamic radius of the control PPE/HA complex was determined to be 79.49 ± 0.18 
nm, with a zeta potential of −32.6 ± 5.6 mV (Figure S2.2). The control PPE/HA was almost 30 nm larger 
than the semi-flexible PPB/HA, implying that more loosely aggregated particles were formed. 
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Atomic force microscopic (AFM) imaging of the semi-flexible PPB/HA nanoparticle supported the formation 
of elongated core−shell nanoparticles with average size of 58 ± 13 nm (by measuring lateral sizes), as shown 
in Figure 2.3c, while the semi-flexible PPB without HA complexation exhibited mixed particles with no 
specific shapes (Figure 2.3a). AFM phase image also showed that core−shell particles were favorably formed 
at a molar ratio of 1:3 of the semi-flexible PPB to HA. Both at the lower and higher ratios, no defined 
core−shell nanoparticles were observed (Figure 2.4a). Higher density (represented as dark color) was 
observed in the center of the nanoparticles, while lower density (bright color) was observed in the shell. Since 
the particles were prepared on an aminosilanized mica surface, it is difficult to determine the shape and size 
of the intact nanoparticles in water by the AFM imaging. The AFM images are believed to be flattened during 
the sample preparation determined by the height analysis (Figure 2.4b). The topographic and phase images 
of the control PPE/HA show circular particles with no core−shell shape, with an average size and height of 
81 ± 9 and 4 ± 0.5 nm, respectively (Figure S2.3). The AFM imaging of the control PPE/HA further supports 
that HA does not cause structural reorganization of rigid rod CPs.  
 
Figure 2.3. AFM topographic (a, c) and phase (b, d) images of the semi-flexible PPB (a, b) and semi-flexible 
PPB/HA nanoparticles formed at 1:3 molar ratio (c, d). The semi-flexible PPB/HA exhibits elongated 
particles on a mica surface (c), and the phase image (d) reveals that the complexes are core−shell 
nanoparticles. 
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Figure 2.4. Topography and phase images (a) and size analysis histograms (b) of semi-flexible PPB, semi-
flexible PPB/HA (1:1), and semi-flexible PPB/HA (1:3), respectively.  
 
Cancer cell specificity of the core−shell nanoparticle was examined by incubating various cells including 
cancer and normal cells with the core−shell nanoparticles for different times, and the normalized mean 
fluorescent intensity ratios to the control cells were plotted by analyzing flow cytometry data (Figure 2.5). 
As shown in Figure 2.5, cancer cells overexpressing CD44 [i.e., human cervical carcinoma (HeLa) and 
human pancreatic carcinoma cell lines (Panc-1)] exhibited an intensity increase as the incubation time 
increased, while normal human embryonic kidney cells (HEK) and cancer cells with low CD44 expression 
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exhibited low fluorescent intensity over the incubation times. The labeling specificity coincided well with 
the CD44 expression levels, which were measured by incubating fluorescently labeled antibody against CD44 
with various cells (inset of Figure 4). As expected, the core−shell nanoparticles exhibit no toxicity measured 
by ATP consumption of the treated cells (Figure S2.4).  
 
Figure 2.5. Normalized fluorescent mean intensity ratios of various cells treated with the semi-flexible 
PPB/HA (1:3) up to 3 h. Cancer cells overexpressed CD44 (inset) exhibit higher fluorescent intensities than 
those from cells with low CD44 expression, supporting specific labeling of cancer cells via HA−CD44 
interaction. 
 
The specific labeling of cancer cells by the core−shell particles was further confirmed by fluorescence 
microscopic imaging of cancer cells co-cultured with normal HEK cells. Before co-culturing, HeLa cells 
were pre-labeled with a fluorescent dye (CellTracker Red) to fluorescently distinguish the cancer cells from 
normal cells. It is known that some fluorescent dyes have poor retention in the cell and can readily diffuse 
through the cell membrane. CellTracker Red was used because it is converted into an impermeable dye by 
forming covalent bonds inside cells. After incubating the cells for 1 h, the cells were rinsed, stained (for 
labeling of nucleus), and fixed for microscopic imaging. Because the cancer cells possibly influence the 
normal cell growth, each cell line was independently cultured and incubated with the core−shell nanoparticles 
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under the same incubation condition. As shown in Figure 2.6, strong green fluorescent signals were observed 
as scattered dots throughout the HeLa cells (pre-labeled with a red fluorescent dye), while much weaker 
green signals were observed from the normal HEK cells, indicating that the core−shell nanoparticles 
preferentially labeled HeLa cells through the specific HA−CD44 binding followed by endocytosis. For the 
control cells cultured independently, HeLa cells exhibited many green fluorescent dots throughout the cytosol 
(Figure 2.6, row 3), while the number and intensity of green dots observed from HEK were significantly low 
(Figure 2.6, row 2). 
 
Figure 2.6. Fluorescent microscopic (b−d) and contrast (a) images of HeLa/HEK mixed cells (1), HEK cells 
(2), and HeLa cells (3) incubated with the semi-flexible PPB/HA for 1 h. HeLa cells were fluorescently pre-
labeled with a red dye (column c) before the core−shell nanoparticle incubation. Core−shell nanoparticles 
were seen under the green channel (column b); the nuclei were stained with a blue dye; and merged images 
were seen in column d. The core−shell nanoparticles preferentially labeled HeLa cells while exhibiting low 
binding to normal HEK cell. 
2.4 Conclusion 
In summary, core−shell nanoparticles were fabricated by complexing a semi-flexible PPB with a linear 
polysaccharide, HA. The resulting fluorescent core−shell nanoparticles exhibited high cancer cell specificity 
with low adsorption to normal cells. Since the size and shape of nanomaterials significantly influence labeling 
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and delivery efficiency of biological substances, the concept of core−shell nanoparticle formation through 
controlled aggregation introduced in this work will contribute to novel biomaterials syntheses and 
fabrications. 
2.5 Outlook 
This chapter presents a strategy for modulating particle shape using ionic complexation in a backbone 
flexibility-dependent fashion. Since the publication of this work in Macromolecules, a systematic 
investigation on ionic complexation of CPNs that vary by side chain and backbone structure was performed 
(detailed in Chapter 3). The subcellular localization of amine-containing CPNs, including PPE and PPB-
based, demonstrated side chain and backbone-dependent cellular uptake.32 The semi-flexible PPB polymer 
showed increased Golgi uptake, compared to non-flexible amine-containing CPNs. The semi-flexible CPN 
also showed improved uptake and accumulation, demonstrating that controlled subcellular localization leads 
to enhanced internalization. The cellular uptake subcellular localization of the semi-flexible CPN complexed 
with HA and a similar polyanion, carboxymethyl cellulose (CMC), was explored. While in this chapter, the 
semi-flexible CPN displayed enhanced targeting of cancer cells over normal cells, there was no significant 
increase in internalization of the polyplexes with HA and CMC. Complexation of the semi-flexible CPN with 
HA and CMC led to increased accumulation in late endosome/lysosome as expected based on the dramatic 
changes from spherical to core-sell particles. While HA complexation leads to increased labelling of cancer 
cells, a strategy to improve targeting and increase internalization of CPNs is needed. A dual ligand approach 
for targeting of folate and hyaluronan receptors is detailed in Chapter 5. 
2.6 Experimental 
Atomic force microscopy (AFM) experiments and analysis were performed by Namuna Panday. Toxicity 
assays and flow cytometry experiments were performed by Yoonmi Na. Microscope imaging and processing 
was completed by Dr. Eladio Mendez. 
2.6.1  General: Chemicals and solvents were purchased from Fisher Scientific and used as received. 
Deuterated solvents were purchased from Cambridge Isotope Laboratories (Cambridge, MA). Molecular 
weight was determined using gel permeation chromatography (GPC) against polystyrene standards on a 
Shimadzu HPLC system equipped with PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet-visible 
29 
(UV-vis) detector. The purification of the CPN was conducted using an Ultrafiltration Stirred Cell (Millipore) 
with a 30 kDa molecular weight cut-off (MWCO) membrane (Ultracel ultrafiltration disc). UV-Vis spectrum 
was recorded using Varian Cary 50 Bio spectrophotometer. Fluorescence spectrum was obtained using a 
FluoroLog-3 Spectrofluorometer (Jobin Yvon/Horiba).  NMR spectrum was recorded on a 600 MHz Avance 
Bruker NMR spectrometer using a 5 mm BBI probe at 298 K. Fourier transform infrared (FT-IR) spectrum 
was obtained on a PerkinElmer Spectrum 100 FT-IR Spectrometer, using sample mounted on an attenuated 
total reflection cell.  
2.6.2 Synthesis of control PPE without flexible linker: A Schlenk ﬂask was charged with M1 (41mg, 
0.056, 1.0 equiv) and M2 (30 mg, 0.056 mmol, 1.0 eqiv) and, along with Pd[(PPh3)2Cl2] (4 mg, 0.0056 mmol 
,0.1 equiv) and CuI (0.3 mg, 0.0028 mmol , 0.05 equiv), as shown in Scheme S2.1. 
Scheme S2.1. Synthesis of control PPE without flexible linker. 
 
The Schlenk ﬂask was evacuated and ﬁlled with N2 three times. A solution of anhydrous dimethylformamide 
(DMF) (4 mL) and freshly distilled triethylamine (1 mL) was degassed, and 1 mL of the mixed solution was 
transferred to the Schlenk ﬂask using a cannular needle. The reaction was heated at 70 °C for 14 h. The 
solution was then cooled to room temperature and transferred dropwise to cold ether, resulting in 
precipitation. After centrifugation (5 min, 4000 rpm), the supernatant was decanted, the precipitate was 
collected and dried to yield product. Yield: 44mg, 73%. 1H NMR (400 MHz, DMSO-d6, δ): 7.16 (s, 1H, Ar-
H), 6.72 (s, 0.2H, NH-Boc), 4.21 (br, 1.84H, Ar-OCH2), 3.80 (br, 2.16H, CH2O), 3.66 (br, 1.34H, OCH2), 
3.52 (br, 2.22H, CH2NH), 1.37 (s, 7.33H, C(CH3)3); FT-IR (Neat): ν = 3366 (br), 2933 (w), 2865 (s), 1704 
(vs; C=O), 1507 (vs), 1457 (w), 1423 (w), 1365 (s), 1277 (w), 1247 (w), 1219 (s), 1172 (w), 1108 (s), 1057 
(s), 1026 (w), 945 (s), 860 cm−1  (m); UV-vis (DMF): λmax 432 nm; ﬂuo λmax(400nm ex) =475 nm; QY = 
37%; GPC Mn: 11.6 kDa, Mw: 16.4 kDa , PDI: 1.41. 
Deprotection of Boc groups was carried out by mixing the polymer solution with acetic acid (2 mL) and 
triﬂuoroacetic acid (1 mL) and allowed to stir at room temperature for 14 days. The mixture was then added 
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to acetic acid (20 mL), allowed to stir overnight, and centrifuged, and supernatant was added drop wise (2 
drops/s) to 500 mL water (18 Ω) while stirring. Using a solvent-resistant stir cell ﬁtted with a 30 kDa-MWCO 
membrane, the solution was concentrated to approximately 10 mL, and dialyzed against 1 L of water. The 
resulting solution was further dialyzed in a 10 KDa membrane for 3 days. 1H NMR (600 MHz, D2O, δ): 7.03 
(br, 1H, Ar-H), 4.24-2.76 (br, 10.74H, CH2CH2OCH2CH2), 1.36 (s, 0.46H); FT-IR (Neat): ν = 3417 (br), 
2925 (w), 2865 (s), 1647 (br), 1495 (w), 1462 (w), 1418 (w), 1357 (w), 1283 (w), 1205 (s), 1094 (s), 1040 
(w), 936 (w), 841 (w) cm−1 ; UV-vis (H2O): λmax 427 nm; ﬂuo λmax(400nm ex) =492 nm; QY = 2%. 
2.6.3 CP/HA complex formation: Sodium hyaluronate (MW 100 K) was purchased from Lifecore and used 
as received. A stock solution was prepared by dissolving 2 mg of HA in 1 mL of deionized water. The CP/HA 
complex was formed by mixing CP (10 µM) with various molar equivalents of HA (i.e., 1:1, 1:3, and 1:9) 
for 1 h. 
2.6.4 Dynamic Light Scattering: Dynamic light scattering and zeta potential experiments were performed 
by Zetasizer nano–ZS (Zen 3600, Malvern Instruments Ltd.) using a microcuvette and a folded capillary cell 
(Catalog # DTS1060), respectively, at room temperature.  At least three independent samples were prepared 
and each sample was measured three times. 
2.6.5 Atomic Force Microscopy: (3-aminopropyl)triethoxysilane (APTES) was vapor deposited to a freshly 
cleaved mica surface for 80 min in a desiccator filled with dry Argon. 30 μL of CP/HA complex in DI water 
was placed on the APTES coated mica and incubated for 30-45 min in a laminar flow hood. The droplet was 
then rinsed away with ~1mL DI water (18 M ohm) and dried gently with dry Argon. Images were acquired 
with a MultiMode5 AFM microscope (Bruker, Santa Barbara, CA) operated in tapping mode in air using a 
1.58-1.62 V oscillation amplitude with uncoated silicon AFM tips (T190, vistaprobes, k ~ 40N/m) at a 
resonance frequency of 190 kHz. Typically, areas of 1 × 1 μm2 were scanned at a rate of 0.5-1 Hz and a 
resolution of 512 × 512 pixels. All the experiments were performed at room temperature. The images were 
further processed by Image Analysis Software Gwyddion. 
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Figure S2.1. DLS (top) and zeta potential (bottom) of the semi-flexible PPB/HA complex. Hydrodynamic 
radius was measured with three replicates and zeta potential was measured with six replicates. 
 
Figure S2.2. DLS (top) and zeta potential (bottom) of the control PPE/HA complex. Hydrodynamic radius 
was measured with three replicates and zeta potential was measured with six replicates. 
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Figure S2.3. Topography (a) and (b) phase images, size distribution (c), and height (d) histograms for control 
PPE/HA. 
 
 
2.6.6 Cell Culture: Human Embryonic Kidney (HEK) and human pancreatic cancer (Panc-1) cells were 
maintained in DMEM (Hyclone, Logan, UT). Human cervical cancer (HeLa) and human breast cancer 
(MCF7) cells were maintained in MEM/EBSS (Hyclone, Logan, UT). Both media contain 10% FBS 
(Hyclone, Logan, UT) and 100 U/ml penicillin. All cells were incubated in a 5% CO2 incubator at 37 °C. 
Cells were seeded in a 12 well-plate and allowed to attach overnight (1 x 105) before incubation with core-
shell nanoparticles for the time course experiments.  
2.6.7 Cytotoxicity: CellTiter-Glo® Luminescent Cell Viability assay (Promega, Madison, WI) was used to 
determine the cytotoxicity of the core-shell nanoparticles. HeLa cells (~5x103 cells/well) were seeded into a 
96 well-plate for 1 day. The cells were then incubated with various concentrations of the core-shell 
nanoparticle for 24 h. After the core-shell nanoparticle incubation and following the manufacturer's protocol 
100 μL of CellTiter-Glo reagent was added to each well and the plate was incubated for 2 minutes. Cell 
viability was monitored by measuring luminescence values of each well using a microplate well reader with 
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a 528/20 emission filter (Synergy 2, BioTek, USA).  Relative cell viability as a function of the core-shell 
nanoparticle concentration was obtained by dividing the luminescence value of each sample by the control 
value. All measurements were triplicated and standard deviation was included in the error bar. 
 
Figure S2.4. Cytotoxicity of the core-shell nanoparticles measured by CellTiter-Glo® Luminescent Cell 
Viability assay. No toxic effects of were observed under the experimental conditions. 
2.6.8 Flow Cytometry: AccuriTM C6 Flow Cytometer (BD Biosciences, San Jose, CA) equipped with a 
fluorescence detector was used to analyze the fluorescence intensity of cells incubated with the core-shell 
nanoparticles. After incubation, cells were rinsed with PBS 2 times followed by centrifugation (Eppendorf 
Centrifuge 5430 R) at 1,000 relative centrifugal force (rcf) for 7 min and resuspension in 400 μL FACS 
buffer. The mean fluorescent intensity of cells treated with the core-shell nanoparticles was normalized to 
that of untreated control cells. All measurements were triplicated and standard deviation was included in the 
error bar. For each measurement, 10,000 events were recorded and analyzed. 
2.6.9 Evaluation of CD44 expression levels: Cells were seeded in an appropriate medium at a density of 1 
x 105 cells/ml in a 12-well plate and cultured for overnight. Each cell line was incubated with FITC-labeled 
mouse anti-human CD44 (BD Pharmingen, San Diego, CA) for 30 min at 4 °C, according to the protocol 
provided by the manufacturer. The cells were washed three times with cold PBS and resuspended in 400 μL 
FACS buffer for flow cytometry. 
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2.6.10 Microscopic imaging of mixed HeLa and HEK cells: To distinguish HeLa cells co-cultured with 
HEK cells, HeLa cells were pre-labeled with the CellTrackerTM Red CMPTX (Invitrogen, Grand Island, NY) 
before co-culturing with HEK cells. 1.75 μM of CellTracker Red was incubated with HeLa cells in a 12-well 
plate (1 x 105 cells/ml) for 30 min at 37 °C. After replacing the labeling solution with a fresh medium (~1 
ml), the cells were further incubated for 30 min at 37 °C. The HeLa cells labeled with CellTracker were then 
trypsinized, washed, and re-suspended in 500 µL of culture medium.  Equal amounts (1 x 105 cells/ml) of 
both HeLa and HEK cells were mixed in DMEM medium (400 µL) containing 10% fetal bovine serum (FBS) 
and 100 U/mL penicillin, and seeded in a glass-bottomed eight-well chamber slide (Lab-Tek, Thermo 
Scientific). After overnight co-culture, cells were incubated with core-shell nanoparticles (final 10 µM) for 
1 h. The cells were rinsed with PBS and were incubated with a Hoechst dye (5 μg/μL) (Invitrogen, Grand 
Island, NY) for 10min. Finally the cells were fixed with 4% paraformaldehyde in PBS for 10 min at room 
temperature. Fluorescence images of the cells were obtained using a DeltaVison microscope equipped with 
40x lens. Band-pass filters were used for imaging nucleus (410-460 nm), core-shell nanoparticles (500-550 
nm), and CellTracker Red (575-620 nm). 
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3.1 Abstract 
Four different conjugated polymer nanoparticles (CPNs) were used to differentiate structurally similar 
glycosaminoglycans (GAGs) in a urine simulant. Unique emission response patterns of CPNs were analyzed 
by linear discriminant analysis (LDA), confirming that structurally diverse CPNs are sensitive and effective 
at differentiating GAGs in a complex biological medium. 
3.2 Introduction 
Changes in urinary glycosaminoglycan (GAG) levels can signify proliferation of several diseases including 
kidney and bladder disorders, polysaccharide storage diseases, and certain cancers.1-4 However, detection or 
differentiation of GAGs in a biological medium has been challenged by the structural similarity of GAGs 
and interferences of the concomitant biomolecules commonly present in biological fluids. Conventional 
GAG detection methods require sample preparation steps followed by complicated instrumental analysis or 
biochemical assays.5-9 Recently, several researchers have developed conceptually important detection 
methods on the basis of pattern recognition using nanoparticles, conjugated polyelectrolytes, and 
liposomes.10-14 In those examples, differentiation of GAGs was demonstrated by using multivariate statistical 
methods including linear discriminant analysis (LDA). While current sensory systems perform well in a 
simplified solution (i.e., highly diluted media with buffers), few sensory systems have been reported for 
sensitive detection of GAGs in complicated biological fluids. Development of simple and sensitive sensory 
systems of GAGs in biological media is highly important and practical for future disease diagnostics. 
Owing to their excellent photophysical properties, conjugated polymers (CPs) have attracted much attention 
for optical detection of chemicals, metal ions, and biological substances.15-18 Many synthetic and fabrication 
methods have been developed to increase aqueous compatibility of CPs to achieve necessary sensitivity for 
specific analytes in aqueous environments.19 Depending on the aqueous solubility of CPs and the nature of 
interaction between CPs and analytes, structural changes can occur in individual CP chains or multiple chain 
aggregates, which correspond to changes in CP optical properties.20,21 
Previously, positively charged conjugated polymer nanoparticles (CPNs) were fabricated by treating a non-
aqueous soluble, primary amine-containing CP [i.e., poly(p-phenyleneethynylene) (PPE)] with organic acids 
followed by dialysis.22 The aggregation structures and sizes of CPNs were dependent on the nature of organic 
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acid treatment. Furthermore, it was found that CPNs fabricated with a semi-flexible CP [i.e., a flexible linker 
containing poly(p-phenylenebutadiynylene) (PPB)] exhibited backbone reorganization to maximize 
hydrophobic chain interaction when treated with an anionic linear polysaccharide, hyaluronic acid (HA).23,24 
The structural reorganization of CPNs was evident by photophysical changes including a new sharp 
absorption peak at longer wavelength and decreased fluorescence intensity. The physical change was 
observed as an elongated particle shape shown in atomic force microscopic images. 
From these observations, it was hypothesized that the aggregation status of cationic CPNs will be different 
upon interaction with GAGs due to the differences in ionic strength of the GAGs exhibiting different degrees 
of acetylation and sulfonation in the repeating disaccharide units (see Figure 3.1). While the hydrophobic 
interaction among non-aqueous soluble CPs provides the structural integrity of CPNs in a biological medium, 
the loosely aggregated CPNs will undergo backbone reorganization under polyelectrolyte interactions with 
GAGs. Depending on the strength of ionic interactions, the aggregation properties of CPNs will change 
accordingly, resulting in measurable spectral changes. 
 
Figure 3.1. Chemical structures of glycosaminoglycans. 
 
In this chapter, four different CPNs were used that act as both analyte receptors and signal transducers, and 
analyzed their differential responses to each GAG in a urine simulant. A systematic investigation of the 
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aggregation properties of CPNs that vary by side chain amine density, backbone flexibility, and type of 
backbone structure in response to GAGs was conducted by monitoring changes in absorption/emission 
profiles and size/size distributions. Finally, entire spectral responses of the structurally diverse CPNs were 
analyzed by LDA to differentiate structurally similar GAGs at a physiologically relevant concentration25 in 
a urine simulant. Side chain and backbone flexibility strongly affects both the physical and photophysical 
properties of CPN/GAG complexes. A clear differentiation of recognition patterns was observed in a LDA 
plot, supporting that structurally diverse CPNs are effective at differentiating GAGs in a complex biological 
medium. 
3.3 Results and Discussion 
Four CPs having different side chain and backbone structures (Figure 3.2) were used to obtain an array of 
CPNs with different aggregation natures. P1 was designed to compare a short ethylene oxide (EO) and 
primary amine [after removal of N-tert-butoxycarbonyl (Boc) group] per repeating unit, to the side chains of 
P2 with a higher amine density by replacing the EO side chain with a guanidinium group. P3 was designed 
to increase backbone flexibility by introducing a non-conjugated, flexible moiety in the conjugated 
phenyleneethynylene (PE) backbone, while maintaining the fluorescent nature and the side chain 
functionality of P1. Lastly, P4 was used because the flexible phenylenebutadiynylene (PB) backbone induces 
higher backbone aggregation than the structurally similar PE analogues. 
 
Figure 3.2. Chemical structures of CPs with different side chains (P1 and P2), PPE with flexible backbone 
(P3), and PPB with flexible backbone (P4). 
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The cationic CPNs were fabricated using our previously published method,23 in which the corresponding P1-
P4 were treated with trifluoroacetic and acetic acid followed by dialysis. The resulting nanoparticles in water 
were homogeneous yellow solutions, and the key characteristic properties are summarized in Table 3.1. 
Table 3.1. Key photophysical and physical properties of CPNs. 
CPN CP Mna 
(kDa) 
λmax, absb 
(nm) 
λmax, emc 
(nm) 
Hydrodynamic 
diameterd (nm) 
Zeta potentiale 
(mV) 
1 P1 17,457 417 482 140 ± 0.9 + 40 ± 1.3 
2 P2 14,079 411 479 179 ± 6.3 + 54 ± 3.1 
3 P3 14,489 422 464 117 ± 10.1 + 48 ± 2.9 
4 P4 35,907 444 466 134 ± 8.1 + 30 ± 1.7 
aDetermined by gel permeation chromatography in tetrahydrofuran (THF) relative to polystyrene 
standard. bMeasured in water. cExcited at 400 nm. dMeasured by single particle tracking analysis at 25°C in 
water. Mean values ± standard deviation. eElectrophoretic measurement in water at pH 7. Mean value ± 
standard deviation. 
 
The hydrodynamic diameters of CPNs were measured using nanoparticle tracking analysis (NTA), which 
tracks the Brownian motion of each particle to accurately calculate the hydrodynamic diameter of particles 
with size distributions.26 The hydrodynamic diameters of CPNs ranged from ~120 to ~180 nm in water. The 
relatively larger diameter of CPN-2 can be attributed to the hydrophilic nature of side chains, which form 
aggregates of more solvated chains. Upon complexation, diameters of CPNs changed as aggregation 
properties of CPNs were affected by GAGs with different ionic strengths. As shown in Figure 3.3, CPN-2 
showed decreased sizes upon complexation, while the rest of the CPNs exhibited increased sizes. The loosely 
aggregated, more solvated P2 chains are believed to form compact and smaller complexes with GAGs (see 
Figure 3.4). Increased sizes observed from the rest of the CPNs were likely due to the formation of 
hydrophilic GAG shells on CPNs. Among them, CPN-4 showed the largest diameter increase, confirming 
that the ionic interaction induces further CP chain aggregation due to the nature of PPB backbone with 
flexibility. A complete summary of NTA results are given in Table S3.1. 
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Figure 3.3. Average hydrodynamic diameters of CPN-1 (black square), CPN-2 (red circle), CPN-3 (blue 
triangle point up), and CPN-4 (green triangle point down) upon complexation with hyaluronic acid (HA), 
chondroitin sulfate (CS), dermatan sulfate (DS), and heparin sulfate (HS), respectively, measured by NTA in 
triplicate. 
 
Figure 3.4. Average size distributions of CPNs complexed with GAGs measured by NTA. 
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The absorption and fluorescent profiles support the NTA data. GAGs induce changes in the aggregation 
structures as evidenced by red shifts in absorption and decreased fluorescent intensity in emission spectra for 
all CPNs (Figure 3.5). As expected, CPN-4 displayed dramatic changes in both absorption and emission 
profiles due to extensive chain reorganization. CPN-3, which also has flexible linkers along the PPE 
backbone, displayed relatively small changes in the absorption, implying that the chemical backbone 
structure of the CP is an important contributor for chain reorganization. The structurally similar GAGs also 
interact differently with CPNs with structural diversity. The carboxylated HA induced higher absorption 
shifts compared to the sulfonated GAGs, although the effects were somewhat minimal, with the exception of 
CPN-4. Due to the relatively weak ionic strength of carboxylic acid, compared to sulfonic acid, HA is 
believed to form outer shell layers by contributing to increase π -π interaction among CPs. Meanwhile, GAGs 
with sulfonic acids interact strongly with CPs, especially with CP chains of low molecular weights, resulting 
in more solvated random complexes. As expected, the emission profiles of all CPNs were unique and 
different upon complexation with GAGs; These spectral changes can then be used for differentiation of 
GAGs. Hierarchical cluster analysis (HCA) of emission profiles show that the sulfonated GAGs cluster 
together, indicating that there is differentiation based on functional group (see Figure 3.6). For simplicity, 
one CPN emission data set in water (triplicate samples) was used for HCA to demonstrate role of functional 
group in differentiation. The most structurally similar chondroitin sulfate (CS) and dermatan sulfate (DS) 
form the closest cluster, and the most structurally different hyaluronic acid (HA) and heparin sulfate (HS) 
form the furthest cluster. 
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Figure 3.5. Effect of GAG complexation on absorption (left column) and emission (right column) for CPN-
1 (first row), CPN-2 (second row), CPN-3 (third row), and CPN-4 (fourth row) in water. Optical density of 
CPNs was fixed at 0.1. 
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Figure 3.6. Hierarchical cluster analysis (HCA) of CPN-2+GAGs in water. 
 
The differentiation ability of CPNs in a complex aqueous medium was verified using LDA of fluorescence 
spectral responses of CPNs to GAGs. This method can be used to establish a pattern for a "chemical nose" 
type array sensor,27 which relies on a differential response of the receptor (i.e., CPN) to the analyte (i.e., 
GAG). After adding CPNs to the GAG solution (100 nM) in a commercially available urine simulant, 
emission spectra (see Figure 3.7) of complexes were recorded and used for LDA. The ratios of fluorescent 
intensity were analysed using the statistical software JMP® (version 11). The LDA plot depicting the first 
two canonicals is shown in Figure 3.8. A summary of canonical scores can be found in Table S3.2. There is 
a clear separation among the GAGs, with no overlap of groups with a 95% confidence limit. Three canonical 
correlations account for 71.1, 16.7, and 12.2% of the variation, occupying 100% of the total variation between 
the groups, indicating that GAG differentiation is maximized. Traditional discriminant functions correctly 
predict 100% of group classification, based on their squared distances to each group centroid (Table S3.3). 
These results confirm that loosely aggregated CPNs can undergo structural reorganization in the presence of 
strong polyelectrolytes in a complex biological medium due to the hydrophobic CP backbone that provides 
the necessary structural integrity to resist interference from environmental factors. 
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Figure 3.7. Emission spectra of CPN-1 (a), CPN-2 (b), CPN-3 (c), and CPN-4 (d) in the presence of GAG-
containing urine simulant. Excitation wavelength for all CPNs was 450 nm with 5 nm slit widths, and 0.5 s 
integration time. 
 
 
Figure 3.8. An LDA plot between two largest canonical correlations of emission intensity ratios of CPNs 
with and without GAGs (100 nM) in a urine simulant. HA in black, HS in red, CS in blue, and DS in green, 
with (+) marking the centroid of each group. 
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3.4 Conclusion 
In summary, a systematic investigation is reported on the aggregation properties of CPNs that vary by side 
chain and backbone structures in response to GAGs by observing changes in absorption/emission profiles 
and complex size/size distributions. This investigation demonstrated that side chain and backbone flexibility 
strongly affect the photophysical and physical properties of CPN/GAG complex. Four CPNs and their 
differential responses to each GAG were analyzed using the LDA method to demonstrate that structurally 
diverse CPNs differentiate GAGs in a complex biological medium. The structure-function relationships 
obtained from this work will lead to further improvements in designing functional polymers for sensing 
biological and biomedical substances. 
3.5 Outlook 
This chapter presented a simple approach to differential sensing of biologically important molecules. A 
systematic approach to understanding the effect of side chain and backbone structure was employed to 
establish a structure-function relationship. To improve differential sensing, an array of more structurally 
diverse CPNs could be utilized, which would lead to more dramatic differential interactions of CPNs and 
analytes. Since publication of this work in Chemical Communications, controlled incorporation of homo-
coupled benzothiadiazole (HBT) blocks into the conjugated polymer backbone has been explored. The HBT 
blocks provide an electron-accepting moiety in the backbone, which modulates the CP’s electronic properties 
towards red emission. By developing a more structural diverse array, the sensitivity can be greatly improved. 
The unique signal amplification of CPNs, where any interaction that occurs along the conjugated backbone 
causes a perturbation in the electron transport that will affect the entire system, makes CPN-based sensors an 
ideal platform for improving interactions with analytes (more in section 4.5). In addition, a more systematic 
investigation of CPN structure was conducted to understand the polyanion complexation behavior.29 A series 
of four conjugated polyelectrolytes (CPEs) with PPE and PPB-type connectivity and incorporation of a 
flexible, non-conjugated linker were prepared and displayed backbone-dependent complexation with HA. 
Cellular uptake and subcellular localization studies of these CPEs would provide more information how 
exactly backbone connectivity affects cellular interactions. 
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3.6 Experimental 
3.6.1 General.  
Chemicals and solvents were purchased from Fisher Scientific and used as received. Deuterated solvents 
were purchased from Cambridge Isotope Laboratories (Cambridge, MA). Molecular weights were 
determined using gel permeation chromatography (GPC) against polystyrene standards on a Shimadzu high 
performance liquid chromatography (HPLC) system equipped with PLgel 5 μm MIXED-D columns and 
SPD-20A ultraviolet-visible (UV-vis) detector a flow rate of 1.0 mL/min. UV-Vis spectra were recorded 
using Varian Cary 50 Bio spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3 
Spectrofluorometer (Jobin Yvon/Horiba). Quantum yields (QYs) were determined using  
9,10-diphenylanthracene (QY= 0.9) in cyclohexane as a fluorescence standard.  Fourier transform infrared 
(FT-IR) spectra were recorded on a PerkinElmer Spectrum 100 FT-IR Spectrometer. Fine powders from 
lyophilized samples were directly mounted on an attenuated total reflection (ATR) cell of the spectrometer. 
The purification of the CPNs was conducted using an Ultrafiltration Stirred Cell (Millipore) with a 10 kDa 
molecular weight cut-off (MWCO) membrane (Ultracel ultrafiltration disc). Nuclear magnetic resonance 
(NMR) spectra for the conjugated polymers (CPs) were recorded on a 400 MHz Avance Bruker NMR 
spectrometer. Chemical shifts were reported in parts per million (ppm) for 1H NMR on the δ scale based on 
the middle peak (δ = 2.50 ppm) of the dimethylsulfoxide (DMSO)-d6 solvent as an internal standard. NMR 
spectra for the conjugated polymer nanoparticles (CPNs) were recorded on a 600 MHz Avance Bruker NMR 
spectrometer using a 5 mm BBI probe at 298 K. The 600 MHz NMR spectrometer is equipped with a gradient 
system capable of producing magnetic field pulse gradients in the z‐direction of about 50 G cm‐1 and allowing 
for water peak suppression [δ = 4.79 ppm in deuterium oxide (D2O)]. Chemical shifts were reported in parts 
per million (ppm) for 1H NMR on the δ scale based on the middle peak (δ = 4.79 ppm) of D2O solvent as an 
internal standard. Graphs were plotted using Origin 9.1 software (OriginLab, Northampton, MA, USA). 
3.6.2 Polymer synthesis general procedure.  
A Schlenk flask was charged with aryl halide monomer (1.0 equiv) and diacetylene monomer (1.0 equiv for 
P2, 0.9 equiv for P3), and cystine linker when applicable (0.1 equiv for P3) along with Pd[(PPh3)2Cl2] (0.1 
equiv) and CuI (0.05 equiv). The Schlenk flask was evacuated and filled with N2 three times. A solution of 
48 
anhydrous dimethylformamide (DMF) (3 mL) and morpholine (1 mL) was degassed, and 2 mL of the mixed 
solution was transferred to the Schlenk flask using a cannular needle. The reaction mixture was heated at 50 
°C for 18 h. The solution was then cooled to room temperature and transferred dropwise to cold ethyl ether, 
resulting in precipitation. After centrifugation (5 min, 4000 rpm), the supernatant was decanted, and the 
precipitate was redissolved in DMF (1 mL). The resulting polymer was characterized using GPC by diluting 
an aliquot of polymer solution in 1 mL of HPLC grade tetrahydrofuran (THF) and filtered through 0.45 μm 
polytetrafluoroethylene (PTFE) syringe filter prior to injection. The absorption and emission profiles were 
measured in a 10 mm quartz cuvette (2 mL) using a diluted aliquot of the polymer solution in DMF. The 
material was then reprecipitated in pure ether, the supernatant was decanted, and the precipitate was purified 
two more times. The precipitated polymer was allowed to dry under high vacuum for 4 hours prior to FT-IR 
and 1H NMR characterization. 
3.6.3 CPN fabrication.  
Boc‐deprotection of the polymer was carried out by adding the polymer solution in DMSO-d6 to a stirred 
mixture of trifluoroacetic acid (2 mL) and acetic acid (2 mL) and allowed to stir at room temperature for 2 
days. The mixture was then diluted by addition of acetic acid (10 mL), and added dropwise (2 drops/s) to 500 
mL water (18 Ω) while stirring. Using a solvent-resistant stir cell fitted with a 10 kDa-MWCO membrane, 
the solution was concentrated to approximately 10 mL, and dialyzed against 2 L of water. The solution was 
subsequently filtered through a cellulose syringe filter (0.45 µm), characterized, and stored for future use. 
P1: Detailed monomer and polymer synthesis, CPN fabrication and characterization is described elsewhere.28 
P2: Detailed monomer synthesis and characterization of monomers A and B1 is described elsewhere.28,29 
Using the general procedure described above, the polymerization of monomer A (7.8 mg, 0.0147 mmol) and 
monomer B1 (15.0 mg, 0.0147 mmol) in the presence of Pd[(PPh3)2Cl2] (1.4 mg, 0.00147 mmol) and CuI 
(0.1 mg, 0.000735 mmol) yielded P2 (11.5 mg, 0.00866 mmol, 58.9%), see scheme S3.1. CPN fabrication 
was carried out as described in the general procedure to yield CPN-2, see scheme S3.2. 
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Scheme S3.1. Synthetic route to P2. 
 
P2: 1H NMR (400 MHz, DMSO-d6): δ 13.19 (s, 0.15H), 12.38 (s, 1.18H), 9.00 (s, 0.15H), 8.19 (s, 1.16 H), 
7.11 (d, 2.07H), 6.70 (s, 1.23), 4.17 (br m, 4.39H), 3.85-3.76 (br m, 7.09H), 3.56-3.45 (br m, 13.5 H), 3.08 
(s, 2.88H), 1.44-1.34 (d, 27.0 H).  FT-IR (neat): 3351, 2973, 2965, 2928, 2256, 1709, 1630, 1583, 1505, 
1455, 1411, 1366, 1301, 1273, 1245, 1146, 1113, 1050, 1023 cm-1. GPC: Mw = 23,618 Da, Mn = 14,079 Da, 
PDI = 1.68. UV-Vis (DMF) λmax = 439 nm, fluo λmax (430 nm ex)  = 475 nm, QY = 20%. 
Scheme S3.2. Boc-deprotection of P2 to yield CPN-2. 
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CPN-2: 1H NMR (600 MHz, D2O, δ): 7.06 (br, 2H, Ar-H), 4.30-3.19 (br, 11.87H, CH2CH2OCH2CH2), 1.16 
(s, 0.02H); FT-IR (Neat): ν = 3310, 2863, 1560, 1419, 1359, 1301, 1273, 1199, 1110, 1053, 1020 cm-1; UV-
vis (H2O): λmax = 411 nm; ﬂuo λmax (400 nm ex) = 479 nm; QY = 0.64%. 
P3: Detailed monomer synthesis and characterization of monomers B2 and C is described elsewhere.1,2 Using 
the general procedure described above, the polymerization of monomer A (20.0 mg, 0.0375 mmol), monomer 
B2 (22.1 mg, 0.0337 mmol), and monomer C (3.2 mg, 0.00375 mmol) in the presence of Pd[(PPh3)Cl2] (2.6 
mg, 0.00375 mmol) and CuI (0.4 mg, 0.00187 mmol) yielded P3 (17.9 mg, 0.0225 mmol, 60.0%), see scheme 
S3.3. CPN fabrication was carried out as described in the general procedure to yield CPN-3, see scheme 
S3.4. 
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Scheme S3.3. Synthetic route to P3. 
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P3: 1H NMR (400 MHz, DMSO-d6): δ 8.70 (s, 0.11H), 7.71 (s, 0.10H), 7.51 (s, 0.13H), 7.16 (s, 2.10), 6.70 
(s, 1.06H), 6.39 (s, 0.12), 5.75 (s, 0.38), 4.00 (br m, 4.00H), 3.80 (br m, 4.87), 3.66 (br m, 2.27H), 3.19 (br 
m, 3.44H), 1.35 (s, 11.18 H). FT-IR (neat): 3002, 2778, 2505, 1654, 1486, 1462, 1429, 1362, 1321, 1244, 
1176, 1133, 1052, 1043 cm-1. GPC: Mw = 23,181 Da, Mn = 14,489 Da, PDI = 1.59. UV-Vis (DMF) λmax = 
439 nm, fluo λmax (400 nm ex) = 511 nm, QY = 39%. 
Scheme S3.4. Boc-deprotection of P3 to yield CPN-3.
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CPN-3: 1H NMR (600 MHz, D2O, δ): 7.00 (br, 2H, Ar-H), 4.24-3.26 (br, 17.34H, CH2CH2OCH2CH2); FT-
IR (Neat): ν = 3357, 2873, 1581, 1444, 1420, 1351, 1302, 1199, 1093, 1047 cm-1; UV-vis (H2O): λmax = 422 
nm; ﬂuo λmax (400 nm ex) = 464 nm; QY = 0.36%. 
P4: Detailed monomer and polymer synthesis, CPN fabrication and characterization is described 
elsewhere.23,28 
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3.6.4 CPN/GAG complexation.  
Sodium hyaluronate (HA) was purchased from Lifecore (MW 100 K) and used as received. A stock solution 
was prepared by dissolving 2.0 mg of HA in 1 mL of deionized water. Heparin sodium was purchased from 
Acros Organics and used as received. A stock solution was prepared by dissolving 4.0 mg of HS in 1 mL of 
deionized water. Chondroitin sulfate A (CS) and chondroitin sulfate B (dermatan sulfate, DS) were purchased 
from Sigma Aldrich and used as received. Stock solutions of CS and DS were prepared by dissolving 2.0 mg 
and 1.0 mg, respectively, in 1 mL of deionized water. CPN and GAG were mixed and allowed to incubate 
for 30 minutes prior to measurements. For consistency between the CPNs, the concentration was adjusted to 
give an optical density of 0.1, which corresponds to approximately 10 μM (based on polymer repeating unit). 
The GAG concentration used was 30 μM (based on GAG repeating unit). Samples were prepared in deionized 
water, unless otherwise stated. 
3.6.5 Determination of hydrodynamic diameters of CPNs.  
Light scattering measurements were performed with a LM10 HS (NanoSight, Amesbury, United Kingdom), 
equipped with a sCMOS camera, sample chamber with a 488 nm blue laser, and Viton fluoroelastomer o-
ring. The samples were prepared in similar manner for absorption and emission measurements using water 
(18 Ω) filtered through 0.45 μm PTFE syringe filters. The samples were injected into the sample chamber 
with 1 mL sterile syringes (Restek Corporation, Pennsylvania, USA) until the liquid reached the tip of the 
nozzle. All measurements were performed at 25°C using a LM14C temperature controller (NanoSight, 
Amesbury, United Kingdom). Each sample was measured three times. 
3.6.6 Determination of zeta potentials of CPNs.  
Dynamic light scattering measurements were performed by Zetasizer nano–ZS (Zen 3600, Malvern 
Instruments Ltd.) using a folded capillary cell (Catalog # DTS1060), at room temperature. The samples were 
prepared at approximately 0.5 mM in water (18 Ω), which was filtered through 0.45 μM PTFE syringe filter. 
Each sample was measured six times. 
 
 
 
52 
3.6.7 Hierarchical cluster analysis (HCA) of emission spectra.  
The commercially available statistical software JMP® (version 11) was used for analysis. For simplicity, one 
CPN emission data set in water (triplicate samples) was used for HCA to demonstrate role of functional group 
in differentiation. The default distance calculation method, Ward's, was used for cluster distances. 
3.6.8 CPN in synthetic urine.  
SurineTM was purchased from Dyna-Tek Industries, Inc. (product #720) and used as received. SurineTM is a 
urine simulant, with a proprietary formula, which contains creatinine and urea, and was used as media for 
CPN/GAG measurements. For the differentiation application and to simulate detection of GAGs present in 
urine, GAGs (100 nM) were mixed in SurineTM, then CPN was added to the GAG-containing urine simulant 
and allowed to incubate for 30 minutes prior to measurements.  
3.6.9 LDA of emission spectra.  
The commercially available statistical software JMP® (version 11) was used for analysis. The data included 
in the training matrix were the emission spectra ratios of CPN to CPN+GAG in urine simulant. The matrix 
training set was 4 CPNs x 4 GAGs x 3 replicates, an input of 48 data sets (spectrum ratios). The discrimination 
method used was the linear, common covariance method. 
3.6.10 Supporting data 
 
Fig. S3.1 Absorption and emission spectra for P2 in DMF (Excitation = 430 nm, slit widths = 3 nm, 
integration time = 0.1 s). 
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Fig. S3.2 1H NMR (400 MHz) of P2 in DMSO-d6. 
 
 
Fig. S3.3 Absorption and emission spectra for CPN-2 in water (Excitation = 400 nm, slit widths = 3 nm, 
integration time = 0.1 s). 
 
 
Fig. S3.4 1H NMR (600 MHz) of CPN-2 in D2O. 
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Fig. S3.5 FT-IR of P2 (neat). 
 
 
Fig. S3.6 Absorption and emission spectra for P3 in DMF (Excitation = 400 nm, slit widths = 3 nm, 
integration time = 0.1 s). 
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Fig. S3.7 1H NMR (400 MHz) of P3 in DMSO-d6. 
 
 
Fig. S3.8 Absorption and emission spectra for CPN-3 in water (Excitation = 400 nm, slit widths = 3 nm, 
integration time = 0.1 s). 
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Fig. S3.9 1H NMR (600 MHz) of CPN-3 in D2O. 
 
 
Fig. S3.10 FT-IR of P3 (neat). 
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Fig. S3.11 NTA of CPN-1 in water. 
 
 
Fig. S3.12 NTA of CPN-2 in water. 
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Fig. S3.13 NTA of CPN-3 in water. 
 
 
Fig. S3.14 NTA of CPN-4 in water. 
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Fig. S3.15 Zeta potential of CPN-1 in water. 
 
 
Fig. S3.16 Zeta potential of CPN-2 in water. 
 
 
Fig. S3.17 Zeta potential of CPN-3 in water. 
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Fig. S3.18 Zeta potential of CPN-4 in water. 
 
Table S3.1 Summary of NTA data for CPN/GAG complexes. 
Sample Mean (nm) 
Mode 
(nm) 
SDa 
(nm) 
CPN-1 140 ± 0.9 108 ± 8.4 63 ± 3.2 
+ HA 174 ± 1.4 145 ± 9.4 65 ± 3.9 
+ HS 171 ± 1.9 142 ± 7.7 58 ± 1.9 
+ CS 177 ± 4.8 148 ± 13.3 82 ± 8.2 
+ DS 167 ± 1.6 159 ± 0.6 58 ± 3.2 
CPN-2 179 ± 6.3 125 ± 6.5 74 ± 5.8 
+ HA 152 ± 2.7 138 ± 8.5 62 ± 5.3 
+ HS 162 ± 1.1 124 ± 7.1 70 ± 3.3 
+ CS 137 ± 2.1 111 ± 6.0 59 ± 3.7 
+ DS 137 ± 2.3 114± 3.2 59 ± 3.7 
CPN-3 118 ± 10.1 90 ± 7.8 66 ± 23.5 
+ HA 150 ± 4.6 125 ± 4.6 57 ± 4.7 
+ HS 151 ± 5.4 125 ± 2.5 45 ± 4.9 
+ CS 165 ± 6.4 149 ± 1.6 60 ± 5.1 
+ DS 140 ± 1.3 125 ± 4.2 47 ± 3.5 
CPN-4 135 ± 8.1 95 ± 8.1 55 ± 3.8 
+ HA 170 ± 4.4 132 ± 6.6 75 ± 8.2 
+ HS 187 ± 2.7 144 ± 5.3 87 ± 11.8 
+ CS 216 ± 2.6 151 ± 3.7 97 ± 5.2 
+ DS 216 ± 1.9 148 ± 6.6 92 ± 2.8 
aSD is the standard deviation characteristic of the width of the mean peak.  
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Table S3.2 Summary of canonical scores from LDA plot. 
Canonical Eigenvalue Percent of variation 
Canonical 
correlation 
Likelihood 
ratio P-value 
1 51.1592 71.0561 0.9903 0.00015 <0.0001 
2 12.0357 16.7166 0.9608 0.00782 <0.0001 
3 8.8034 12.2273 0.9476 0.10200 <0.0001 
 
Table S3.3 Squared Mahalanobis distances to each group centroid. 
Row Actual CS DS HA HS 
1 CS 40.333331755 12294.647468 4063.5247309 7101.4731662 
2 CS 40.33333189 12318.702339 4091.8694316 7100.0157848 
3 CS 40.333331247 12295.354372 4055.8629135 7077.7114241 
4 CS 40.333332814 12320.127561 4063.8690325 7028.8745497 
5 CS 40.333332332 12284.219683 4022.5165612 7068.8817155 
6 CS 40.33333311 12305.608646 4078.0823462 7070.0813947 
7 CS 40.333332299 12324.225381 4101.1928134 7029.6991414 
8 CS 40.333332583 12297.892499 4043.5769265 7080.2601624 
9 CS 40.333332368 12290.603231 4079.2351324 7099.9786147 
10 CS 40.333332042 12317.900963 4084.3114748 7104.2194088 
11 CS 40.333332023 12321.138359 4086.9472166 7088.7210233 
12 CS 40.333331329 12327.718608 4068.9691099 7091.0784818 
13 DS 12336.168794 40.333332198 4485.4027952 5017.6750565 
14 DS 12308.32746 40.333331405 4461.5478914 5024.6443335 
15 DS 12285.66102 40.333332437 4444.505515 4960.6845733 
16 DS 12322.927181 40.333333024 4494.3974088 5092.3506657 
17 DS 12284.738557 40.33333405 4431.2023819 5018.2556851 
18 DS 12309.48622 40.333333605 4465.5395729 4968.2806311 
19 DS 12308.350358 40.333333771 4497.3940618 4981.3115882 
20 DS 12299.854928 40.333333821 4458.0858604 5006.5912977 
21 DS 12288.977123 40.333333818 4449.3440504 5029.0243225 
22 DS 12316.660014 40.333333525 4479.2810227 5006.1744725 
23 DS 12309.957045 40.333332342 4471.8327096 5016.2428069 
24 DS 12327.030404 40.333332195 4490.8880232 5031.904691 
25 HA 4071.5727552 4479.4540603 40.333334415 4189.6090669 
26 HA 4051.7432194 4464.1781327 40.333333094 4181.7118782 
27 HA 4038.7851613 4447.7852168 40.333333772 4226.4907325 
28 HA 4069.2033941 4452.9086196 40.333333224 4166.0945872 
29 HA 4043.7940084 4465.4116832 40.33333387 4101.2929977 
30 HA 4091.1485334 4485.9916447 40.333333783 4207.6709894 
31 HA 4087.8395223 4435.7896652 40.333333211 4216.5914613 
32 HA 4079.9438813 4435.5311514 40.333333177 4219.9600424 
33 HA 4067.9651299 4520.1123035 40.333333286 4148.2627038 
62 
34 HA 4091.700492 4486.0424938 40.333333274 4184.9552956 
35 HA 4093.2678457 4481.8711676 40.333333602 4202.0467871 
36 HA 4052.9937363 4474.345146 40.333333464 4153.3574859 
37 HS 7096.5304652 5022.950778 4191.1591296 40.333333658 
38 HS 7074.0622865 5010.9473948 4206.4649295 40.333333755 
39 HS 7059.2479562 4991.6573071 4181.3105117 40.333334356 
40 HS 7096.8954728 5039.1040348 4194.8850944 40.333334461 
41 HS 7070.6823557 4973.1371849 4165.069548 40.33333396 
42 HS 7087.2351087 5032.825679 4206.7409419 40.333333788 
43 HS 7056.5975622 4986.0591011 4134.249703 40.33333355 
44 HS 7081.3330154 5052.2305167 4202.4199089 40.3333335 
45 HS 7060.9924572 4989.4852004 4150.13598 40.333333518 
46 HS 7083.6742369 5025.4448787 4194.4434217 40.333333149 
47 HS 7095.8214509 5018.3121938 4188.5907513 40.333333749 
48 HS 7077.9224838 5010.9858432 4182.5741073 40.333332594 
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4.1 Abstract 
Biodegradable conjugated polymer nanoparticles (CPNs) were prepared for high mitochondria targeting in 
live cancer cells. The degradable CPNs are nontoxic and specifically localized to mitochondria of live tumor 
cells through macropinocytosis followed by intracellular degradation and trafficking. 
4.2 Introduction 
Conjugated polymer nanoparticles (CPNs) are intrinsic fluorescent soft materials fabricated by self-assembly 
of non-aqueous soluble conjugated polymers (CPs) in an aqueous solution.1, 2 Owing to their excellent 
photophysical (i.e., high brightness and photostability) and biophysical properties (i.e., high cellular entry 
and nontoxicity), CPNs have recently gained much attention for microscopic live cell/tissue imaging,3-5 
biological sensing,6, 7 and nucleic acid delivery.8, 9 By introducing non-conjugated degradable linkers along 
the conjugated backbones, biodegradable CPs were synthesized and exhibit similar fluorescent properties of 
fully conjugated CPs.10 The backbone modification with flexible linker affects the self-assembly properties 
of CPs, resulting in significantly changed cellular entry pathways.11 
Despite successful cellular applications, the high molecular weights of CPs are not ideal for labelling or 
delivery to intracellular organelles due to inefficient diffusion and trafficking ability. For organelles with 
additional membranes such as nucleus and mitochondria, the necessary penetration of the organelle 
membranes further decreases the labeling and delivery efficiency. For the first time, presented here is a 
strategy to achieve efficient mitochondria labeling of live cells using intracellular degradation of CPNs. 
Biodegradable CPNs were designed by self-assembly of disulfide containing CPs. Upon endocytosis, CPNs 
were disassembled and degraded to low molecular weight, fluorescent conjugated oligomers (COs) that were 
efficiently trafficked to mitochondria (Fig. 4.1). The results support that biodegradable CPNs are promising 
materials for labeling and therapeutic delivery to mitochondria, which is an important therapeutic target given 
that mitochondria dysfunction is related to various diseases such as cancer, obesity, diabetes, and 
neurodegenerative disorders.12 
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Figure 4.1. Chemical structures of PPEs with (PPE-1) and without (PPE-2) biodegradable linkers in the 
backbone and a schematic illustration of cellular entry and mitochondria localization of biodegradable CPNs. 
CPN-1 and CPN-2 were fabricated with the corresponding PPEs via self-assembly in water. 
 
4.3 Results and Discussion. 
Biodegradable poly(p-phenyleneethynylene)s (PPEs) were synthesized by polymerizing monomers 
including a disulfide-containing monomer (see experimental). Disulfide bonds are reducible under a high 
concentration of intracellular glutathione (~0.5-10 mM)13. To obtain the fluorescent properties comparable 
to a fully conjugated PPE, the amount of disulfide monomer in the PPE backbone was maintained less than 
50%. To improve mitochondria targeting function, triphenylphosphonium (TPP) salts were introduced by 
reacting the PPEs containing bromine side chains with triphenylphosphine (see experimental). TPP is a well-
known mitochondria-targeting small molecule and has been used for modifying small molecules, 
nanoparticles, and liposomes.14, 15 Proton and phosphorus nuclear magnetic resonance (NMR) spectroscopy 
confirmed the quantitative introduction of TPP salts (see experimental). The resulting PPE-1 (Mn = 9,300) 
and -2 (Mn = 16,000) were soluble in organic solvents such as dimethylsulfoxide (DMSO) and methanol. 
The ratio of repeating units of PPE-1 was calculated as ~1.0:0.8 using proton NMR integration values, 
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indicating that the average length of COs along PPE-1 backbone is around 5 repeating units (i.e., pentamer) 
or slightly larger. 
CPNs were prepared by diluting TPP-modified PPEs in DMSO with an excess amount of water (i.e., final 
DMSO concentration of less than 1 %). Using fully conjugated PPEs, non-degradable CPNs were also 
fabricated to support the concept that the degradability of CPNs is crucial for high intracellular organelle 
targeting. The photophysical and physical properties of both CPNs were somewhat similar. Both CPNs 
exhibit broad emission spectra centered on ~470 nm. Using nanoparticle tracking analysis, the mean 
hydrodynamic diameters of CPN-1 and -2 were determined as 139.9 ± 3.0 and 152.7 ± 6.7 nm, respectively 
(see Figure S4.25 and S4.27). The difference in the average size is believed to associate with the size 
distribution of CPNs. Indeed, both CPNs exhibit very similar mode diameters (i.e., the diameter of the major 
population) of 92–93 nm. Zeta potentials of CPN-1 and -2 were +24 and +29 mV, respectively. Attempts to 
take transmission electron microscopic (TEM) images were not successful as CPNs heavily aggregated on a 
copper grid during sample preparations. 
The metabolic activities of human cervical carcinoma (HeLa) cells incubated with biodegradable CPN-1 and 
non-degradable CPN-2, respectively, for overnight were monitored to evaluate the toxicity of CPNs. 
Interestingly, while degradable CPN-1 exhibits no viability inhibition up to 40 µM, non-degradable CPN-2 
exhibits substantially high toxicity starting from 10 μM (see Figure S4.35). To test whether the molecular 
weights of PPEs are associated with the toxicity, a low molecular weight (Mn = 6,960) non-degradable PPE 
(PPE-3) as synthesized by breaking the monomer stoichiometric balance in polymerization. The CPN 
fabricated with low molecular weight PPE (i.e., CPN-3) exhibits very similar toxicity to that of CPN-2, 
suggesting that the toxicity of CPN-2 is not related to the molecular weight of the corresponding PPE. 
Although further systematic investigations are necessary to better understand the backbone structure and the 
cellular toxicity relationship, it is speculated that the degraded oligomers containing thiols may contribute to 
the lower toxicity by reducing the level of reactive oxygen species.17 
CPNs were taken up by live cells and found in the cytosolic compartment (Fig.4.2). Unlike CPN-2, which 
exhibits a characteristic punctuated pattern, the fluorescent image of CPN-1 was somewhat diffused along 
with some granular patterns (Fig. 4.2). The diffused pattern is indicative of disassembly of CPNs followed 
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by degradation to COs via disulfide degradation under high intracellular glutathione concentration. Non-
degraded CPNs were seen as punctuated dots. Nonetheless, the microscopic images are clearly different 
between biodegradable CPN-1 and non-degradable CPN-2. The possibility of pre-degradation of CPN-1 in 
extracellular environment followed by diffusion or uptake of COs by cells was ruled out , as disulfide 
reduction at the extracellular environment will be very inefficient due to lower glutathione concentration (i.e., 
one to three orders of magnitude lower).13 
 
Fig. 4.2. Microscopic images of HeLa cells incubated with CPNs for 18 h followed by mitochondria (red) 
and nuclear (blue) staining. The scale bar is 20 µm. 
 
The PPE stock concentration in DMSO is influential for CPN formation and thus for fluorescent microscopic 
imaging. The higher stock concentration, the more punctuated spots observed in the microscopic images (see 
Fig 4.3). As polymer concentration increases, the chances of interpolymer aggregation via π- π staking in a 
poor solvent increase. The punctuated spots are indicative of aggregated nondegraded CPNs. Attempts to 
degrade CPNs under high reducing conditions were not conclusive, assuming that the strength of 
interpolymer interactions in an aqueous environment are somewhat strong. Partial backbone degradation to 
induce de-aggregation of CPNs was speculated from slight blue shifts on both absorption and emission 
wavelengths upon treating CPNs with excess amount of glutathione (see Fig. 4.4). 
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Fig. 4.3. Confocal microscopic images of HeLa cells incubated with CPN-1 0.2 µM (top row) and 2 µM 
(bottom row) for 18 h followed by mitochondria (red) staining. Scale bar is 20 µm. 
 
 
Fig. 4.4. Absorption (left) and emission (right) spectra of CPN-1 treated with 10 mM glutathione (GSH) for 
0 and 18 h at 37˚C. 
 
For analyzing subcellular localizations of CPNs, various organelles (i.e., nucleus, Golgi, endosome, and 
mitochondria) were post-stained using commercially available dyes. The Pearson's Correlation Coefficient 
(PCC) was used to quantitatively evaluate co-localization.18 PCC scores of 0 and 1 correspond to uncorrelated 
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and perfectly linearly correlated colors, respectively. Mean PCC scores from three independent images of an 
entire cell were selected and analyzed to increase the analysis objectivity. CPN-1 exhibited high 
mitochondrial co-localization (PCC ~0.8), while minimal endosome (~0.3) and Golgi apparatus (~0.2) co-
localizations were observed. Meanwhile, CPN-2 showed high endosomal co-localization (~0.7) with minimal 
mitochondrial and Golgi apparatus co-localization. Non-degradable CPN-3, which was fabricated with low 
molecular weight PPE-3, also exhibits punctuated staining pattern with low mitochondria localization (~0.4), 
supporting that the degradability of CPNs is an important factor increasing mitochondria trafficking (see Fig. 
4.5). 
 
Fig. 4.5. Microscopic images of HeLa cells incubated with CPN-3 for 18 h followed by mitochondrial (red) 
and nuclear (blue) staining. The scale bar is 15 μm. 
 
The presence of punctuated spots in microscopic images and inefficient degradation of CPN-1 in a highly 
reducing environment imply that CPNs are somewhat hydrophobic despite of the charged TPP groups. To 
increase the hydrophilicity, CPNs were further complexed with an anionic linear polysaccharide, hyaluronic 
acid (HA). When the same biodegradable CPN-1 was complexed with HA (CPN-1/HA) followed by 
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incubation with HeLa cells for overnight, the mitochondria imaging pattern was improved substantially with 
reduced punctuated spots (Fig. 4.6). As shown in Fig.4.6, CPN-1/HA exhibits characteristic mitochondrial 
granular patterns and high PCC scores, while no changes were observed from CPN-2/HA complex. Non-
degradable CPN exhibit punctuated fluorescent image patterns regardless of HA complexation. 
 
Fig. 4.6. Confocal microscopic images of HeLa cells incubated with CPN/HA (green) for 18 h followed by 
mitochondria (red) and nucleus (blue) staining. The scale bar is 20 µm. 
 
To further confirm that CPN-1 indeed trafficked to mitochondria, live cells incubated with CPNs were treated 
with a commercial mitochondria isolation kit followed by centrifugation to isolate a mitochondria fraction. 
Fluorescence spectroscopic analysis of the mitochondrial fraction of live HeLa cells clearly supports the high 
mitochondrial localization of CPN-1. As shown in Fig. 4.7, fluorescent signals were exclusively observed 
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from the mitochondria fraction of live HeLa cells incubated with CPN-1. CPN-2 exhibited high cytosolic 
fluorescent intensity compared to the mitochondria fraction, supporting the data from microscopic image 
analysis.  
  
Fig. 4.7. Fluorescence analysis of mitochondrial and cytosolic fractions of HeLa cells incubated with CPNs. 
CPN-1 was found at the mitochondrial fraction, while CPN-2 was found mainly in the cytosolic fraction. The 
error bar represents ±standard deviation (n = 3). 
 
This dramatic subcellular localization difference between CPNs with the same side chains (i.e., TPP) implies 
that self-assembly structures of CPNs possibly influence cellular entry routes and the intracellular fates. 
Previously, it was found that CPs with flexible linkers tend to form aggregates with high interpolymer 
interactions compared with CPs without the flexibility.19 Because of the flexible disulfide containing units, 
the surface properties of CPN-1 will be different and influential for cellular interactions and subsequent 
cellular entry. To test endocytosis pathways, live HeLa cells pretreated with pharmacological inhibitors of 
various endocytosis pathways were incubated with CPNs for 2 h and mean fluorescence intensity of live cells 
was monitored by flow cytometry.20 As shown in Fig. 4.8, CPNs use various endocytosis pathways to enter 
HeLa cell, determined by the reduced uptake of CPNs under the inhibitors tested. In addition to caveolae-
mediated endocytosis (CvME), uptake of CPN-1 via macropinocytosis (MPC) was also noticeably reduced. 
Although further mechanistic and trafficking studies are needed, it is speculated that the high mitochondria 
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localization of CPN-1 is closely related to a series of cellular processes of MPC internalization of CPN-1, 
better escape of macropinosomes, degradation of disulfide bonds to generate low molecular weight COs, and 
increased diffusion for trafficking to mitochondria. 
 
Fig. 4.8 Endocytosis inhibition study under pharmacological inhibitors treatments. Mean fluorescence 
intensity of HeLa cell (Control), CPNs only (CPN), chlorpromazine (24.0 mM, CME), genistein (0.21 mM, 
CvME), methyl-β-cyclodextrin (1.00 mM, CvME/MPC), LY294002 (0.12 mM, MPC1), and cytochalasin D 
(0.04 mM, MPC2) were measured using flow cytometry. Error bars represent standard deviation. *p < 0.05 
 
To determine whether the observed CPN-1 mitochondrial specificity is related to the degradation kinetics, 
endosome and mitochondrial co-localizations were measured as a function of incubation time. Subcellular 
localization was monitored by fluorescent microscopic imaging, with CPNs incubated for 3, 6, 12, and 18 h 
in live HeLa cells. PCC scores between CPNs and mitochondrial or endosomal markers were measured and 
averaged from three independent trials (Fig. 4.9). CPN-1 exhibited a time-dependent mitochondrial and 
endosomal co-localization. As incubation time increased, CPN-1 localized more strongly toward the 
mitochondria, with almost exclusive mitochondrial localization at 18 h incubation. CPN-2, meanwhile, did 
not show time-dependent co-localization, exhibiting no significant change in mitochondrial or endosomal 
localization as incubation time increased. Although CPN-2 has high concentration of mitochondria targeting 
TPPs, the non-degradability, large molecular weight, and poor endosome escaping and diffusion efficiency 
limit mitochondria targeting. The time-dependency of CPN-1 on co-localization supports that intracellular 
degradation of biodegradable linkers play a significant role in mitochondrial trafficking of TPP functionalized 
COs. 
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Fig. 4.9. Time-course localizations of A) CPN-1 and B) CPN-2 on endosomes (open circles) and 
mitochondria (filled circles). Subcellular localization of CPN-1 changes from endosome to mitochondria, 
while CPN-2 remains constant regardless of incubation time. Error bars represent standard deviation from n 
= 3. 
 
4.4 Conclusion 
In conclusion, a new strategy to achieve a unique mitochondrial-specific localization of CPs was presented. 
It was demonstrated that disulfide-containing CPNs exhibit active cellular internalization as polymer 
nanoparticles via a variety of endocytosis, and undergoes degradation to low molecular weight oligomers 
that were efficiently trafficked to target mitochondria. The concept demonstrated here will lead to the 
development of novel CP-based materials for improved intracellular sensing, labeling, and potential 
therapeutic delivery. 
4.5 Outlook 
This chapter presented a strategy for mitochondrial targeting that was dependent on the biodegradability and 
flexibility of the conjugated backbone. With mitochondria-specificity, CPNs could be used for sensing and 
delivery applications by incorporating a reactive oxygen species (ROS)-sensitive functionality. Since the 
writing of this chapter, a series of non-flexible-containing TPP copolymers with varying molecular weight 
and a series of flexible TPP-containing copolymers with varying flexible unit incorporation were synthesized 
and screened for mitochondrial-specificity. Preliminary results indicated that the presence of the flexible 
linker and at relatively higher percentage (>40%) was crucial for mitochondrial localization. This is could be 
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due to the hydrophobicity of the polymer backbone, which causes aggregation in aqueous environment. If 
the polymer aggregates, the availability of the degradable linker in the backbone would be compromised and 
degradation by glutathione would be difficult. A series of TPP-containing polymers that also incorporated 
the hydrogen peroxide-sensitive moiety, aryl boronate, and degradable linker (Scheme 4.1). However, due to 
the hydrophobicity of this group and in combination with the bulky TPP group, dense aggregation was 
observed both in photophysical properties (red shifted spectra) and decreased emission intensity. The dense 
aggregation led to non-specific binding to the cellular membrane, and low mitochondria localization, for both 
linker and non-linker CPNs. 
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Scheme 4.1: TPP (R1)-containing polymers with (PPE-L) and without (PPE) biodegradable linker and 
boronate-moiety (R2). 
To address these issues, more in-depth studies on the effect of the flexible linker for subcellular targeting are 
needed. In addition, improving the hydrophilicity of the TPP-containing CPNs would provide information as 
to how polymer solubility, CPN aggregation, and cellular uptake/trafficking can be modulated. 
4.6 Experimental 
Dr. Rajesh Kumar completed polymer synthesis and characterization. Dr. Eladio Mendez completed time-
course imaging and flow cytometry experiments. 
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4.6.1 General Information 
Chemicals, including solvents, were purchased from Fisher Scientific and used as received. Deuterated 
solvents were purchased from Cambridge Isotope Laboratories (Cambridge, MA). UV-vis spectra were 
recorded using a Varian Cary 50 Bio spectrophotometer. Fluorescence spectra were obtained using a 
FluoroLog-3 Spectrofluorometer (Jobin Yvon/Horiba). 9, 10-diphenylanthracene (QY = 1.0) in cyclohexane 
was used as a fluorescence standard for QY determination. The average molecular weight (Mn) and 
polydispersity (PDI = Mw/Mn) of the polymers were determined by gel permeation chromatography (GPC) 
against polystyrene standards using a Shimadzu high performance liquid chromatography (HPLC) system 
fitted with PLgel 5 μm  MIXED‐D  columns  and  SPD‐20A  ultraviolet−visible (UV−vis) detector. Nuclear 
magnetic resonance (NMR) spectra were recorded on a 400 MHz Avance Bruker NMR spectrometer. 1H and 
13C NMR chemical shifts are given in ppm relative to Si(CH3)4, with the solvent resonance used as an internal 
reference. 1H NMR on the scale based on the middle peak (δ = 2.50 ppm) of the dimethyl sulfoxide DMSO-
d6 solvent as an internal standard or 7.26 ppm for chloroform (CDCl3) experiments. 31P NMR chemical 
shifts are reported in ppm relative to H3PO4. The mass spectrometric data were obtained at the mass 
spectrometry facility of Florida International University. Analytical thin layer chromatography (TLC) was 
performed on TLC Silica gel 60 F254. The TLC plates were visualized by shortwave (254 nm) or longwave 
(360 nm) UV light. Flash chromatography on silica gel (230–400 mesh) was performed. Fourier transform 
infrared (FT-IR) spectrum was obtained on a PerkinElmer Spectrum 100 FT-IR Spectrometer; fine powder 
sample was mounted on an attenuated total reflection cell. 
4.6.2.1 Monomer Synthesis 
Scheme S4.1: Synthetic route to M1 
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4.6.2.2 Synthesis of compound 120 
1, 4-Dihydroxy-2, 5-diiodobenzene (5.00 g, 13.80 mmol) was dissolved in acetone (20 mL) and the resulting 
solution was added slowly to a stirred suspension of K2CO3 (7.60 g, 55.25 mmol) and NaI (8.30 g, 55.25 
mmol). The reaction mixture was allowed to stir for 10 min, followed by the slow addition of triethylene 
glycol monochlorohydrin (TEG-Cl) (5.80 g, 34.53 mmol).  The reaction was heated to 80 ºC for 12 h. The 
solution was cooled to room temperature, the solvent was removed, and the resulting slurry was re-dissolved 
in CH2Cl2 (100 mL). The solution was extracted with water (100 mL x3) and the organic fractions were 
collected and concentrated in vacuo until an oily residue remained. The crude product was purified by silica 
gel chromatography (95:5 EA/Hexane). The product was off-white solid. Yield: 5.80 g (67.0%). 1H NMR 
(400 MHz, CDCl3): δ 7.24 (s, 2H), 4.09- 4.15 (t, 4H), 3.86-3.92 (t, 4H), 3.77-3.82 (m, 4H), 3.69-3.76 (m, 
8H), 3.60-3.66 (m, 4H), 2.29 (br, 2H); 13C NMR (100 MHz, CDCl3): δ 153.51, 123.21, 86.52, 72.51, 71.22, 
70.54, 70.28, 69.66, 61.82. 
4.6.2.3 Synthesis of monomer M121 
A suspension of compound 1 (5.00 g, 7.98 mmol) was dissolved in 25 mL of DCM. Carbon tetrabromide 
(8.00 g, 23.95 mmol) and triphenyl phosphine (12.60 g, 23.95 mmol) were added slowly to the reaction mass. 
The mixture was stirred at room temperature for 2 h. The solvent was removed and the crude product was 
purified by column chromatography (1: 4 EA / Hexane). The product was white solid. Yield:  5.30 g (81.2%). 
1H NMR (400 MHz, CDCl3): δ 7.30 (s, 2H), 4.10-4.15 (t, 4H), 3.89-3.92 (t, 4H), 3.85-3.87 (t, 4H), 3.68-3.76 
(m, 4H), 3.60-3.65 (m, 4H), 3.45-3.51 (m, 4H). 13C NMR (100 MHz, CDCl3): δ 153.37, 123.49, 86.47, 71.30, 
71.19, 70.71, 70.33, 69.70, 30.42. 
Scheme S4.2: Synthetic route to M2
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Monomer 2 (M2) was synthesized according to literature procedure (Scheme S4.2).22 
Scheme S4.3: Synthetic route to M3 
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4.6.2.4 Synthesis of monomer M3 
3,3'-Dithiodipropionic acid, 6 (1.00 g, 4.76 mmol) was dissolved in anhydrous THF (20 mL) in a round 
bottom flask, which was evacuated and filled with nitrogen. N-methylmorpholine (0.90 g, 9.52 mmol) was 
added, and the suspension was allowed to stir until the entire solid was dissolved. Isobutyl chloroformate 
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(1.30 g, 9.52 mmol) was added, and the mixture was allowed to stir at room temperature for 15 min. A 
solution of 4-ethynylaniline, 5 (1.10 g, 9.52 mmol) in anhydrous THF (10 mL) was prepared under a 
N2 atmosphere and transferred into the reaction flask using a cannula. The reaction was allowed to proceed 
overnight, after which the reaction mixture was filtered. The filtrate was concentrated in vacuo and the 
resulting solid was precipitated overnight from the DCM / diethyl ether solvent system. Yield: 0.70 g 
(36.0%). 1H NMR (400 MHz, DMSO): δ 10.20 (s, 2H), 7.50-7.61 (d, 4H), 7.39-7.41 (d, 4H), 4.07 (s, 2H), 
2.99-3.03 (t, 4H), 2.74-2.77 (t, 4H). 13C NMR (100 MHz, DMSO): δ 169.53, 139.68, 132.36, 118.94, 116.12, 
83.49, 79.65, 36.08, 33.38. HRMS (ESI): Calc for C22H20N2O2S2 [M+Na]+: 431.0858; found [M+Na]+ : 
431.0801. 
 
Figure S4.1. 1H NMR of M3 in DMSO-d6 
80 
 
Figure S4.2. 13C NMR of M3 in DMSO-d6 
 
4.6.3.1 Polymer Synthesis 
General Procedure. A Schlenk flask was charged with monomer M1 (1.00 eqiv.), M2 (0.5 eqiv.), M3 (0.5 
eqiv.), Pd[(PPh3)2Cl2] (0.10 equiv.), and CuI (0.05 equiv.). The Schlenk flask was evacuated and filled with 
N2 and solution of anhydrous dimethylformamide (4 mL) and diisopropylamine (1 mL) was degassed, and 
2.5 mL of the mixed solution was transferred to the Schlenk flask using a cannular needle. The reaction was 
allowed to stir at room temperature for 12 h. The solution was then added drop wise to methanol, resulting 
in precipitation. After centrifugation (3 min, 4000 rpm) the supernatant was decanted, and the precipitate was 
redissolved in DCM (1 mL) for further purification. 
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4.6.3.2 Synthesis of PPE-1 
Scheme S4.4: Synthetic route to PPE-1 
 
PPE-1-Br. Using the general procedure described above, the polymerization of monomer M1 (100 mg, 0.133 
mmol), M2 (30 mg, 0.066 mmol) and M3 (28 mg, 0.066 mmol) was carried out in presence of Pd[(PPh3)2Cl2] 
(9.3 mg, 0.013 mmol), and CuI (1.3 mg, 0.007 mmol). The resulting mixture was purified by precipitation in 
methanol (x3) Yield: 105 mg (42.5 %). An aliquot was redissolved in THF, and the molecular weight was 
obtained, and photo physical properties were characterized in DCM. 
PPE-1-Br: GPC: Mw =13.66 kDa; Mn = 09.30 kDa; PDI = 1.42. UV-vis: λmax = 400 nm; fluo λmax = 467 
nm; QY = 69% and ε = 42716.79 M-1 cm-1(Per repeating Unit) in DCM. 1H NMR (400 MHz, CDCl3): δ 7.91 
(br, 1H), 7.51 (br, 2H), 7.39 (br, 2H), 6.96 (br, 4H), 4.16 (br, 8H), 3.84 (br, 8H), 3.70 (br, 15H), 3.57 (br, 
10H), 3.44 (br, 4H), 3.54 (br, 4H), 3.27 (br, 4H) 3.02 (br, 2H), 2.75 (br, 2H). FT-IR (neat): ν = 2924, 2868, 
1671, 1589, 1512, 1408, 1352, 1265, 1214, 1097, 1041, 937, 838 cm-1.  
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Synthesis of PPE-1. 
Triphenyl phosphine (141 mg, 0.540 mmol) was dissolved in chloroform and the resulting solution was added 
to a stirred suspension of PPE-1-Br (100 mg, 0.054 mmol). The reaction was heated to 85 ºC for 12 h. The 
resulting mixture was purified by precipitation in ethyl acetate (x5). Yield: 70 mg (44.7%).  
PPE-1: UV-vis: λmax = 405 nm; fluo λmax = 472 nm; QY = 40% and ε = 67606.65 M-1cm-1 (Per repeating 
Unit) in DMSO. 1H NMR (400 MHz, DMSO-d6): δ 10.34 (br, 1H), 7.75 (br, 33H), 7.41 (br, 4H), 7.24 (br, 
2H), 7.14 (br, 2H), 4.16 (br, 9H), 3.89 (br, 5H), 3.78 (br, 6H), 3.62 (br, 17H), 3.47 (br, 8H), 3.28 (br, 3H), 
3.17 (br, 4H), 2.81 (br, 2H). 31P NMR (161.9 MHz, DMSO-d6): 25.38. FT-IR (neat): ν = 2921, 2870, 1683, 
1597, 1520, 1430, 1408, 1210, 1099, 1047 cm-1. 
CPN-1: UV-vis: λmax = 407 nm; Emission λmax = 470 nm; QY = 14% were measured using 1% DMSO in 
water (v/v). 
 
Figure S4.3. 1H NMR of PPE-1-Br in CDCl3. 
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Figure S4.4. 1H NMR of PPE-1 in DMSO-d6. 
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Figure S4.5. 31P NMR of PPE-1 in in DMSO-d6. 
 
Figure S4.6. FT-IR of PPE-1-Br (neat). 
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Figure S4.7. FT-IR of PPE-1 (neat). 
 
 
Figure S4.8. UV-vis and emission spectra of PPE-1-Br in DCM. 
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Figure S4.9. UV-vis and emission spectra of PPE-1 in DMSO. 
 
 
Figure S4.10. UV-vis and emission spectra of CPN-1 1% DMSO in water (v/v). 
4.6.3.3 Synthesis of PPE-2. 
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Scheme S4.5: Synthetic route to PPE-2 
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PPE-2-Br. Using the general procedure described above, the polymerization of monomer M1 (100 mg, 0.133 
mmol) and M2 (60.0 mg, 0.133 mmol) was carried out in presence of Pd[(PPh3)2Cl2] (9.3 mg, 0.013 mmol), 
and CuI (1.3 mg, 0.007 mmol). The resulting mixture was purified by precipitation in methanol (x3) Yield: 
0.15 g (88.5 %). An aliquot was redissolved in THF, the molecular weight was obtained, and photo physical 
properties were characterized in DCM. 
PPE-2-Br: GPC: Mw = 26.36 kDa; Mn = 15.98 kDa; PDI = 1.65. UV-vis: λmax = 432 nm; fluo λmax = 473 
nm; QY = 53% and ε = 23526.82 M-1 cm-1(Per repeating Unit) in DCM. 1H NMR (400 MHz, CDCl3): δ 7.06 
(br, 4H), 4.24 (br, 8H), 3.92 (br, 9H), 3.78 (br, 12H), 3.64 (br, 13H), 3.52 (br, 5H), 3.43 (br, 4H), 3.35 (br, 
7H). FT-IR (neat): ν = 2923, 2870, 2197, 1510, 1423, 1270, 1241, 1092, 1060 cm-1. 
Synthesis of PPE-2. 
Triphenyl phosphine (270 mg, 1.02 mmol) was dissolved in chloroform and the resulting solution was added 
to a stirred suspension of PPE-2-Br (100 mg, 0.102 mmol). The reaction was heated to 85 ºC for 12 h. The 
resulting mixture was purified by precipitation in ethyl acetate (x5). Yield: 95 mg (61.7%). 
PPE-2: UV-vis: λmax = 436 nm; fluo λmax = 478 nm; QY = 25% and ε = 46128.66 M-1 cm-1(Per repeating 
Unit) in DMSO. 1H NMR (400 MHz, DMSO-d6): δ 7.75 (br, 30H), 7.15 (br, 4H), 4.13 (br, 8H), 3.91 (br, 
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4H), 3.77 (br, 6H), 3.61 (br, 16H), 3.45 (br, 12H), 3.27 (br, 4.H), 3.15 (br, 10H). 31P NMR (161.9 MHz, 
DMSO-d6): 24.85. FT-IR (neat): ν = 3393, 2874, 2190, 1625, 1493, 1437, 1420, 1353, 1207, 1102, and 1046 
cm-1. 
CPN-2: UV-vis: λmax = 431 nm; fluo λmax = 469 nm; QY = 5% were measured using 1% DMSO in water 
(v/v). 
 
Figure S4.11. 1H NMR of PPE-2-Br in CDCl3. 
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Figure S4.12. 1H NMR of PPE-2 in DMSO-d6. 
 
 
Figure S4.13. 31P NMR of PPE-2 in DMSO-d6. 
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Figure S4.14. FT-IR of PPE-2-Br (neat). 
 
 
Figure S4.15. FT-IR of PPE-2 (neat). 
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Figure S4.16. UV-vis and emission spectra of PPE-2-Br in DCM. 
 
 
Figure S4.17. UV-vis and emission spectra of PPE-2 in DMSO. 
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Figure S4.18. UV-vis and emission spectra of CPN-2 1% DMSO in water (v/v). 
4.6.3.4 Synthesis of non-degradable PPE with low molecular weight. 
PPE-3-Br. Using general procedure described above, the polymerization of monomer M1 (104.0 mg, 0.138 
mmol) and M2 (50.0 mg, 0.110 mmol) in presence of Pd[(PPh3)2Cl2] (9.3 mg, 0.013 mmol), and CuI (1.3 
mg, 0.007 mmol). Resulting mixture was purified by precipitation in methanol (x3) Yield: 0.09 g (67.6%). 
An aliquot was redissolved in THF and molecular weight obtained and photo physical properties 
characterized in DCM. 
PPE-3-Br: GPC: Mw = 09.62 kDa; Mn = 06.96 kDa; PDI = 1.38. UV-vis: λmax = 428 nm; fluo λmax = 473 
nm; QY = 15% and ε = 15931.37 M-1 cm-1(Per repeating Unit) in DCM. 1H NMR (400 MHz, CDCl3): δ 7.05 
(br, 4H), 4.24 (br, 9H), 3.92 (br, 9H), 3.78 (br, 12H), 3.72 (br, 2H), 3.65 (br, 13H), 3.51 (8H), 3.44 (br, 4H), 
3.35 (br, 9H). 
Synthesis of PPE-3. 
Triphenyl phosphine (90 mg, 1.02 mmol) was dissolved in chloroform and resulting solution was added to a 
stirred suspension of PPE-3-Br (33 mg, 0.102 mmol). The reaction was heated to 85ºC for 12 h. The resulting 
mixture was purified by precipitation in ethyl acetate (x5). Yield: 26 mg (52.0%). 
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PPE-3: UV-vis: λmax = 428 nm; fluo λmax = 476 nm; QY = 6% and ε = 29777.78 M-1 cm-1(Per repeating 
Unit) in DMSO. 1H NMR (400 MHz, DMSO-d6): δ 7.76 (br, 30H), 7.14 (br, 4H), 4.16 (br, 8H), 3.91 (br, 
4H), 3.76 (br, 6H), 3.61 (br, 14H), 3.45 (br, 12H), 3.26 (br, 4H), 3.14 (br, 9H). 31P NMR (161.9 MHz, DMSO-
d6): 24.84.  
CPN-3: UV-vis: λmax = 427 nm; fluo λmax = 468 nm; QY = 5% were measured using 1% DMSO in water 
(v/v). 
 
Figure S4.19. 1H NMR of PPE-3-Br in CDCl3. 
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Figure S4.20. 1H NMR of PPE-3 in DMSO-d6. 
  
Figure S4.21. 31P NMR of PPE-3 in DMSO-d6. 
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Figure S4.22. UV-vis and emission spectra of PPE-3-Br in DCM. 
 
Figure S4.23. UV-vis and emission spectra of PPE-3 in DMSO. 
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Figure S4.24. UV-vis and emission spectra of CPN-3 1% DMSO in water (v/v). 
4.6.3.5 Particle formation and HA complexation. 
Particles were prepared prior to each experiment from a concentrated polymer stock solution in DMSO by 
diluting with an appropriate volume of filtered (0.22 µm PTFE syringe filter) deionized water (18 Ω). Sodium 
hyaluronate (HA) was purchased from Lifecore (MW 40 KDa) and used as received. A stock solution was 
prepared by dissolving 2.0 mg of HA in 1 mL of deionized water. CPN/HA complexes were prepared by 
mixing CPN and HA at a molar ratio of 1 to 3 (based on polymer and disaccharide repeating unit) then 
diluting to the desired concentration with deionized water. CPN/HA complexes were allowed to incubate for 
30 minutes prior to measurement. 
4.6.3.6 Determination of hydrodynamic diameters of CPNs and CPN/HA complexes. 
Nanoparticle tracking analysis (NTA) measurements were performed with a LM10 HS (NanoSight, 
Amesbury, United Kingdom), equipped with a sCMOS camera, sample chamber with a 488 nm blue laser, 
and Viton fluoroelastomer o-ring. The CPN samples were prepared from concentrated stock solutions of 
polymer in DMSO, at approximately 10 μM in a 0.5% DMSO (v/v) solution using deionized water (18 
Ω) filtered through 0.22 μm polytetrafluoroethylene (PTFE) syringe filter. The samples were injected into 
the sample chamber with 1 mL sterile syringes (Restek Corporation, Pennsylvania, USA) until the liquid 
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reached the tip of the nozzle. All measurements were performed at 25°C using a LM14C temperature 
controller (NanoSight, Amesbury, United Kingdom). Each sample was measured three times. 
Table S4.1. Hydrodynamic diameters and zeta potential of CPNs. 
Entry Hydrodynamic  diameter (nm) 
Zeta potential  
(mV) 
CPN-1 139.9 ± 3.0 + 23.5 ± 1.84 
CPN-1/HA 191.8 ± 2.6 - 44.4 ± 1.01 
CPN-2 152.7 ± 6.7 + 29.2 ± 3.56 
CPN-2/HA 223.1 ± 6.9 - 42.7 ± 0.83 
CPN-3 158.8 ± 16.4 + 20.1 ± 5.87 
 
 
Figure S4.25. NTA for CPN-1. 
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Figure S4.26. NTA for CPN-1/HA. 
 
 
Figure S4.27. NTA for CPN-2. 
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Figure S4.28 NTA for CPN-2/HA. 
 
 
Figure S4.29. NTA for CPN-3. 
4.6.3.7 Determination of zeta potentials of CPNs and CPN/HA complexes 
Dynamic light scattering (DLS) measurements were performed by Zetasizer nano-ZS (Zen 3600, Malvern 
Instruments Ltd.) using a folded capillary cell (Catalog # DTS1060), at room temperature. The CPN samples 
were prepared from concentrated stock solutions of polymer dissolved in DMSO, at approximately 0.1 mM 
in a 5% DMSO (v/v) solution using deionized water (18 Ω) filtered through 0.22 μm PTFE syringe filter. 
Each sample was measured six times. 
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Figure S4.30. Zeta potential of CPN-1. 
 
Figure S4.31. Zeta potential of CPN-1/HA. 
 
  
Figure S4.32. Zeta potential of CPN-2. 
Average = - 44.4 ± 1.01 mV
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Figure S4.33. Zeta potential of CPN-2/HA. 
 
  
Figure S4.34. Zeta potential of CPN-3. 
4.6.3.8 Degradation of CPN-1. 
To test degradation under intracellular conditions, CPN-1 (5 µM in H2O) was treated with excess glutathione 
(GSH) at 10 mM. The UV-vis and fluorescence emisson spectra (see Figure S34) were recorded for CPN-1 
only, upon immediate addition of GSH, and after 18 h at 37˚C with GSH. 
 
 
Average = - 42.7 ± 0.83 mV
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4.6.4.1 General Cell Culture. 
HeLa cells (human cervical cancer, purchased from ATCC) were seeded into a 100 x 20 mm style sterile 
tissue culture dish (#353003 BD Falcon, Durham, NC, USA). Then, they were cultured in complete media: 
Dulbecco’s minimum essential medium (DMEM)/high glucose (10 mL, HyClone, SH3024301) medium 
containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin (P/S) for 24 h 
under 5% CO2 at 37°C. Then, they were subcultured every 48 h. pHRhodo Dextran 10 kDa (#P10361 
Molecular probes, Life technologies, New York, USA), MitoTracker Deep Red (#M22425 Molecular probes, 
Life technologies, New York, USA) and BODIPY-TR C5-ceramide-BSA complex (#B34400 Molecular 
probes, Life technologies, New York, USA) were used for endosome, mitochondria, and Golgi apparatus 
staining, respectively.  The isolation of mitochondrial and cytosolic fractions of HeLa cells was performed 
using an Eppendorf Centrifuge 5430R, Mitochondria Isolation Kit for for cultured cells (#89874, Thermo 
Fisher Scientific), and Pierce BCA Protein Assay Kit (#23227, Thermo Fisher Scientific). Pharmacological 
endocytosis inhibitors such as chlorpromazine hydrochloride (#ALX-270-171-G005, Enzo Life Sciences, 
Inc.), genistein (#AC32827-1000, Acros Organics), methyl-β-cyclodextrin (#377110050, Acros Organics), 
LY2994002 (#70920, Caymen Chemical), and cytochalasin D (#BML-T109-0001, Enzo Life Sciences, Inc.) 
were purchased from Fisher Scientific. 
4.6.4.2 Toxicity Assay 
HeLa cells (ca. 10,000 cells per well), in 200 μL of complete medium, were seeded into a 96-well plate and 
cultured for one day in a 5% CO2 incubator at 37 °C. 4 mM of CPN-1, CPN-2 and CPN-3 stock solutions 
were prepared by dissolving dried powder in DMSO. 2 mM, 1 mM, 0.5 mM, and 0.1 mM substock solutions 
were made by diluting with DMSO. Final concentrations of 40 μM, 20 μM, 10 μM, 5 μM, and 1 μM of CPNs 
were added into complete media by dilution with CPN-1, CPN-2, and CPN-3 stock solutions and then 
incubated for 18 h. To measure toxicity, 10 μL of MTT solution (5 mg mL-1 in PBS, CALBIOCHEM, 
Germany) and 90 μL of complete medium were then added into each well, and the plate was further incubated 
for 4 h at 37 °C. After the formed MTT formazan crystals were dissolved in dimethyl sulfoxide (100 μL), the 
absorbance intensity was measured by a microplate well reader (infinite M1000 PRO, TECAN, Switzerland) 
at 540 nm. Relative cell viability (%) as a function of CPN concentration was expressed as a percentage 
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relative to the untreated control cells. All measurements were performed in triplicate and standard deviation 
was included in the error bar (see Figure S30). 
  
Figure S4.35. Cellular toxicity of CPN-1, CPN-2, and CPN-3. 
4.6.4.3 Microscopic imaging, co-localization, and time-course subcellular localization. 
10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber slide (Lab-Tek Thermo Scientiﬁc) 
and cultured in complete media (400 μL) for 24 h under 5% CO2 at 37 °C. 80 μL of 20 μM CPNs in water 
was added to the culture medium directly, and the cells were further cultured overnight (ﬁnal CPN 
concentration: 4 μM). For endosome staining, pHRhodo Dextran 10kDa (5µM) was incubated for 30 min at 
37°C. For Golgi apparatus staining, BODIPY-TR C5 -ceramide-BSA complex (ﬁnal 10 μM) was incubated 
for 30 min at 4°C. For mitochondria staining, MitoTracker Deep Red (100 nM) was incubated for 30 min at 
37°C. After washing with fresh medium, the cells were further incubated for 15 min at 37 °C. A 1 μL aliquot 
of Hoechst (5 μg/mL) was added to the culture medium and incubated with the cells for 10 min at 37°C, and 
washed two times with phosphate bu ﬀered saline (PBS          
10 min. Fluorescent images of the cells were obtained using a DeltaVision Elite Microscope System (Applied 
Precision, Issaquah, Washington, USA) equipped with bandpass ﬁlters such as blue (410−460 nm, Hoechst), 
green (500−550 nm, CPNs), and red (595-635nm, Golgi apparatus, endosome, and mitochondria) using a 
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60X oil immersion lens (NA 1.42) and n = 1.520 immersion oil. Top and bottom of the chosen cells was 
identified, and a Z-stack plot was imaged for each channel. Z-stack microscope images of each sample was 
obtained as described above. Colocalization analysis was conducted for three independent cells per polymer 
and per organelle (Golgi apparatus, endosome, and mitochondria). Colocalization analysis was conducted 
using the microscope software (Softworx 5.0 application, Applied Precision, Issaquah, Washington, USA). 
Region of interest (ROI) was selected to contain all of the cell. Pearson’s Correlation Coefficient (PCC) was 
used to determine colocalization. Negative control of colocalization was performed by analysis of blue and 
green channels staining the nucleus and CPN, respectively. Three independent images of an entire cell were 
selected and analyzed to increase analysis objectivity. 
 
Figure S4.36. Microscopic images of HeLa cells incubated with CPN-2 for 18 h followed by endosome 
(red) and nuclear (blue) staining. The scale bar is 20 μm. 
 
4.6.4.4 Confocal microscopic imaging, CPN/HA co-localization, and concentration-dependent co-
localization. 
HeLa cells were seeded into a 12-well plate (~50,000/well) with glass coverslip (#1254584, Fisher Scientific) 
one day prior to CPN treatment and cultured in complete media (500 μL) for 24 h under 5% CO2 at 37°C. 
After cell attachment, fresh complete media (500 µL) containing 50 µL of 2 µM or 20 µM CPN in H2O (ﬁnal 
CPN concentration: 0.2 μM or 2 µM, see Figure S37) was added and cultured for 18 h. For CPN/HA, fresh 
complete media (500 µL) containing a premixed solution of 50 µL of 2 µM CPN in H2O (ﬁnal CPN 
concentration: 0.2 μM) and 15 µL 20 µM HA was added and cultured for 18 h After incubation, cells were 
washed with 1X PBS and stained with MitoTracker Deep Red (50 nM) in DMEM only (no FBS or P/S) for 
30 min at 37°C. After washing with fresh DMEM for 15 min at 37°C, cells were ﬁxed with 4% 
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paraformaldehyde for 10 min at room temperature. After washing with 1X PBS, a 1 μL aliquot of Hoechst 
(5 μg/mL) was added to 199 μL PBS and incubated with the cells for 10 min at room temperature. Nuclear 
staining is not shown in Figure S37 due to non-specific binding of aggregated CPNs at high concentration. 
Cells were then washed three times with 1X PBS and coverslips were mounted on microscope slides 
(#1125441, Fisher Scientific) using a 1:1 glycerol/PBS mounting medium. Fluorescent images of the cells 
were obtained using an Olympus FluorView FV1200 confocal microscope (Melville, NY USA) equipped 
with bandpass ﬁlters such as blue (417–477 nm, nucleus), green (513-556 nm, CPNs), and deep red (672-
712 nm, mitochondria) using a 60X oil immersion lens (NA 1.35) and n = 1.519 immersion oil. The top and 
bottom of the samples were identified, and a Z-stack plot was imaged for each channel. Co-localization 
analysis of the green (CPN) and red (mitochondria) channels was conducted for three independent images 
using ImageJ software (version 1.50b, U. S. National Institute of Health, Bethesda, Maryland, USA). PCC 
scores were calculated to determine co-localization by setting pixel threshold for the entire image per channel 
and per sample in order to exclude noise and background signal.23 
4.6.4.5 Isolation of Mitochondrial and cytosolic fractions of HeLa cells. 
HeLa cells (ca. 10,000,000) were seeded into a 100 x 20 mm style sterile tissue culture dish (#353003 BD 
Falcon, Durham, NC, USA) with 10 mL of complete medium. After 24 h incubation at 37 °C, cells were 
treated with 5  M  of C PN-1 and CPN-2, respectively, for 24 h. After washing with PBS three times, the 
mitochondrial and the cytosolic fractions were isolated using a commercial kit (Mitochondria Isolation Kit 
for cultured cells #89874, Thermo Fisher Scientific). Briefly, HeLa cells were isolated by scraping and 
washed with PBS. The kit reagent A was added followed by incubating on ice for 2 min. The kit reagent B 
was added followed by vortexing and incubation on ice. After 5 min of incubation, the kit reagent C was 
added and the cells were centrifuged (700 x g at 4 °C). The pellet containing nuclei and cellular debris was 
discarded and the supernatant was centrifuged (12,000 x g at 4 °C). The supernatant containing the cytosolic 
fraction was removed and the pellet composed of mitochondria was washed with the kit reagent C. The pure 
mitochondria fractions were isolated by centrifugation (12,000 x g at 4 °C). The mitochondrial fraction and 
the cytosolic fraction were diluted to 200 µL 100% DMSO and 200 µL of 50% DMSO, respectively. Then 
the total fluorescence intensities of the mitochondrial and the cytosolic fractions resulting from the excitation 
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at 455 nm were measured, normalized by the amount protein (µg) of the fraction, and determined by BCA 
protein assay (Pierce BCA Protein Assay Kit #23227, Thermo Fisher Scientific). 
4.6.4.6 Flow Cytometry 
HeLa cells incubated with CPNs were treated with trypan blue (Amresco Inc.) before flow cytometry 
measurements (Accuri C6, USA). HeLa cells incubated with 10 μM of CPN for 4 h were treated with trypan 
blue (200 μM) for 10 min. After washing with 1X PBS buffer three times, cells were detached by 
trypsin/EDTA and fixed with 4 % paraformaldehyde. Post-cell treatment with trypan blue was conducted for 
all flow cytometry analyses for entry kinetics and mechanisms. 
4.6.4.7 Endocytosis Inhibition Assay 
For endocytosis inhibition studies, HeLa cells were seeded into a 6-well plate (~200,000/well) one day before 
CPN treatment. Cells were then treated without (control) or in the presence of pharmaceutical inhibitors 
chlorpromazine (24.0 mM), genistein (0.21mM), methyl-β-cyclodextrin (1.00 mM), LY294002 (0.12 mM), 
or cytochalasin D (0.04 mM) for 30 min before CPN treatment. After CPN treatment, cells were washed with 
1X PBS three times followed by trypan blue treatment (0.20 mM) for 10 m. The detached cells were fixed 
with 4 % paraformaldehyde in 1x PBS for 10 m and resuspended in a flow cytometry buffer (1X PBS 
containing 5 % bovine serum albumin and 0.02 % sodium azide). 10,000 events per measurement were 
counted and mean fluorescence intensity of CPN (FL2 channel, 518-548 nm wavelength range) was 
measured. Averaged mean fluorescent intensity was calculated using three independent sample sets. 
 
Figure S4.37. Fluorescent intensity plots obtained at the FL2 channel (518-548 nm).  
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5.1 Abstract 
Red emissive conjugated polymer nanoparticles (CPNs) grafted with folic acid (FA)-modified poly(ethylene 
glycol) (PEG2000) side chains were fabricated and complexed with hyaluronic acid (HA) for improved 
targeting and labelling of HeLa cells. Modulation of uptake kinetics and amount of internalized CPNs was 
achieved by electrostatic complexation as measured by flow cytometry and visualization by high resolution 
fluorescence microscopy. These dual ligand-targeting CPNs designed for folate and hyaluronan receptors are 
effective for labelling and bioimaging. 
5.2 Introduction  
Conjugated polymer nanoparticles (CPNs) possess excellent light harvesting and light amplifying properties 
owing to their delocalized electronic structure along a π-conjugated backbone, making them excellent 
materials for a variety of applications, such as optoelectronic devices, sensing, imaging, and drug delivery.1-
4, 7, 28 These CPNs have become of significant interest in therapeutics and diagnostics (theranostics) as a 
consequence of their desirable properties including low cytotoxicity, biocompatibility, facile synthesis, high 
sensitivity and superior photostability.5 Structural modifications of CP side chains to incorporate ionic and 
hydrophilic moieties (e.g.; charged functional groups and polyethylene glycol chains) allow for tunable 
biophysical properties for improved biocompatibility and functionalized performance.10,31 Recently, CPNs 
have been utilized as sensitive tumor imaging probes for both in vitro and in vivo applications.6,8,27,29 More 
importantly, efficient delivery of CPNs to tumor cells has been achieved in theranostics and bioimaging by 
utilizing cell surface receptors.8,26 Rapid delivery of desired materials in large quantities to a wide variety of 
tumor cells has become feasible using targeting delivery vehicles.9 In these approaches, ligands are covalently 
attached to CPNs to selectively interact/bind with overexpressed receptors on the cell surface. Although these 
targeting approaches improves selectivity of CPNs towards tumor cells, it still suffers from the fact that these 
nanomaterials (e.g., drug candidates, imaging agents) are often not highly tumor specific, and cause toxicity 
to normal cells. To overcome this problem, some research groups have utilized a dual targeting approach to 
improve the tumor selectivity of chemotherapy and imaging agents aiming to simultaneously target multiple 
receptors on the cell surface.21 In their designs, two ligands are conjugated to the cargo via covalent 
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attachment. Upon interaction with cancer cells, each ligand binds to their specified receptors resulting in 
improved selectivity while sparing unintentional targets (i.e., healthy cells).22 
To address these issues, “dual targeting” CPNs have been designed for improved labelling and bioimaging. 
In our approach, folic acid (FA) binding folate receptors (FR) and hyaluronic acid (HA) binding hyaluronan 
receptors were chosen as targeting components as these will ultimately increase interactions between CPNs 
and tumor cells. Folate receptors are composed of a glycosylphosphatidylinositol (GPI)-linked membrane 
glycoprotein that exists in two membrane-bound isoforms, FR-α and FR-β,which are overexpressed in 
ovarian, breast, endometrial, colorectal, and lung carinomas.23 Folic acid is easily internalized into the 
cytoplasm as it has a very high affinity to these receptors (Kd ~ 1 nM), which is an advantage for efficient 
intracellular delivery,24 The binding affinity of FA to FR has been shown to remain very high even when 
conjugated to other materials.11  Conjugation of FA to macromolecules presents synthetic issues given its 
hydrophobic nature and limited solubility. However, FA has been shown to take on the properties of the 
material after conjugation.32 Hyaluronic acid is an anionic, hydrophilic, and biodegradable high molecular 
weight polymer (106 to 107 Da) that interacts through several receptors, including CD44 (Cluster Determinant 
44), RHAMM (receptor for HA-mediated motility), HARE (HA receptor for endocytosis), and ICAM-1 
(Intercellular Adhesion Molecule-1), which are overexpressed in tumor cells and multiple carcinomas.19,20 
Hyaluronic acid is an excellent candidate for cancer cell targeting and has been used for more than 30 years 
as a drug carrier and/or targeting moiety for biomaterials to target cancer cells. 
Reported herein are highly fluorescent far-red emissive (600-800 nm) conjugated polymeric nanomaterials 
bearing two types of targeting ligands: covalently attached FA and electrostatically complexed HA. The CP 
contains a benzothiadiazole (BT)-doped poly(p-phenyleneethynylene) (PPE) hydrophobic backbone, which 
emits in the far-red region. In general, the hydrophobic backbone of CPs causes polymer chains to aggregate 
in aqueous solvent, resulting in decreased quantum yield and undesired nonspecific binding. To overcome 
these drawbacks, the side chain of the polymer was modified with a quaternary ammonium group in a one-
pot synthesis, and poly(ethylene glycol) (PEG2000) was conjugated onto the side chain of the CPs to improve 
water solubility, reduce undesirable aggregation, and eliminate nonspecific interactions with cells. Folic acid 
and PEG2000 were attached to the CP side chain via simple “click reaction”, whereas HA was incorporated 
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into the polymers via mixing in solution, by taking advantage of electrostatic and hydrophobic interactions. 
Thus, the design principle reduces tedious synthetic effort to conjugate high molecular weight HA onto PPE. 
Moreover, non-covalent complexation provided the freedom of fine-tuning the outer surface of the 
nanomaterials with various HAs (i.e.; molecular weight and molar ratio).  
Chapter V describes the  synthesis, characterization, and effectiveness of a conjugated polymer-based dual-
targeting imaging system. The hypothesis was tested in HeLa cells, which express both folate and hyaluronan 
receptors. The results demonstrated that the dual-targeting imaging system can indeed be employed to image 
cancer cells with heightened efficiency. 
5.3 Results and Discussion 
The grafted copolymers for CPN-PEG2000-FA and CPN-PEG2000, (shown in Figure 5.1) were prepared 
utilizing azide functionalized PPE copolymers coupled with alkynyl end of PEG2000-FA and PEG2000, 
respectively (see experimental). Grafting efficiency of PEG2000-FA to the copolymer was determined to be 
40% resulting in a triblock copolymer (see Figure S5.1). The grafting of PEG2000 only was much more 
efficient with all of the azide functionalized side chain converted resulting in a 1:1 copolymer. In addition, 
the one-pot conversion to quaternary ammonium salt was only 50% because of synthetic conditions to control 
benzothiadiazole incorporation (see Figure S5.4) After purification via dialysis and followed by freeze 
drying, both PEG2000 only and FA-attached PEG2000 grafted conjugated polymers were used to construct 
nanostructures through a self-assembly process. The polymers were first dissolved in good solvent (DMSO) 
then added to deionized water under vigorous stirring to induce self-assembly.  
 
Figure 5.1. Chemical structures CPNs grafted with folic acid-modified PEG2000 (CPN-PEG2000-FA) and 
PEG2000 only (CPN-PEG2000). 
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The UV-vis absorption and emission spectra of CPN-PEG2000-FA and CPN-PEG2000 in water are shown in 
Figure 5.2. The absorption maxima for CPN-PEG2000-FA and CPN-PEG2000 are 488 and 483 nm, 
respectively. These values are ~30 nm higher than the absorption maxima in THF, indicating hydrophobic 
main chain induced aggregation and lengthening of the conjugated chains (see Figure S5.21). The emission 
maxima for CPN-PEG2000-FA and CPN-PEG2000 in water are 618 nm and 620 nm, respectively. The 
significantly red emission compared to structurally similar PPE polymers without BTz units suggests 
efficient donor-acceptor type energy transfer from PPE unit to BTz unit. Moreover, a slight increase in 
emission maxima (~20 nm) in water compared to organic solvents such as chloroform, DCM and THF 
indicates minimal chain-chain type aggregation in water. The emission quantum yields (Φ) for CPN-
PEG2000-FA and CPN-PEG2000 are 0.55 and 0.50, respectively, calculated using coumarin 6 in ethanol as 
the standard. The incorporated bulky side-chains (i.e.; PEG2000, FA, and quaternary ammonium moieties) 
likely sterically hinder excessive inter-chain aggregation in water. Compared to the more green and red 
emissive conjugated polymers typically used for nanoparticle fabrication and imaging, CPN-PEG2000-FA 
and CPN-PEG2000 have relatively higher quantum yields in water, which is ideal for NPs used in bioimaging. 
 
Figure 5.2. Absorption and emission spectra for (a) CPN-PEG2000-FA and (b) CPN-PEG2000 in water 
(Excitation = 480 nm, slit width = 3 nm, integration time = 0.1 s). 
 
The resulting NPs had diameters ranging from 105 to 108 nm, as determined by NTA analysis (see Figure 
5.6). The side chains with the nonionic diethylene oxide moiety and hydrophilic PEG2000 apparently stabilize 
the surface of the NPs, thereby hindering aggregation and precipitation. Typically, hydrophobic NPs 
aggregate in water as a mechanism of water exclusion from the hydrophobic surface. It was expected that the 
CPN-PEG2000-FA CPN-PEG2000
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CPNs fabricated from polymers containing hydrophilic side chains (i.e., PEG2000) and ionic side chains (i.e.; 
quaternary ammonium salt) will remain stable over time. To more thoroughly asses the stability of these NPs, 
the size distribution of the colloidal suspension was checked after one month. No significant change to the 
size distribution of the NPs, suggesting NPs are highly stable in water. High colloidal stability of the CPNs 
and uniform particle formation were also confirmed by zeta potential measurements. Both CPN-PEG2000-
FA (ζ +89.7 ± 2.21 mV) and CPN-PEG2000 (ζ +44.7 ± 1.02 mV) have very high positive surface charge with 
narrow charge distribution in water (shown in Figure S5.22). The high positive charges can be attributed to 
the presence of quaternary ammonium ions on the nanoparticle surface. While the high zeta potentials of 
CPNs may cause issues upon interactions with cellular proteins, the particle surface can be further modified 
with optimization of quaternary ammonium salt incorporation. 
Both CPNs (FA functionalized and non-functionalized) showed limited cytotoxicity after 18 h of incubation, 
only decreasing to 80% viability upon treatment with 40 µM CPN-PEG2000-FA (see Figure S5.23). 
Moreover, this concentration of CPNs was approximately seven times higher than that of CPNs used for in 
vitro experiments. The minimal toxicity of the CPNs towards HeLa cells, in spite of presence of ionic side 
chains, was attributed to the presence of biocompatible PEG2000 in the outer layer of the polymer.5 Toxicity 
of the CPN/HA complexes were not measured, since HAs are known to be nontoxic and have been used to 
reduce toxicity of polyethyleneimine (PEI) cationic polymers. 
Flow cytometry experiments were performed to quantitate the efficacy of CPNs for dual-targeting in tumor 
cells. The CPNs were complexed with HA at different ratios using 40 and 100 kDa HA, as it is known that 
molecular weight of HA plays a role in receptor interactions and biodistribution.27 It was expected that the 
molar ratio between CPN and HA will be an important factor to optimize when using different MW HAs. 
Our previous work indicated that complexation of cationic CPNs with 30 µM of 100 kDa HA increased 
cancer cell labelling and this served as a starting point for screenings.29  To improve maximum fluorescence 
signal from cell internalized CPN/HA complexes, several ratios of CPN/HA complexes were investigated. 
The HeLa cells were incubated for 18 h in presence of CPN/HA complexes at molar ratios of 1:1, 1:2, and 
1:5. After incubation, cells were treated with trypan blue (200 µM) to quench fluorescence originating from 
CPNs attached to the cell membrane, which was verified in solution (Figure S5.24). Trypan blue is known to 
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absorb energy in the wavelength range that CPNs emit fluorescence, and treatment is an established method 
to quench extracellular fluorescence.33-36 Mean fluorescence intensities (average of three replicates) 
determined by the scattering of control cells (Figure S5.25) were plotted against different ratios of CPN/HA 
complexes with 40 and 100 kDa HA as shown in Figure 5.3. From these results, it was concluded that 40k 
HA showed higher fluorescence for internalized CPN/HA complexes. The HeLa cells exhibited maximum 
fluorescence intensity at CPN-PEG2000-FA/HA ratio of 1:1, with a two-fold increase using 40k HA. Any 
excess of HA further reduced the fluorescence intensity, which could be the result of excess HA and negative 
charges that will not favor uptake of the CPNs at the cell surface. The control CPN-PEG2000 showed 
maximum fluorescence intensity at 1:2 ratio (CPN-PEG2000/HA), however, the increase in fluorescence was 
very minimal compared CPN-PEG2000-FA. A similar trend was observed for 100 kDa HA, with a greater 
reduction in fluorescence compared to 40 kDa HA. Moreover, complexation with 100 kDa HA gave viscous 
solutions with aggregated particles for both CPN-PEG2000-FA and CPN-PEG2000. Thus, on the basis of 
these experiments we optimized CPN/HA formulation ratio to 1:1 for CPN-PEG2000-FA and 1:2 for CPN-
PEG2000 complexed with 40 kDa HA for further studies. 
 
Figure 5.3. Cellular uptake of CPN-PEG2000-FA (a) and CPN-PEG2000 (b) complexed with 40 kDa and 100 
kDa HA at various ratios after 18 h incubation. Error bars represent standard deviation from n = 3. 
 
The effectiveness of the dual targeting CPNs was investigated in a time course experiment. It was anticipated 
that internalization of the CPN-PEG2000-FA/HA complex would occur via both folate and hyaluronan 
receptors, and these events would enhance uptake of the complex resulting in an increased fluorescence signal 
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from inside the cells. Figure 5.4 shows a comparison plot for fluorescence associated with internalized CPNs 
and CPN/HA complexes at different incubation time. In the case of CPN-PEG2000-FA only, maximum 
fluorescence was obtained after 18 h of incubation. Typically, folate receptor mediated endocytosis is rapid 
(~0.5 h) for free FA and FA conjugated to small molecules,11 but when FA is conjugated to macromolecules 
(i.e., PPEs), maximum uptake can range 4-24 h.12,13 Upon complexation of CPN-PEG2000-FA with HA (1:1) 
ratio, the maximum fluorescence was obtained at 8 h, with 6X increase in intensity compared to CPN-
PEG2000-FA only. The maximum uptake time of 8 h has been for reported for similar HA-conjugated NPs 
under various formulations.14 This observation indicates an increase in CPN uptake in shorter time because 
of hyaluronan mediated endocytosis, and more importantly, modulation of endocytosis can be achieved for 
enhanced uptake by simple mixing with HA. It is hypothesized that the substantial increase in uptake of the 
CPN-PEG2000-FA/HA complex results from increased interactions through hyaluronan receptors as HA has 
been shown to modulate multiple receptors during mediated endocytosis.14 By utilizing HA with CPN-
PEG2000-FA, it is also hypothesized that a cooperative effect contributes to the substantial uptake increase 
due to multiple ligands/receptors and CPNs at the cell surface.18 The cooperative effect can be attributed to 
the availability of both FA and HA on the outside of CPN/HA complex for receptor –ligand interactions. It 
is assumed that the CPNs form random complexes with HA as there are no significant changes in UV 
absorption and emission spectral shapes upon complexation with HA, indicating no significant structural 
reorganization of polymer chains (see Figure 5.5). There is also an increase in particle size and broadening 
of particle size distributions (see Figure 5.6), which indicate random complex formation. Similar uptake 
values at 18 h for both CPN-PEG2000-FA and CPN-PEG2000-FA/HA are speculated to be driven by FR 
mediated endocytosis with recycling of receptors back to the cell surface.11 Time course experiments with 
CPN-PEG2000 exhibited a more intense signal (3X) from cells upon incubation with mixing with HA (1:2) 
for 4 h, with similar maximum uptake time. This suggests that the kinetics of endocytosis for both CPN-
PEG2000 and CPN-PEG2000/HA are driven by factors independent from hyaluronan mediated endocytosis. 
Both CPN/HA complexes display a decrease in uptake after maximum uptake time, which could be attributed 
to inefficient endosomal escape at longer incubation times. Further studies are needed to better understand 
the kinetics of the dual ligand system.  
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Figure 5.4. Plot of fluorescence intensities of CPN vs incubation time at optimized formulation of CPN/HA 
showing, (a) six-fold enhancement of CPN-PEG2000-FA uptake (8h vs 18h), (b) three-fold enhancement of 
CPN-PEG2000 uptake at 4 h. Error bars represent standard deviation from n = 3. 
 
 
Figure 5.5. UV-absorption (top row) and emission (bottom row) spectra for CPN-PEG2000-FA (left 
column) and CPN-PEG2000(right column) complexed with 40 kDa HA at 1:1 and 1:2 molar ratios, 
respectively. 
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Figure 5.6. Mean sizes (a) and size distributions (b) as measured by NTA of CPN/HA complexes. 
 
The results from the previous flow cytometry uptake studies and microscopic imaging experiments suggest 
different endocytosis mechanisms involved during uptake of CPNs and CPN/HA complexes. Mechanistic 
studies for CPN and CPN/HA complexes were performed using several known endocytic inhibitors and 
competitive inhibition by adding free FA and free HA to the culture medium prior to CPN treatment. As 
shown in Figure 5.7, there was a significant reduction in uptake of CPN-PEG2000-FA via CvME, as well as 
reduced uptake via MPC and excess FA. These results are expected as FR are known to be on the cell surface 
and as well as within caveolae.16,23 Similar pathways were inhibited for CPN-PEG2000-FA/HA, with 
CPN-PEG2000-FA
CPN-PEG2000-FA/HA
CPN-PEG2000
CPN-PEG2000/HA
Sample Mean size (nm)
CPN-PEG2000-FA 105.5 ± 1.4
CPN-PEG2000-FA/HA 202.6 ± 2.2
CPN-PEG2000 107.9 ± 4.5
CPN-PEG2000/HA 233.4 ± 22.7
(a)
(b)
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significant reduction from excess HA. The inhibition studies indicate that CPN-PEG2000-FA follows typical 
folate-mediated endocytosis and when electrostatically complexed with HA, displays both folate and 
hyaluronan receptor mediated endocytosis. The control CPN-PEG2000 displayed reduced update via CME, 
CvME, and MPC pathways, whereas CPN-PEG2000/HA showed reduced uptake via MPC and excess HA. 
These results suggest that CPN-PEG2000 has multiple endocytosis pathways, which could be attributed to 
the hydrophilic nature of the PEG2000 side chain that allows for longer circulation time,17 and may not be as 
specific as CPN-PEG2000-FA. While it is evident that there are different uptake mechanisms for CPNs only 
and CPN/HA complexes, mechanistic studies did not provide definitive results, which could be the explained 
by the differences in optimal uptake times and the time dependence of intracellular trafficking. 
 
Figure 5.7. Effect of endocytosis inhibitors of CPN-PEG2000-FA (left) and CPN-PEG2000 (right) using 
chlorpromazine (24 µM) for clathrin mediated endocytosis (CME), genistein (210 μM) for caveolae mediated 
endocytosis (CvME), methyl-β-cyclodextrin (1000 μM) for CME and macropinocytosis (CvME/MPC), 
LY294002 (120 μM) for macropinocytosis (MPC1), or cytochalasin D (0.04 mM) for macropinocytosis 
(MPC2) incubated 30 minutes before CPN treatment. For blocking any potential pathways of FA (folate) and 
HA (hyaluronan), cells were treated with excess FA (1 mM) and HA (100 kDa, 1.5 mM), respectively, for 
one hour before CPN treatment. Average values are reported (n = 3) with standard deviation represented in 
error bars. *p = 0.01. 
 
High resolution fluorescence microscopy was used to visualize the distribution of internalized CPNs. After 
incubation of cells with CPNs and CPN/HA complexes for desired time, cells were washed with PBS, fixed 
with 4% paraformaldehyde, and then treated with Hoechst dye to differentiate nuclei. After a final washing 
with PBS, the fixed cells were observed under a high resolution microscope. For each sample top and bottom 
of the selected cells were identified, and a Z-stack plot was imaged for each channel. Although some 
internalization of CPNs was observed after just 2 h incubation, the optimal incubation time for each CPN/HA 
complex is reported here, which is 8 h and 4 h for CPN-PEG2000-FA/HA and CPN-PEG2000/HA, 
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respectively. As shown in Figure 5.8a, the overlay image obtained from the blue and red channels for CPN-
PEG2000-FA showed red fluorescence dots in the cytoplasm and surrounding the nucleus, as well as outside 
of the cell. The incorporation of PEG2000 to the side chains was intended to prevent nonspecific binding, yet 
some is still observed. Interestingly in the case of CPN-PEG2000-FA/HA complex, it is speculated that the 
polymers were internalized as large dense aggregates as seen in the contrast image (Figure 5.8f), indicating 
a strong non-covalent association between CPN-PEG2000-FA and HA, with essentially no nonspecific 
binding observed after complexation. Moreover, the fluorescence intensity of CPN-PEG2000-FA/HA 
complex increased significantly compared to the only CPN-PEG2000-FA, shown in the overlay image (Figure 
5.6b). Similarly, a stronger more fluorescent signal was observed when cells were treated with CPN-
PEG2000/HA (Figure 5.8d) than CPN-PEG2000 only (Figure 5.8c). While CPN-PEG2000 displayed punctuated 
dots in the cytoplasm, CPN-PEG2000/HA shows punctuated dots as well as diffuse red signal throughout the 
cytoplasm, indicating a difference in uptake mechanism. These results emphasize and visually display the 
involvement of hyaluronan mediated endocytosis for significantly enhancing internalization of CPN/HA 
complexes. 
 
Figure 5.8. High-resolution fluorescence microscopic images (top row) of blue (nuclei) and red (CPNs) 
channel overlay, and contrast images (bottom row) of cellular uptake in HeLa cells for CPN-PEG2000-FA (a 
and e), CPN-PEG2000-FA/HA (b and f), CPN-PEG2000 (c and g), and CPN-PEG2000/HA (d and h). Scale 
bar is 15 µm. 
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5.4 Conclusion 
In conclusion, highly fluorescent “dual-targeting” CPNs for bioimaging have been developed. The design 
utilizes simple synthetic strategies to modify the side chain of the conjugated polymer while conserving the 
emission of the polymer backbone in water. Specifically, ionic side chains and PEG2000 were incorporated 
into the polymer to create stable water-soluble nanomaterials. During PEG conjugation, the FA was 
selectively attached to the one end of PEG to ensure than they are available on the surface of the CPNs to 
bind with folate receptors of overexpressing cancer cells. The second ligand, HA, was incorporated as an 
electrostatic complex with CPNs via non-covalent interactions. High resolution fluorescence microscopy and 
inhibition studies confirmed that enhanced uptake of CPNs/HA complex was via receptor mediated 
endocytosis. Improved uptake was quantified as 6X higher for CPN-PEG2000-FA/HA complex and 3X 
higher for CPN-PEG2000/HA complex than CPNs only. Furthermore, these CPNs show minimal inherent 
toxicity toward HeLa cells. Therefore, the present study suggests that the dual ligand approach enhances the 
targeting efficiency of CPNs and could be very useful as nontoxic, biocompatible, highly fluorescent 
bioimaging agents. Utilization of these CPNs as far-red emissive imaging agents for sensitive animal study 
is underway. Moreover, incorporation of therapeutic agents in the side chain of the polymers will be 
investigated to develop water-soluble CPNs as a nontoxic and biodegradable delivery agent. 
5.5 Outlook 
This chapter presented a dual ligand approach to improve cellular interactions and uptake in cancer cells. The 
incorporation of the PEG2000 side chain provides increased solubility, but PEG2000-FA side chain poses a 
synthetic challenge to control the amount of incorporation as a result of the poor solubility of FA. An 
alternative method would be to modify the azide functionalized monomer side chain to increase 
hydrophilicity to then use a shorter ethylene oxide coupled to FA. By utilizing a shorter ethylene oxide chain, 
a clear understanding of uptake kinetics and pathways would provide useful information as to the role that 
folate and hyaluronan receptors play. Another alternative approach would be use microwave-assisted 
polymerization, which the Moon lab has recently started exploring. Under microwave irradiation, 
polymerization conditions are much more controlled and produce more reproducible results because of 
uniform heating and shorter reaction times. In order to accurately assess the dual ligand approach, a series of 
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three CPNs are needed: CPN with PEG only side chain, CPN with PEG-FA side chain, and CPN with PEG-
FA complexed with HA. Since copolymers were used, a variation in co-polymer blocks was obtained based 
on synthetic approach. The first step would be to make an CPN array composed of non-BTZ doped PPEs 
with controlled incorporation of FA to accurately assess cellular interactions of FA and HA. Next, controlled 
incorporation of BTz units to the PPE backbone would provide a unique red emissive platform for improved 
sensitivity compared to green CPNs. A clear understanding of uptake pathways as function of the folate and 
hyaluronan receptors could be discerned from a defined CPN array. Subcellular localization studies of the 
dual targeting CPNs would provide information how modulating cell surface interactions affects subcellular 
trafficking and intracellular fate. 
5.6 Experimental 
All monomer and polymer synthesis/characterization and cell toxicity assay were completed Dr. Rajib 
Choudhury. 
5.6.1 Materials.  
Aluminium oxide (neutral, STD grade, 150 mesh, 50 Å), Dimethyl formamide (99.8%), methyl sulfoxide 
(99.0%+), dichloromethane (99.8%+), hydroxybenzotriazole (HPLC, 99.0%+), folic acid (97.0%+), 5-
hexynoic acid (97%) and N-(dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride were purchased 
from Sigma-Aldrich. Sodium chloride (laboratory grade), sodium azide (laboratory grade), silver oxide 
(99.0%+), sodium iodide, sodium sulfate, magnesium sulfate, ammonium chloride, sulfuric acid, 
hydrochloric acid, ethyl acetate (99.0%+), hexane, tetrahydrofuran (99.0%+), N,N,N',N'-
tetramethylethylenediamine (97%+), N, N´-dicyclohexylcarbodiimide (99.0%+) and diethyl ether (99.8%+) 
were purchased from Fisher Chemical. Celite-545, triethyl amine (99.0%+), tetrahydrofuran (99.0%+), 
copper iodide (98%+), potassium iodide (99.0%+), triphenyl phosphine (99.0%+), p-toluenesulfonyl chloride 
(99.0%+), 4-dimethylaminopyridine (99.0%+), diisopropylethyl amine (99.5%+) and 
bis(triphenylphosphine)palladium (II) chloride (98%) were purchased from Acros. Acetone and methyl 
alcohol (anhydrous >99.9%) were purchased from Marcon Fine Chemicals. PEG2000 was obtained from Alfa 
Aesar. Copper bromide (99.0%+) was obtained from Fluka. 4,7-dibromo-2,1,3-benzothiodiazole was 
purchased from Ark Pharm Inc. Carbon tetrabromide (99%) and (trimethylsilyl)acetylene (99%) were 
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purchased from Oakwood Chemical. Silica gel (40-63 µm) was obtained from Silicycle Inc. Thin layer 
chromatography plates (TLC silica gel 60 F254) was obtained from Merck. All deuterated solvents were 
purchased from Cambridge Iosotope Laboratories, Inc (Cambridge, MA). PEG2000 was freeze dried before 
use. N, N´-dicyclohexylcarbodiimide was recrystallized from chloroform and dried overnight under high 
vacuum before use. All chemicals were used without further purification unless stated otherwise. 
All biological reagents were used without further purification. HeLa cells (human cervical cancer) was 
purchased from ATCC. 100 x 20 mm style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, 
USA), 96-well plate (#3795 Costar clear polystyrene 96-well plates, Corning Life Sciences Plastic), 12-well 
plate (#130185 BioLite 12-well plates, Thermo Scientific), minimum essential medium (MEM)/Earle’s 
balanced salt solution (EBSS, HyClone, SH30024), fetal bovine serum (FBS, Hyclone FetalClone I serum, 
SH3008002, GE Healthcare), 100 U/mL penicillin and 100 μg/mL streptomycin (Penicillin/Streptomycin 
Mixture, Fisher BioReagents, BP2959-50), and MTT(CALBIOCHEM, Germany) were purchased from 
Fisher Scientific.  Sodium hyaluronate (HA) was purchased from Lifecore (MW 40K and 100 K) and used 
as received. Stock solutions were prepared by dissolving 2.3 mg and 2.2 mg of 40K and 100K HA, 
respectively, in 1 mL deionized water. Pharmacological endocytosis inhibitors such as chlorpromazine 
hydrochloride (Assay Designs, Inc), genistein (Acros Organics), methyl-β-cyclodextrin (Acros Organics), 
LY2994002 (Caymen Chemical), and cytochalasin D (Assay Designs, Inc) were purchased from Fisher 
Scientific. Trypan blue was purchased from Amresco, Inc. and used as received. 
5.6.2 Instrumentation. 
Nuclear magnetic resonance (NMR) data were recorded on a Bruker Avance 400 spectrometer operating at 
400 MHz for 1H NMR and 100.6 MHz for 13C NMR at 25 oC. The acquired data was processed in the 
TOPSPIN 3.1 software. Chemical shifts are represented in parts per million (ppm) and referenced to CDCl3 
(δ ~7.26 ppm), DMSO (δ ~2.50 ppm) solvent peak. The spectra were recorded with a spectral width (SW) of 
8 ppm and 64 k data points. UV-vis data were collected on a Varian Cary 50 Bio spectrometer. Fluorescence 
spectra were obtained using a FluoLog-3 Spectrofluorometer (Jobin Yvon/Horiba). Quantum yields were 
calculated using Coumarin 6 (QY = 0.6) in ethyl alcohol as a fluorescence standard. Graphs were plotted 
using Origin 9.1 software (OriginLab, Northampton, MA, USA). Fourier transform infrared (FT-IR) spectra 
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were recorded on a PerkinElmer Spectrum 100 FT-IR Spectrometer. For each sample, 16 spectra were 
collected at a 4 cm-1 spectral resolution and with a spectral width ranging from 4000 cm-1 to 700 cm-1. 
Background subtraction and pick picking were performed in the OMNIC software. High-resolution mass 
spectrometry data were recorded on a Bruker Daltonics ultrOTOF Q mass spectrometer with electron 
ionization mode.  
5.6.3 Monomer design.  
Monomers were synthesized according to procedures described in literature and synthetic routes for 
monomers M1 and M2 are shown Scheme S5.1. Alkoxy side chains were incorporated in the aromatic rings 
to enhance solubility of the monomers and corresponding conjugated polymers in organic solvents. 
Moreover, to enhance aqueous solubility of the resulting polymer nanoparticles (NPs), bromo groups were 
incorporated in the terminal position of the alkoxy side chain of M1 which was replaced in situ by triethyl 
amine during Sonogashira polymerization at elevated temperature, resulting in a water soluble quaternary 
ammonium ion. 
Compound 3 (1,4-bis(2-(2-(2-bromoethoxy)ethoxy)ethoxy)-2,5-diiodobenzene) was prepared from readily 
available compound 2. Compound 4 was obtained via Sonogashira reaction of 3 with trimethylsilyl acetylene, 
which was then stirred in the solution of methanol and potassium carbonate to afford final M1 in 58% yield. 
Presence of two terminal alkyne protons was confirmed by comparing the integration ratio of signal at 3.34 
ppm with aromatic signals at 7.00 ppm (see Figure S1 for full NMR spectra). Compound 6 was prepared 
from 5 via Appel reaction, then the terminal bromides were converted into azides by reaction with sodium 
azide in DMF at 70oC for 6 hours. 1H-NMR and 13C NMR spectroscopy confirmed that the conversion of the 
terminal bromides into azides was quantitative (see figure S2, S3 for 1H and 13C NMR of M2). The product 
was also characterized by IR spectroscopy. The typical band at ~2100 cm−1 owing to the conversion of the 
bromide termini into azide group appeared as expected (Figure S4). 
M3 (FA-PEG2000-propargyl) was prepared using a modified procedure reported by Mahou et.al. (as shown 
in Scheme S5.1).25 First, mono-tosyl PEG2000 was synthesized with 90% yield. Subsequently, the tosyl end 
group was converted into azide and then into amine group. 1H NMR spectroscopy confirmed that conversion 
of azide to amine was quantitative. The amine end group of compound 9 was then successfully coupled to 
124 
hex-5-ynoic acid to afford 10. Finally, M3 was prepared from DCC/DMAP coupling reaction of FA with 10, 
as a 1:1 mixture of 10 and M3. The mixture was used without further purification for grafting of conjugated 
polymers. 
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Scheme S5.1. Synthesis of monomers (M1, M2) and heterodifunctional PEG2000 (M3). 
5.6.4 Monomer synthesis. 
Synthesis of 1,4-bis(2-(2-(2-bromoethoxy)ethoxy)ethoxy)-2,5-diethynylbenzene (M1). Following literature 
procedure, synthesis of M1 was carried out in three steps starting from readily available compound 2. Briefly, 
Carbon tetrabromide (8.0 g, 23.95 mmol) and triphenyl phosphine (12.60 g, 23.95 mmol) were added to a 
stirred solution of 2 in DCM under nitrogen atmosphere. The resulting solution was stirred for 2 h at room 
temperature. After the solvent was removed the residue was purified by silica gel chromatography (ethyl 
acetate/hexane 1:4) to give a white solid compound (3). Yield (5.3 g, 81.2%).  1H NMR (400 MHz, CDCl3) 
δ 7.26 (s, 2H), 4.14 (t, 4H), 3.91 (t, 4H), 3.85 (t, 4H), 3.81 (t, 4H), 3.73 (t, 4H), 3.50 (t, 4H). 13C NMR (100.6 
MHz, CDCl3) δ 153.4, 123.5, 86.5, 71.3, 71.2, 70.7, 70.3, 69.7, 30.4. 
Under nitrogen atmosphere, Pd(PPh3)2Cl2 (0.23 g, 0.33 mmol) and CuI (0.031 g, 0.16 mmol) were added to 
a solution of 3 (2.24 g, 3.3 mmol) in 30 mL of anhydrous THF and trimethylamine mixture (2:1). 
Trimethylsilylacetylene (0.97 g, 9.8 mmol) was slowly added to the mixture at room temperature. The 
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reaction mixture was then refluxed under nitrogen for 3 h. The solvent was removed under reduced pressure. 
The residue was passed through a short column of silica gel with hexane as the eluent. The evaporation of 
the solvent led to a yellow solid which was used in next step without further purification. In a 100 mL round 
bottom flask, 4 (4.38 g, 6.0 mmol), K2CO3 (1.65g, 12 mmol) were added in 30 mL MeOH. The resulting 
slurry was stirred for 3 h. The progression of the reaction was monitored by thin layer chromatography. After 
4 h, solvent was evaporated to dryness and purified by silica gel column chromatography (hexane as eluent). 
Yield (2.0 g, 58%). 1H NMR (400 MHz, CDCl3) δ 7.00 (s, 2H), 4.15 (t, 4H), 3.87 (t, 4H), 3.81 (t, 4H), 3.78 
(t, 4H), 3.76 (t, 4H), 3.69 (t, 4H), 3.47 (t, 4H), 3.33 (s, 2H). 13C NMR (100.6 MHz, CDCl3) δ 154.1, 118.5, 
113.6, 82.7, 79.6, 71.3, 71.1, 70.7, 69.7, 69.6, 30.3. HRMS (ESI) m/z calcd. for [C22H28Br2O6] 548.0232; 
found for [C22H28Br2O6+ H]+ 549.0295. 
Synthesis of 1,4-bis(2-(2-azidoethoxy)ethoxy)-2,5-diiodobenzene (M2). This compound was synthesized 
according to procedures described in literature. The product was white crystals (0.5g, 43%). 1H NMR (400 
MHz, CDCl3) δ 7.24 (s, 2H), 4.10 (t, 4H), 3.88 (t, 4H), 3.79 (t, 4H), 3.69 (t, 4H), 3.39 (t, 4H). 13C NMR 
(100.6 MHz, CDCl3) δ 153.2, 123.5, 86.5, 71.3, 71.2, 70.8, 70.3, 70.1, 69.7, 50.7.  
Synthesis of α-tosyl-ω-hydroxyl PEG2000 (7). PEG (2000 g/mol, 20.0 g, 0.01 mol), previously freeze-dried, 
was dissolved in 250 mL of anhydrous DCM.  Ag2O (1.5 eqv., 3.55 g, 0.015 mol) and KI (0.2 eqv., 0.332 g, 
0.002 mol) were added. To this rapidly stirred solution, TsCl (1.05 eqv., 2.0 g, 0.0105 mol) was added in one 
portion. The reaction mixture was stirred for 18h at room temperature before filtration over a filter cell cake 
and solvent removal by rotary evaporation was performed. The crude product was dissolved in 30 mL DCM 
and then precipitated by dropwise addition into diethyl ether (300 mL, 3x). The white hygroscopic compound 
was collected by vacuum filtration under nitrogen atmosphere and dried overnight under high vacuum. Yield 
(18 g, 83%). 1H NMR (400 MHz, DMSO-d6) δ 7.78 (d, 2H), 7.48 (d, 2H), 4.56 (t, 1H), 4.11 (d, 2H), 3.50 
(br, 191H), 2.42 (s, 3H). 13C NMR (100.6 MHz, DMSO-d6) δ 144.9, 132.4, 130.1, 127.6, 72.4, 69.9, 69.8, 
67.9, 60.2, 21.0. IR (neat) υ 3454, 2882, 2865, 1464, 1339, 1098, 1055 cm-1.  
Synthesis of α-azide-ω-hydroxyl PEG2000 (8). In a 250 mL round-bottom flask α-tosyl-ω-hydroxyl PEG (7, 
10 g, 0.0046 mol) was dissolved in 50 mL dry DMF. Then NaN3 (5.0 eqv., 1.5 g, 0.023 mol) was added in 
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one portion. The reaction mixture was stirred overnight at 70 °C under nitrogen atmosphere. After cooling 
down to room temperature and filtration, DMF was removed under vacuum. Excess NaN3 was quenched by 
addition of water. The crude product was dissolved in 200 mL DCM and washed thrice with brine and twice 
with water. The organic layer was dried over sodium sulfate, reduced to a small volume by rotary evaporation, 
and finally precipitated by dropwise addition into diethyl ether (250 mL, 3x). The white precipitate was 
collected by vacuum filtration and dried overnight under high vacuum. Yield (8.7 g, 92%). 1H NMR (400 
MHz, DMSO-d6) δ 4.57 (br, 1H), 3.68 (t, 2H), 3.50 (br, 206H). 13C NMR (100.6 MHz, DMSO-d6) δ 72.3, 
69.8, 69.2, 60.2, 49.9. IR (neat) υ 3454, 2882, 2865, 2108, 1464, 1343, 1274, 1103, 1055 cm-1. 
Synthesis of α-amine-ω-hydroxyl PEG2000 (9). α-azide-ω-hydroxyl PEG2000 (8, 4.0 g, 0.00195 mol) and PPh3 
(3.0 eqv., 1.53 mg, 0.00585 mol) were dissolved in 30 mL MeOH. The resulting mixture was refluxed 
overnight under nitrogen atmosphere at 70 oC and then cooled down to room temperature. After solvent 
removal by rotary evaporation, the crude mixture was dissolved in 20 mL DCM, washed twice with brine 
and dried over sodium sulfate. Solvent was evaporated to dryness, dissolved in 5 mL DCM and precipitated 
in diethyl ether (200 mL, 3x). White powder was collected by vacuum filtration and dried overnight under 
high vacuum. Yield (2.7 g, 69%). 1H NMR (400 MHz, DMSO-d6) δ 4.58 (br, 1H), 3.51 (br, 204H), 2.64 (t, 
2H). 13C NMR (100.6 MHz, DMSO-d6) δ 72.3, 69.8, 60.2. IR (neat) υ 3454, 2879, 1466, 1344, 1276, 1098 
cm-1.  
Synthesis of α-(hex-5-ynamide)-ω-hydroxyl PEG2000 (10). α-amine-ω-hydroxyl PEG2000 (9, 4.63g, 0.0023 
mol), 5-hexynoic acid (0.283 g, 0.0025 mol) were dissolved in 10 mL anhydrous DMF, followed by addition 
of EDC (1.2 eqv., 0.431 g, 0.00278 mol), HOBt (1.2 eqv., 0.375 g, 0.00278 mol) and DIPEA (1.2 eqv., 0.359 
g, 0.00278 mol). The reaction mixture was stirred for 24 h under nitrogen atmosphere at room temperature 
and then filtered to remove insoluble byproducts. The filtrate was concentrated under high vacuum and 
precipitated in diethyl ether (100 ml). Solid precipitate was collected under vacuum filtration, dissolved in 
20 mL DCM, washed thrice with deionized water and then dried over sodium sulfate. Solvent was evaporated 
under rotary evaporation, precipitated in diethyl ether (100 mL, 2x) and collected under vacuum filtration. 
Yield (2.5 g, 51%). 1H NMR (400 MHz, DMSO-d6) δ 7.89 (t, 2H), 4.59 (t, 2H), 3.51 (br, 200H), 2.77 (s, 
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1H), 2.12-2.18 (m, 4H), 1.61-1.68 (m, 2H). 13C NMR (100.6 MHz, DMSO-d6) δ 171.7, 84.1, 72.3, 71.3, 
69.7, 60.1, 34.4, 24.3, 17.2. IR (neat) υ 3424, 3274, 2887, 1651, 1467, 1340, 1103 cm-1. 
Synthesis of heterodifunctional α-(hex-5-ynamide)-ω-folic acid PEG2000 (M3). Folic acid (92.74 mg, 0.210 
mmol), DCC (43.32 mg, 0.210 mmol) were dissolved in 10 ml anhydrous DMSO, under nitrogen atmosphere, 
followed by addition of DMAP (10 mol%, 2.56 mg) and α-(hex-5-ynamide)-ω-hydroxyl PEG2000 (10, 400 
mg, 0.191 mmol). The reaction mixture was stirred in the dark at room temperature for 24h and then 
centrifuged to remove the insoluble byproduct, dicyclohexylurea. The supernatant was concentrated in vacuo 
to 2 mL and precipitated into 50 mL DCM. The insoluble, unreacted folic acid was removed via vacuum 
filtration and the filtrate concentrated in vacuo. The resulting residue was dissolved in 2 mL DCM and 
precipitated in 50 mL diethyl ether. The step was repeated two more times. The precipitated product was 
collected via centrifugation and dried overnight under high vacuum. 1H NMR signal integration was used to 
determine the conjugation efficiency (50%) and the mixture was not separated. Yield (200 mg, 41%). 1H 
NMR (400 MHz, DMSO-d6) δ 11.49 (s, 1H), 8.65 (d, 1H), 8.19 (d, 1H), 7.88 (t, 1H), 7.65 (d, 2H), 7.45 (d, 
2H), 6.93 (d, 1H), 6.62 (m, 2H), 4.57 (t, 2H), 4.48 (t, 1H), 3.52 (br, 219H), 2.76 (s, 1H), 2.31 (t, 1H), 2.15 
(m, 4H), 1.63 (m, 2H). IR (neat) υ 3500-2500 (br), 1692, 1601, 1510, 1300, 1205 cm-1. 
5.6.4 Polymer synthesis. 
Conjugated polymers PPE1 and PPE2 were obtained by Sonogashira cross-coupling polymerization 
between monomers M1 and M2 and commercially available monomer 4,7-
dibromobenzo[c][1,2,5]thiadiazole in yield of 50~60% as red solids (Scheme S5.2 and S5.3). Both polymers 
are partially soluble in boiling THF and chloroform but fully soluble in DMF, DMSO, MeOH, and H2O. 
Upon drying they strongly aggregate and do not redissolve in H2O but solubility in DMSO and DMF remains 
unaffected. Minimal solubility in THF and cationic side chains of the polymers precluded the measurement 
of their molecular weight by gel permeation chromatography (GPC).  
5.6.4.1 Synthesis of PPE1. 
 A Schlenk flask was loaded with 1,4-bis(2-(2-(2-bromoethoxy)ethoxy)ethoxy)-2,5-diethynylbenzene (M1, 
26.4 mg, 0.048 mmol), 1,4-bis(2-(2-azidoethoxy)ethoxy)-2,5-diiodobenzene (M2, 14.15 mg, 0.024 mmol), 
4,7-dibromobenzo[c][1,2,5]thiadiazole (7.07 mg, 0.024 mmol), Pd(PPh3)2Cl2 (1.69 mg, 0.0024 mmol) and 
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CuI (0.228 mg, 0.0012 mmol). The flask was degassed and back-filled with nitrogen for 2 minutes and 4 mL 
of air-free solvent (Et3N : DMF; 2:1) was added via a cannula. The mixture was heated at 65 oC for 12 h 
under nitrogen atmosphere. The solution was then cooled to room temperature and transferred dropwise to 
ethyl acetate, resulting in precipitation. Precipitate was collected via centrifugation (3 mins., 4000 rpm), 
dissolved in 1 mL DMF and mixed with 10 mL MeOH. The resulting viscous solution was filtered through 
PTFE syringe filter (cut-off 0.45 µm). Filtrate was evaporated to low volume (~0.5 mL) in vacuo, precipitated 
in 40 mL ethyl acetate (3x). The supernatant was discarded and the solid red precipitated was collected, dried 
under high vacuum for 12 h prior to 1H NMR and FTIR characterization. Yield (39 mg, 50%). 1H NMR (400 
MHz, DMSO-d6) δ 7.99 (br m, 0.5 H), 7.34 (br, 1H), 7.20 (br, 2H), 4.24 (br, 6H), 3.86-3.39 (br, 26H), 3.28 
(br, 12H), 1.13 (br, 18H). IR (neat) υ 3411, 2926, 2870, 2100, 1492, 1463, 1417, 1275, 1216, 1117 cm-1. UV-
Vis (THF) λmax = 452nm, ε = 59171.59 M-1cm-1 (per repeating unit), emission (THF) λmax = 578 nm, Q.Y. = 
0.31 (in THF). 
5.6.4.2 Synthesis of CPN-PEG2000-FA.  
Heterodifunctional α-(hex-5-ynamide)-ω-folic acid PEG2000 grafted conjugated polymer (CPN-PEG2000-
FA) was synthesized by click reaction. PPE1 (7.0 mg, 0.0076 mmol) and M3 (29.2 mg, 0.0114 mmol) were 
dissolved in 4 mL of anhydrous DMF in a flame-dried and nitrogen-purged vial. Then, CuBr (0.33 mg, 0.0023 
mmol) and TEMED (0.267 mg, 0.0023 mmol) were added sequentially. The vial was degassed and back-
filled with nitrogen for 2 minutes and stirred for 48 h at 30 oC. The reaction mixture was exposed to air and 
passed through a short column of alumina to remove unreacted CuBr. The crude polymer was obtained by 
precipitation into diethyl ether. Then it was dissolved in 1 mL of  DMSO, added into 10 mL deionized water 
and washed with 10 mL DCM (10x). The aqueous fraction was collected, dialyzed (dialysis membrane, 
MWCO: 5000) with 2 L deionized water to remove DMSO and unreacted PEG2000. The pure polymer was 
recovered by lyophilization. 1H NMR (400 MHz, DMSO-d6) δ 8.02 (br, 0.7 H), 7.88 (br, 0.3H), 7.79 (br, 
0.7H), 7.56 (br, 0.54H), 7.5-7.1 (br, m, 4.2H), 4.64 (br, 0.78H),4.24 (br, 6H), 4.0-3.52 (br, m, 23H), 3.51 (br, 
68H), 3.28 (br, 12H), 2.15 (br, m, 1.6H), 1.65 (br, m, 0.72H), 1.13 (br, 18H). IR (neat) υ 3600-2500 (br), 
2104, 1642, 1603, 1492, 1454, 1342, 1275, 1101 cm-1. UV-Vis (H2O) λmax = 481 nm, emission (H2O) λmax 
= 618 nm, Q.Y. = 0.55 (in water). 
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5.6.4.3 Characterization of PPE1 and CPN-PEG2000-FA. 
Comparison between the integrated areas for the methyl groups of quaternary ammonium ion at 1.13 ppm 
and methylene hydrogens at 3.28 ppm to that of aryl hydrogens at 7.20-7.34 ppm and hydrogens on ethoxy 
chains at ~3.59-4.24 ppm in the 1H NMR spectrum of PPE1 reveals that 50% of M1 has been incorporated 
as quaternary ammonium ions in the side chain. Similarly, integration comparison between the aromatic 
signals in BTz and all other signals from polymeric backbone, as well as side chains, suggest 25% 
incorporation of BTz units in the polymer. 
 
Scheme S5.2. Synthesis of water-soluble PPE1 from readily available monomers via Sonogashira coupling 
and grafting to yield CPN-PEG2000-FA. 
 
The quantitative character of the ‘click’ reaction was determined by 1H-NMR in DMSO-d6. Figure S5.1 
shows the comparison of 1H-NMR spectra of PPE1 (top spectra) with the final PEG2000-FA grafted 
copolymer (CPN-PEG2000-FA, bottom spectra) obtained after the dipolar cycloaddition with PEG2000-FA. 
New signal at 3.51 ppm is assigned to the repeat unites –CH2–CH2–O– from PEG2000, while signals at 1.65 
ppm and 2.15 ppm are assigned to methylene protons r and q+s, respectively. The peak at 4.64 ppm is related 
to the protons from FA. Moreover, signals at δ 7.20-7.56, 7.79 and 8.01 are assigned to FA, where signal at 
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7.88 ppm is characteristic to amide signal of the PEG derivative. Also, NMR signal integration indicates 
presence of proton from triazole linkage buried at δ 7.20-7.56 ppm. Similarly, the ratio of proton integrals 
belonging to PPE1 to that of PEG2000-FA suggests 40% incorporation of the latter via click reaction. 
 
 
Figure S5.1. 1H NMR spectra of PPE1 (top) and CPN-PEG2000-FA (bottom) in DMSO-d6. *indicates 
unassigned signal. 
To prepare the grafted copolymers CPN-PEG2000-FA and CPN-PEG2000, the azide functionalized PPEs 
were coupled with alkynyl end of PEG2000-FA and PEG2000, respectively, by the Huisgen 1,3-dipolar 
cycloaddition. For CPN-PEG2000-FA, “click reaction” between PPE1 and M3 in presence of catalytic 
amount of TEMED and CuBr in DMF at room temperature afforded CPN-PEG2000-FA in 45% yield. An 
excess of alkynyl-terminated PEG2000-FA (2.0 equivalent) was used in order to increase the grafting 
efficiency. The crude copolymer was first washed with excess DCM (10x) to remove unreacted PEG2000 and 
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other organic impurities followed by dialysis (5 kDa molecular weight cut-off dialysis membrane). Complete 
removal of free FA was confirmed by monitoring absorption of FA in the aqueous supernatant (Figure S5.2).  
 
Figure S5.2. UV-vis absorption spectra of folic acid in the supernatant showing complete removal of folic 
acid from CPN-PEG2000-FA solution via dialysis (dialysis membrane, MWCO: 5000). 
 
FTIR was utilized as the preliminary characterization method to determine whether the azide displacement 
and click reaction occurred. The organic azide provides a unique absorbance in the IR spectrum at ~2100-
2108 cm-1.  The absorption at 2107 cm−1 for CPN-PEG2000-FA characteristic of the azide termini which 
almost disappeared in favor of a new absorptions at 1642 cm−1 and 1603 cm-1 characteristic of the amide 
group and triazole unsaturations, respectively. Additionally, the acid functional group of PEG2000-FA gives 
rise to a characteristic broad and strong stretch from 3600 to 2500 cm−1. 
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Figure S5.3. FTIR spectra of PPE1 (gray line) and CPN-PEG2000-FA (black line). 
 
5.6.4.4. Synthesis of PPE2.  
Using the general polymerization procedure described above, polymerization of 1,4-bis(2-(2-(2-
bromoethoxy)ethoxy)ethoxy)-2,5-diethynylbenzene (M1, 26.4 mg, 0.048 mmol), 1,4-bis(2-(2-
azidoethoxy)ethoxy)-2,5-diiodobenzene (M2, 14.15 mg, 0.024 mmol), 4,7-
dibromobenzo[c][1,2,5]thiadiazole (7.07 mg, 0.024 mmol) in presence of Pd(PPh3)2Cl2 (1.69 mg, 0.0024 
mmol) and CuI (0.228 mg, 0.0012 mmol) yielded polymer PPE2 in 57% (47mg). 1H NMR (400 MHz, 
DMSO-d6) δ 8.11-7.82 (br m, 0.45H), 7.31 (br, 1H), 7.18 (br, 2H), 4.23 (br, 6H), 3.87-3.58 (br, 27.6H), 3.27 
(br, 6.6H), 1.12 (br, 6.79H). IR (neat) υ 3403, 2924, 2869, 2102, 1489, 1454, 1414, 1276, 1216, 1221 cm-1. 
UV-Vis (THF) λmax = 448nm, ε = 57876.53 M-1cm-1 (per repeating unit), emission (THF) λmax = 575 nm, 
Q.Y. = 0.35 (in THF). 
5.6.4.5. Synthesis of CPN-PEG2000. 
Using the general click reaction procedure described above, reaction of PPE2(13.18 mg, 0.016 mmol) and 
α-(hex-5-ynamide)-ω-hydroxyl PEG2000 (10, 34 mg, 0.016 mmol), in presence of CuBr (0.6864 mg, 0.0048 
mmol) and TEMED (0.557 mg, 0.0048 mmol) yielded CPN-PEG2000. 1H NMR (400 MHz, DMSO-d6) δ 
7.87 (t, 1H), 7.29-7.17 (br, 4H), 4.56 (t, 0.5H), 4.23 (br, 6H), 3.85-3.67 (br, 26H), 3.50 (br, 212H), 2.15 (m, 
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4H), 1.65 (m, 2H), 1.13 (br, 9H). IR (neat) υ 3600-2500 (br), 2104, 1642, 1603, 1492, 1454, 1342, 1275, 
1101 cm-1. UV-Vis (H2O) λmax = 480 nm, emission (H2O) λmax = 620 nm, Q.Y. = 0.48 (in water). 
 
Scheme S5.3. Click reaction of alkyne end-functionalized PEG2000 onto azide end-functionalized PPE2 to 
yield CPN-PEG2000. 
4.6.4.6 Characterization of PPE2 and CPN-PEG2000. 
A similar “click reaction” strategy was employed to synthesize CPN-PEG2000 (Scheme S5.3). After 
purification via dialysis and freeze drying, a red solid powder was collected which was used for nanoparticle 
preparation. 1H NMR integral ratio between PPE2 and alkynyl ended PEG2000 (10) indicates incorporation 
complete of PEG2000 into the polymer chain.  
CPN-PEG2000
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Figure S5.4.1H NMR spectrum of PPE2 in DMSO-d6. 
 
 
Figure S5.5.1H NMR spectra of CPN-PEG2000 in DMSO-d6. 
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Figure S5.6. FTIR spectra of PPE2 (green line) and CPN-PEG2000 (black line). 
 
5.6.5 Nanoparticle preparation. 
PEG2000-folic acid grafted conjugated polymers were dissolved in HPLC grade DMSO by stirring overnight. 
The conjugated polymer nanoparticles were prepared by adding the stock solution in deionized water with 
vigorous stirring. DMSO and unreacted PEG2000-Folic acid were removed by washing the water dispersible 
with HPLC grade dichloromethane. Finally, the nanoparticles were filtered through a 0.5 µm PTFE syringe 
filters. 
5.6.6 Determination of hydrodynamic diameter of CPNs. 
Light scattering measurements were performed using a NanoSight LM10 HS Instrument (Nanosight Ltd., 
Amesbury, UK) equipped with a sCMOS camera using deionized water (DI H2O, 18 Ω) as dispersant. A 
Class 3B laser (488 nm blue laser) source was used as the light source and all experiments were performed 
at a temperature of 25oC monitored by a LM14C temperature controller (NanoSight, Amesbury, United 
Kingdom). CPN samples in water were filtered through PTFE syringe filters (cut-off 0.45 µm) prior to 
injecting in the sample chamber to remove dust or any larger aggregates. Samples were then injected into the 
PPE2
CPN-PEG2000
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chamber with 1 mL sterile syringes (Restek Corporation, Pennsylvania, USA) until the liquid reached the tip 
of the nozzle. A video of typically 60 seconds duration was taken, with a frame rate of 30 frames per second. 
Each video was then analyzed by NTA software (NanoSight Ltd.) to give the mean, mode, and standard 
deviation of nanoparticle size distribution together with an estimate of concentration (particles/mL). Each 
sample was measured three times. 
5.6.7 Determination of zeta potential of CPNs. 
Zeta potential of CPNs were measured by Zetasizer nano–ZS (Zen 3600, Malvern Instruments Ltd.) using a 
folded disposable capillary cell (Catalog # DTS1060) at 25oC. The nanoparticle dispersions (in DI water) 
were concentrated to approximately 0.5 mM to achieve reliable results. Instrument settings were 
automatically determined by Malvern technology software on a sample-to-sample basis for measurement 
position (in mm), attenuator intensity (laser power), and number of runs per measurement. Each sample was 
measured six times. 
5.6.8 General cell culture. 
HeLa cells (human cervical cancer, purchased from ATCC) were seeded into a 100 x 20 mm style sterile 
tissue culture dish (#353003 BD Falcon, Durham, NC, USA). The cells were grown in minimum essential 
medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL, HyClone, SH30024) medium supplemented 
with 10% fetal bovine serum (FBS), and 100 µg/mL penicillin and 100 µg/mL streptomycin  for 24 h under 
5% CO2/ 95% air at 37 °C. The cells were continuously maintained in the culture medium and subcultured 
every 48 h. 
5.6.9 Cellular toxicity study. 
HeLa cells (ca. 10,000 cells per well), in 200 μL of complete medium, were seeded into a 96-well plate and 
allowed to attach for one day at 37 °C under a humidified atmosphere of 5% CO2 / 95% air. Stock solution 
of CPNs were added into complete media and diluted to the required amount of CPNs. After addition of 
CPNs, the cells were incubated for another 18 h. Cells were washed with warm PBS and incubated with fresh 
medium containing MTT (5 mg mL-1 in PBS, CALBIOCHEM, Germany) for 4 h at 37 oC. Dimethyl sulfoxide 
(100 µL) was added to solubilize the purple formazan crystals formed by proliferating cells. Absorbance was 
measured by a microplate well reader (infinite M1000 PRO, TECAN, Switzerland) at 590 nm. Relative cell 
137 
viability (%) as a function of CPNs concentration was expressed as a percentage relative to the untreated 
control cells. All measurements were performed in triplicate and standard deviation was included in the error 
bar. 
5.6.10 Cell uptake studies by flow cytometry. 
HeLa cells were seeded into a 12-well plate (~40,000/well) one day prior to CPN treatment. Cells were then 
incubated with 6 µM of CPN for 1, 2, 4, 8, and 18h. For complexation with HA, CPN was mixed with HA 
(40K and 100K) at molar ratios (based on repeating unit of CPN and HA) of 1:0 (control), 1:1, 1:2, and 1:5. 
The CPN/HA complexes were allowed to incubate approximately 30 minutes prior to incubating with cells. 
After incubation with cells, samples were treated with trypan blue (200 μM) for 10 minutes at 37˚C and 
washed three times with 1X PBS. Cells were detached with trypsin/EDTA and fixed with 4% 
paraformaldehyde for 10 minutes at room temperature, then resuspended in flow cytometry buffer (1X PBS 
containing 5% bovine serum albumin and 0.02% sodium azide). 10,000 events per measurement were 
recorded within the gate of control cells, which was selected based on forward and side scattering of control 
cells to eliminate data collection from dead cells and artifacts. Mean fluorescence intensity of CPNs (FL3 
channel, 590-620 nm wavelength range) was obtained using three independent sample sets and accounting 
for variation in cell autofluorescence. For uptake plots, values were normalized to control cells.  
5.6.11 Cell inhibition assays. 
For endocytosis pathway studies, HeLa cells were seeded into a 12-well plate (~40,000/well) one day prior 
to CPN treatment. Cells were then treated without (control) or in the presence of pharmaceutical inhibitors 
chlorpromazine (24 µM) for clathrin mediated endocytosis (CME), genistein (210 μM) for caveolae mediated 
endocytosis (CvME), methyl-β-cyclodextrin (1000 μM) for CME and macropinocytosis (CvME/MPC), 
LY294002 (120 μM) for macropinocytosis (MPC1), or cytochalasin D (40 µM) for macropinocytosis 
(MPC2) for 30 minutes before CPN treatment. For blocking any potential pathways of FA and HA, cells 
were treated with excess FA (1 mM) and HA (100K, 1.5 mM) for one hour before CPN treatment. After CPN 
treatment, cells were prepared as discussed in previous section. For inhibition assays, values were normalized 
to CPN. 
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5.6.12 Cell uptake studies by microscopy. 
HeLa cells were seeded into a 12-well plate (~20,000/well) with glass coverslip (#1254584, Fisher Scientific) 
one day prior to CPN treatment  and cultured in a minimum essential medium (MEM)/Earle’s balanced salt 
solution (EBSS) (500 μL) medium containing 10% fetal bovine serum (FBS) and 100 U/m penicillin for 24 
h under 5% CO2 at 37 °C. CPNs and CPN/HA complexes were prepared in fresh culture medium (500 μL), 
and added to cells after washing with 1X PBS and removing media, then cultured for 4, 8, and 18 h (ﬁnal 
CPN concentration: 6 μM). After incubation, cell were washed with PBS and ﬁxed with 4% 
paraformaldehyde for 10 min. After washing with 1X PBS, a 1 μL aliquot of Hoechst (5 μg/mL) was added 
to 1X PBS and incubated with the cells for 10 min at room temperature. Cells were then washed three times 
with 1X PBS and coverslips were mounted on microscope slides (#1125441, Fisher Scientific) using a 1:1 
glycerol/PBS mounting medium. Fluorescent images of the cells were obtained using a DeltaVision Elite 
Microscope System (Applied Precision, Issaquah, Washington, USA) equipped with bandpass ﬁlters such as 
blue (410−460 nm, Hoechst) and red (595-635nm, CPNs) using a 60X oil immersion lens (NA 1.42) and η 
= 1.520 immersion oil . Top and bottom of the chosen cells was identified, and a Z-stack plot was imaged 
for each channel. Deconvolution of each channel was performed using the microscope software (Softworx 
5.0 application, Applied Precision, Issaquah, Washington, USA) and supplied method file using 50 iterations 
per channel and high noise filtering setting. 
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5.6.13 Characterization data. 
 
Figure S5.7. 1H NMR spectrum of M1 in CDCl3. 
 
Figure S5.8. 1H NMR spectrum of M2 in CDCl3. 
 
 
140 
 
Figure S5.9. 13C NMR spectrum of M2 in CDCl3. 
 
Figure S5.10. IR Spectrum of M2 showing –N3 stretch at 2095.8 cm-1. 
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Figure S5.11. 13C NMR spectrum of M1 in CDCl3. 
 
Figure S5.12. 1H NMR spectrum of 7 in DMSO-d6. 
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Figure S5.13. 13C NMR spectrum of 7 in DMSO-d6. 
 
Figure S5.14. 1H NMR spectrum of 8 in DMSO-d6. 
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Figure S5.15. 13C NMR spectrum of 8 in DMSO-d6. 
 
Figure S5.16. 1H NMR spectrum of 9 in DMSO-d6. 
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Figure S5.17. 13C NMR spectrum of 9 in DMSO-d6. 
 
Figure S5.18. 1H NMR spectrum of 10 in DMSO-d6. 
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Figure S5.19. 13C NMR spectrum of 10 in DMSO-d6. 
 
Figure S5.20. 1H NMR spectrum of 1:1 mixture of M3 and 10 in DMSO-d6. 
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Figure S5.21. Absorption and emission spectra for PPE2 in THF (Excitation = 400 nm, slit width = 2 nm, 
integration time = 0.1 s). 
 
Figure S5.22. Zeta potential for CPN-PEG2000-FA (a) and CPN-PEG2000 (b). 
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Figure S5.23. Toxicity of CPNs toward HeLa cells. Cell viability against varying concentration of CPNs is 
plotted as columns. 
 
Figure S5.24. Quenching experiment showing normalized emission spectra of CPN-PEG2000-FA and CPN-
PEG2000 with (dashed lines) and without (solid lines) trypan blue (TB) treatment of 200 µM in water for 10 
minutes at 37˚C. 
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Figure S5.25. Representative scatterplots (top row) and intensity plots (bottom row) for optimized conditions 
for CPN-PEG2000-FA/HA (8 h, 40K 1:1), and CPN-PEG2000/HA (4 h, 40K 1:2). 10,000 events per 
measurement were recorded within the gate of control cells, which was selected based on forward and side 
scattering of control cells (top left) to eliminate data collection from dead cells and artifacts. 
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CHAPTER VI 
General Conclusions 
 
The development of CP-based biomaterials would provide a novel class of polymeric materials useful for a 
variety of applications. The use of CPNs has become of significant interest in biomedical applications as a 
consequence of their desirable properties including facile synthesis, high sensitivity, superior photostability, 
low cytotoxicity, and biocompatibility. The photophysical excellence and robustness of CP-based 
nanomaterials are particularly useful for labelling target cells. The synthetic versatility of CPs allows the easy 
modification of the conjugated backbone to tune emission and side chain structures to adjust biocompatibility 
through increased water solubility, controlled biodegradability, and incorporation of targeting. Structural 
modifications of CP side chains to incorporate ionic and hydrophilic moieties allow for tunable biophysical 
properties for improved biocompatibility and functionalized performance. Depending on the solubility of CP 
chains and the nature of interaction between CPs and analytes, structural changes can occur in individual CP 
chains or multiple chain aggregates, which correspond to changes in CP optical properties. These changes in 
optical properties present the opportunity of a CP-based sensor. Structural modifications result in changes in 
self-assembly and subsequent cellular interactions, which allows for a structure-function relationship to be 
established. 
The second chapter presented a strategy for modulating particle shape using ionic complexation with HA in 
a backbone flexibility-dependent fashion. The incorporation of a semi-flexible, non-conjugated moiety into 
the backbone resulted in the formation of core-shell nanoparticles when a cationic CPN was treated with a 
polyanion compared to the control CPN with a rigid, fully conjugated backbone. The core-shell nanoparticles 
exhibited high specificity to cancer cells with low adsorption to normal cells, because of HA’s affinity to 
overexpressed receptors on cancer cells. While in Chapter II, the semi-flexible CPN displayed enhanced 
targeting of cancer cells over normal cells, additional work showed there was no significant increase in 
internalization of the semi-flexible CPN, only changes to subcellular localization. Complexation of the semi-
flexible CPN with polyanions led to increased accumulation in different organelles compared to control 
polymers with rigid backbone. Differences in subcellular localization were expected based on the dramatic 
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changes from spherical to core-sell particles. While ionic complexation led to increased labelling of cancer 
cells, a strategy to improve targeting and increase internalization of CPNs was explored in Chapter V using 
a dual ligand targeting approach. 
The dramatic differences in ionic complexation determined by backbone flexibility led to the work in Chapter 
III. A systematic investigation on ionic complexation of CPNs that vary by side chain and backbone structure 
with biologically important anionic polysaccharides was conducted in the third chapter. A simple approach 
to differential sensing of biologically important molecules was presented. A systematic approach to 
understanding the effect of side chain and backbone structure was employed to establish a structure-function 
relationship. To improve differential sensing, an array of more structurally diverse CPNs could be utilized, 
which would lead to more dramatic differential interactions of CPNs and analytes. By developing structural 
diverse arrays, sensitivity can be greatly improved. Additional work using a controlled series of CPNs with 
PPE and PPB-type connectivity and incorporation of a flexible, non-conjugated linker displayed backbone-
dependent complexation with HA. The work in Chapters II and III presented how backbone flexibility affects 
ionic interactions, but subcellular localization studies would provide more information how exactly backbone 
connectivity affects cellular interactions, which was the explored in the fourth chapter  
Chapter IV presented a strategy for mitochondrial targeting using the triphenylphosphonium (TPP) group 
that was dependent on the biodegradability and flexibility of the conjugated backbone. The subcellular 
localization and cellular toxicity were affected by backbone flexibility and molecular weight, in a time-
dependent fashion. The degradable, flexible linker allowed the CPN to be degraded to conjugated oligomers 
that could more easily diffuse after endocytosis and traffic to the mitochondria. The TPP-containing CPNs 
were treated with HA to improve solubility, and displayed modulated cellular interactions based on backbone 
structure. Additional work using a series of varying molecular weight nonflexible TPP-containing 
copolymers and flexible TPP-containing copolymers with varying flexible unit incorporation indicated that 
the presence of the flexible linker and at relatively higher percentage (>40%) was crucial for mitochondrial 
localization. This finding could be the result of the hydrophobicity of the polymer backbone, which causes 
aggregation in aqueous environment, and compromises the availability of the degradable linker to 
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intracellular glutathione. A series of TPP-containing polymers that also incorporated the hydrogen peroxide-
sensitive moiety, aryl boronate, and degradable linker were synthesized. However, because of the 
hydrophobicity of this group and in combination with the bulky TPP group, dense aggregation was observed. 
To address these issues, additional more in-depth studies on the effect of the flexible linker for subcellular 
targeting are needed. In addition, improving the hydrophilicity of the TPP-containing CPNs would provide 
information as to how polymer solubility, CPN aggregation, and cellular uptake/trafficking can be modulated. 
Chapter V detailed the synthesis of dual-targeting red emissive CPNs grafted with folic acid (FA) side chains 
and complexed with hyaluronic acid (HA). Modulation of uptake kinetics and amount of internalized CPNs 
was achieved by the dual ligand-targeting CPNs designed for folate and hyaluronan receptors. The grafting 
of PEG2000-FA side chain posed a synthetic challenge to control the amount of incorporation because of the 
poor solubility of FA. The synthetic approach would need to be modified to increase hydrophilicity to favor 
coupling of FA. Additional work is under way to use microwave-assisted polymerization, which would 
provide more reproducible results because of uniform heating and shorter reaction times. To assess accurately 
the dual ligand approach, a series of three CPNs are needed: CPN with PEG only side chain, CPN with PEG-
FA side chain, and CPN with PEG-FA complexed with HA. Since copolymers were used, a variation in co-
polymer blocks was obtained based on synthetic approach. A CPN array with controlled incorporation of FA 
to accurately assess cellular interactions of FA and HA would provide a clearer understanding of uptake 
pathways as function of the folate and hyaluronan receptors. Subcellular localization studies of targeting 
CPNs would provide information how modulating cell surface interactions affects subcellular trafficking and 
intracellular fate.  
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